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ABSTRACT
Obesity, metabolic syndrome and type 2 diabetes are all characterised by insulin resistance 
and in most cases large intra-abdominal fat stores. Insulin resistance is associated with the 
dysregulation of adipose tissue (AT) Metab including a reduced effectiveness for insulin to 
suppress lipolysis. Although patients with type 2 diabetes are treated with metformin 
initially, the majority of patients eventually need treatment with insulin to maintain glucose 
control. Insulin treatment with most types of insulin therapy is associated with weight gain. 
However the insulin analogue detemir is weight neutral or causes weight loss and it has 
been suggested that this may be related to a reduced effect of this insulin in peripheral 
tissues such as AT. A high sugar intake (fructose and sucrose) is associated with insulin 
resistance but the effects on AT Metab are not established.
Methods were developed to measure cell sizes, in vitro basal, stimulated and insulin 
inhibited lipolysis and lipoprotein lipase (LPL) activity in AT biopsies. These methods 
were then applied to study a) subcutaneous AT (SCAT) and omental AT (OMAT) biopsies 
from twelve participants, seven non-diabetic subjects and five patients with type 2 diabetes 
treated with metformin (T20H) undergoing abdominal surgery and b) the effect of 
treatment of patients with type 2 diabetes with insulin detemir (n=7) or insulin neutral 
protamine hagedom (NPH) (n=5), in a 16 week parallel group study. The effect of sugar 
intake on the in vivo rate of lipolysis and post-heparin lipolysis was investigated in 25 men 
at risk of metabolic syndrome. In a cross-over study design participants were studied after 
a 12 week diet high in extrinsic sugars and low in extrinsic sugars.
Ill
Adipocyte size of SCAT and OMAT was significantly larger in T20H than healthy
participants (p<0.001, ^<0.05 respectively). In healthy subjects OMAT had higher basal,
isoproterenol stimulated and insulin inhibited lipolysis than SCAT (p<0.01, p<0.001,
p<0.05 respectively). In participants with T20H, stimulated lipolysis with isoproterenol in
SCAT was significantly higher than OMAT, but there was no significant difference in
basal and insulin inhibited lipolysis. There was no significant difference between healthy
and T20H in SCAT lipolytic activity, but OMAT has higher basal, isoproterenol
stimulated and insulin inhibited lipolysis than SCAT (p<0.05, ^<0.001, /><0.01
respectively) in healthy participants. LPL activity in OMAT was significantly higher than
SCAT in both healthy and T20H group (p<0.001,/?<0.05 respectively).
In the insulin detemir clinical trial, fasting non-esterified fatty acids (NEFA) decreased
significantly with detemir compared to NPH (p<0.05). Basal lipolysis in the fat biopsies
showed a significant reduction with detemir treatment (p<0.05) with no significant change
following NPH treatment. LPL mass and activity increased significantly after 16 weeks
treatment with detemir compared to NPH (p=0.006, j9=0.005). No significant differences
were observed on stimulated lipolysis or adipocyte size following either of the treatments.
In the dietary intervention study after the high sugar diet compared with low sugar diet,
liver fat, lasting plasma glucose and NEFA concentrations were significantly higher in
men with higher liver fat at screening (all p<0.05). In the low-liver fat group, plasma TG
(p=0.07) NEFA (p=0.04) and LPL activity (p<0.05) were higher after the low versus high
sugar diet, whereas, in the high-liver fat group, hepatic lipase (HL) activity was higher
after the high versus the low sugar diet (p<0.05). The palmitate (PA) concentration
decreased significantly after the high sugar diet compared with low sugar diet (p<0.001) in
the high liver fat group. In this group, the percentage of palmitate to total NEFA in the
circulation (PAiNEFA) decreased significantly after the high sugar diet, this value was
significantly lower than the value after the high sugar diet in the low liver fat group
iv
(p<0.05). However, the palmitate rate of appearance increased after the high sugar diet in 
the high liver fat group, but did not reach significance (p=0.06).
Conclusion: This study showed that OMAT had less sensitivity to insulin action than 
SCAT in T20H. In the clinical trial of insulin detemir, the decrease in basal NEFA levels 
and basal lipolysis and the increased LPL mass and activity suggests that detemir improves 
fasting insulin sensitivity. This may be due to a greater hepatoselective action of detemir 
reducing over-insulinisation of adipose tissue and skeletal muscle. The change in plasma 
lipid Metab and pattern of response in lipase activities in response to a diet high in 
extrinsic sugars increased the availability of NEFA from peripheral and endothelial 
lipolysis; this may be due to reduced insulin sensitivity in participants with high liver fat.
V
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This thesis has two sets of studies; each study was treated separately with its own 
introduction, methods, results and discussion sections. The first study was to 
investigate white adipose tissue Metab in healthy participants and participants with 
type 2 diabetes (on oral hypoglycaemic treatment and on insulin treatment). These 
were included in chapter 1,2, 3, 4 and 5. Chapter 1 is a general introduction, chapter 
2 describes the method development to investigate adipose tissue mtabolism in 
freshly isolated adipocytes. Chapter 3 describes the application of the developed 
methods to investigate 1) the regional differences in healthy participants vs. 
participants with type 2 diabetes on oral hypoglycaemic treatment and 2) the effect of 
insulin detemir and insulin NPH on adipose tissue Metab in patients with type 2 
diabetes. Chapter 4 shows the results of the regional differences of adipose tissue 
Metab between healthy vs. type 2 diabetes. Chapter 5 presents the results of insulin 
detemir study.
The second study was a cross-over dietary intervention study, looking at the effect of 
a high and low sugar diet on plasma lipids, the in-vivo rate of lipolysis and post­
heparin lipolysis in men at risk of metabolic syndrome. The introduction, methods, 
results and discussion for this study are all included in chapter 6.
Chapter 7 is a general discussion which outlines the key observations, their 
implications and thesis speculations.
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CHAPTER ONE: INTRODUCTION TO THE INVESTIGATION 
OF ADIPOSE TISSUE METABOLISM
1.1 Adipose Tissue
Adipose tissue (AT) is a specialized connective tissue that functions as the major 
storage site for fat in the form of triglycerides (TGs). In mammals, adipose tissue is 
found in two different forms; white adipose tissue (WAT) and brown adipose tissue 
(BAT). Most AT in the body is white, which is the focus of this research. WAT has 
three functions; heat insulation where subcutaneous adipose tissue (SCAT) found 
directly below the skin conducts heat only one third as readily as other tissues. The 
second function is a mechanical cushion where it surrounds internal organs and 
provides protection. The third, most important function, is that it is a source of 
energy where TGs are synthesised, stored, and hydrolysed (Devlin 2002). WAT is 
the largest energy storage organ of the body. It accounts for around 10-15 kg in a 
non- obese young adult (Large et al. 2004). Fifteen kilograms of body fat stores 
135,000 kcal of energy (Ryan and Curri 1989). Adipocytes regulate the energy 
balance of the entire body by storing excess energy intake as TGs and releasing 
stored energy when needed. TGs are stored as lipid droplets in the cytoplasm of the 
adipocyte but this is not ‘a dead storage’ since TGs turn over with an average half- 
life of only a few days. Thus, there is continuous synthesis and breakdown of TGs in 
adipose tissue. More than 95% of the body’s lipids are found in AT stores as TGs 
with small amounts in other tissues such as liver and muscle. TG droplets which are 
stored in the skeletal muscles are called intramuscular triglycerides (IMTG) and they 
may hold 2,000 to 3,000 kcal (Manore and Thompson 2000). In addition to the 
stored fat, some TGs travel freely in the blood. During certain physiological
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condition such as exercise, TG in adipocytes, muscle cells, and in the blood can be 
hydrolysed (lipolysis) and used as fuel by the exercising muscles. Less than 0.1% of 
the body’s lipids are in the plasma (Lofgren et al. 2005).
Adipose tissue is no longer considered an inert tissue devoted to energy storage, and 
it is well established that it has a fourth function where it secretes bioactive peptides, 
called adipokines (from the Greek adipo-, fat and -kinos, movement) which contend 
with cell-to-cell signalling, which act locally through autocrine effects, distally 
through paracrine effects (that secretes its products into the surrounding tissues and 
act in the close surrounding area) and endocrine effects (that secretes its product into 
the blood and transfers it to the distant tissues) effects (Friihbeck et al. 2001, 
Trayhum 2005 and Galic et al. 2010). This characteristic influences many aspects of 
Metabolism through a network of local and systemic signals, which interact with the 
conventional neuro-endocrine and hormonal regulators of adipose tissue. Various 
adipokines synthesized and released by adipocytes have been described (Mohamed- 
Ali et al. 1998, Lan et al. 2005, Ronti et al. 2006) (Figure 1.1).
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Figure 1.1: Autocrine, paracrine and endocrine activity of adipose 
tissue. Adapted from Turgeon et al. (2006).
In humans, 80% of white AT is localised in the subcutaneous area which includes 
abdominal and gluteal, as well as femoral, the rest is localised abdominally (Amer
2005). Abdominal AT is distributed in subcutaneous and visceral depots which is 
associated with internal organs. Visceral fat includes the omental, the largest 
peritoneal fold within the abdomen which is attached to the stomach, the mesenteric 
which lies within the thin layers of the peritoneal of the intestine, the epiploic which 
is associated with the colon. Perinephric or perirenal fat surrounds the kidney and 
retroperitoneal fat is located in the retroperitoneal compartment (Figure 1.2) (Lee et 
al. 2013).
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Figure 1.2: Major adipose depots in the human body.(Lee et al. 2013)
As Figure 1.2 shows, some fat is stored in the liver as well. Magnetic resonance 
imaging (MRI) scan is a very common procedure used to determine body fat content 
and distribution, Figure 1.3 shows body fat distribution in an obese individual and a 
non-obese individual.
I
Figure 1.3: Magnetic resonance imaging (MRI) scans of body 
fat distribution in an obese individual and a non-obese 
individual. (Heber, 2010).
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Several studies have suggested that the visceral fat component of abdominal fat is the 
most strongly correlated with risk factors (Bjomtorp 1988, Fujioka et al. 1987, 
Després et al. 1989, Pouliot et al. 1992). However, other studies showed that the 
subcutaneous AT is the most highly correlated with insulin resistance (Abate et al. 
1995, Abate et al. 1996, and Goodpaster et al. 1997).
1.2 White Adipose Tissue Histology
The cellular content of WAT is composed approximately of 50% adipocytes and 
50% other structures such as stromal vasculature fibroblasts, endothelial cells, 
macrophages, and pre-adipocytes (Singh 2011) (Figure 1.4).
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Figure 1.4: Schematic representation of adipose tissue in 
subcutaneous and visceral fat depots (in rodents). Modified from 
(Berryman et al. 2011)
Each adipocyte contains roughly 0.04-0.06 pg of fat which accounts for 
approximately 60 to 85% of the weight of adipose tissue with 90-99% being TGs 
(Ryan and Curri 1989). The fat droplets combine to a single, large droplet, which 
often becomes very big in cellular tenns, reducing the cytoplasm to a small rim 
around the droplet, in which the nucleus lies, as a thin, flattened crescent, permitting
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maximum storage of fat globules. Fat globules appear as empty spaces because the 
fat has been dissolved out by solvents used in the preparation of the tissue (Figure 
1.5).
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Figure 1.5: Fixed human fat cells using 10% formalin, H. and 
E., 612x.(Ross 2002)
Fixed frozen sections of white adipose tissue, show fat cells occurring in clusters, 
with typically a hexagonal or polygonal shape (Rogers 1983) (Figure 1.6).
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Figure 1.6: Frozen section of human adipose tissue. Fat droplet 
occupies nearly the entire area of the cell. Cytoplasm and nucleus are 
forced to the periphery. Magnification power x 200. (Rogers 1983)
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Otherwise, in a freshly isolated adipocyte cell suspension, adipocytes appear as 
spherical cells completely filled with fat (Figure 1.7).
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Figure 1.7: Freshly isolated human adipocytes under normal light 
microscope look like fat globules. Magnification power x 100. 
(Tchoukalova et al. 2008)
The integrity of AT metabolism regulation is essential to maintain body weight 
homeostasis and any disorder of these processes may play an important role in 
pathologies such as obesity, insulin resistance and type 2 diabetes (Langin 2006). 
Adipocyte size is an important determinant of adipocyte function (Tchemof et al.
2006). Large adipocytes synthesize more triglycerides than smaller adipocytes and 
release more FF As through lipolytic pathways (Edens et al. 1993). Large adipocytes 
are more resistant to insulin induced glucose Metabolism , and large adipocyte size 
is an independent risk factor for the development of type 2 diabetes (Lofgren et al. 
2005).
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1.3 Lipolysis
Lipolysis is the chemical breakdown and release of fat from adipose tissue. The 
hydrolysis of one molecule of TG produces one molecule of glycerol and three 
molecules of non-esterified fatty acids (NEFAs) (Amer 2005). NEF As are then 
moved out of adipocytes either by passive diffusion, or are carried across the cell 
membrane by fatty acids transporters. Very little glycerol is re-utilized because 
adipocytes contain very low levels of the enzyme glycerol kinase (Langin 2006). 
NEFAs enter their common pool where they may be re-esterified, undergo 13- 
oxidation, or released into the circulation as substrates for tissues that can use them 
as an energy source i.e. the skeletal muscles, cardiac muscles, and liver. Long-chain 
NEFAs can enter the cells of these tissues by passive diffusion but transport proteins 
can increase transportation (Delame and Magnan 2007), and their rate of uptake is 
proportional to their difference in concentration inside and outside of the cell. Once 
inside the cells, the process of p-oxidation begins which is a series of biochemical 
and hormonal reactions that ultimately result in ATP production. Some physiological 
factors stimulate or inhibit AT lipolysis and lipid mobilization into the bloodstream 
and hormones tightly regulating the entire process (Figure 1.8).
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Figure 1.8: Illustration of the differences in normal human 
adipocyte lipolysis during fasting and fed state (Freudenrich 2000).
Fasting, feeding, exercise and stress have definite and rapid effects on lipolysis via 
hormones and other endogenous substances (Table 1.1). Some pathological factors 
such as inflammation, diabetes and obesity are associated with changes in lipolysis. 
Age and gender are also of importance.
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Table 1.1: Some physiological factors which affect lipolysis in humans. 
Adapted from (Chaves et al. 2011)
Ï Physiological 
factor
Effect on 
lipolysis
Regulating hormones
Age Decreases Reduction in SNS activity and 
catecholamines
: Gender Varies Sex hormones; regional deposit variations
Feeding Inhibits Increase in insulin inhibits HSL
Fasting Increases Increase in catecholamines and decrease 
in insulin
Exercise Increases Increase in catecholamines and decrease 
in insulin
1.4 Adipose Tissue Lipolysis Regulation
AT lipolysis involves the action of at least three adipocyte-specific enzymes. They
are: monoglyceride lipase (MGL), hormone sensitive lipase (HSL) and adipose
triglyceride lipase (ATGL) which remove the three F As of a TG molecule
sequentially (Frayn 2010). First, the TG molecule is hydrolyzed by two enzymes
ATGL and HSL producing a monoacylglycerol. MGL which is not under hormonal
control is essential in the final hydrolysis of the 2-monoacylglycerols produced
(Fredrikson et al. 1986). HSL is the key enzyme in lipolysis, which is regulated by a
series of metabolic processes in the cell, mediated by hormones and receptors in the
cell membranes. Despite the central role of HSL in adipocyte lipolysis, the available
evidence suggests that HSL is not the only hormone-responsive triglyceride lipase in
adipocytes, ATGL which was discovered recently (Zimmermann et al. 2004) also has
triglyceride-specific lipase activity (Kershaw et al. 2006). ATGL shares a large
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sequence homology with adiponutrin, a nutritionally regulated protein of unclear 
biological function. Kershaw et al (2006) reported that, adipose tissue expression of 
ATGL and adiponutrin are reciprocally regulated by nutritional status and by insulin 
in-vitro and in vivo. Further research, including in vivo gain and loss of function 
studies, is required to further explain the role of ATGL and adiponutrin in whole- 
body metabolism and to assess their possible role in disorders such as obesity and 
diabetes. Currently, this enzyme is under investigation by research groups around the 
world. There is some evidence in humans that HSL is the major lipase for 
catecholamine and natriuretic peptide stimulated lipolysis, whereas ATGL mediates 
TG hydrolysis during basal lipolysis (Langin et al. 2005).
1.5 Adrenoceptors and Lipolysis
The physiological role of the sympathetic nervous system (SNS) is a major target of 
research for both body weight and composition modulation. The major receptors in 
the adipocyte membrane are the adrenergic receptors, or adrenoceptors, which are 
members of the G-protein-coupled receptor family. Their most common feature is 
the long polypeptide chain that loops back and forth through the membrane seven 
times. This chain is physically and functionally linked to G-proteins within the cell 
(Bums et al. 1981). The key role players in the SNS are the hormones 
catecholamines and the adrenergic receptors (adrenoceptors) upon which they act.
Newsholm and Leech (1983) stated that, catechol is the dihydroxyphenol with two
adjacent hydroxyl groups. Derivatives with a side chain bearing an amino group are
known as catecholamines. Those of importance as neurotransmitters are dopamine,
noradrenaline and adrenaline also called epinephrine and norepinephrine.
Catecholamines are found in the central nervous system, peripheral nerves and the
41
adrenal medulla. Adrenaline and noradrenaline, are secreted by adreno-medullary 
secretory cells and both are stored in Chromaffin granules (Macdonald and Chaney
2007) . They serve as chemical neurotransmitters for nerve impulse transmission. In 
terms of the catecholamines the human adrenal medulla produces and releases about 
80% adrenaline and 20% noradrenaline. The adrenal is the source of essentially all 
the adrenaline produced in the body, whereas the majority of noradrenaline is 
produced by sympathetic postganglionic fibers (Newsholm and Leech 1983). Both 
are secreted in response to fright, stress, exercise, cold and low levels of blood 
glucose and trauma. Under these conditions, the release is controlled mainly by the 
nervous system (Champe et al. 1987).
Chemically, the two compounds differ only slightly; and they exert similar 
pharmacological actions, which resemble the effects of stimulation of the 
sympathetic nervous system. Both serve as the first messengers by binding to the 
adrenoceptors and stimulating the cascade system. The signal transduction depends 
on the type of adrenoceptor both adrenaline and noradrenaline vary in their affinities 
for adrenergic receptor types (a and P). Noradrenaline binds primarily with a l and 
pi receptors located near postganglionic sympathetic-fibre terminals. Adrenaline 
interacts with the same receptors as noradrenaline, but adrenaline has greater affinity 
to ai-receptors compared to noradrenaline. Adrenaline is relatively nonspecific, 
stimulating a2, pi and p2 adrenoceptors more or less equally. Both hormones have 
the same potency towards pi receptors which is why both show the same effects in 
many tissues.
In contrast, noradrenaline exerts mainly a activity, although it does stimulate the p 
receptor to a lesser degree. Also, as mentioned, noradrenaline acts as a
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neurotransmitter in the brain too, playing a role in alertness, arousal and reward 
pathways (Goldstein et al. 2003). Adrenaline has a direct effect on energy mtabolism 
by its rapid mobilization of energy-yielding fuels i.e. glucose (produced by 
glycogenolysis or gluconeogenesis in the liver) and free fatty acids (produced by 
lipolysis of triacylglycerol in the adipose tissue).
Human adipocytes have two types of adrenoeceptors, alpha a- and beta P- 
adrenoceptors (Bums et al. 1981). These are further sub-typed depending on 
stmcture, pharmacological response and second messenger. The a:, Pi, P2 and p3 
adrenoceptors are present in human AT and play a key role in lipolysis; they share 
the same second messenger, cyclic adenosine monophosphate (cAMP) (Figure 1.9). 
The ai adrenoceptor is also present in small amounts and its second messenger is the 
calcium or phosphatidylinositol messenger and has less significance in lipolysis. The 
heterogeneity of the adrenoceptors on the adipocyte offers a dual control of lipolysis 
by differential recmitment by the catecholamines (Mauriege et al. 1987) based on 
their relative affinity for the different subtypes. Lipolysis is facilitated primarily by 
the three beta-adrenoceptors (pi, p2 and ps respectively). Stimulation of the ai- 
adrenoceptor is anti-lipolytic i.e. its activation inhibits lipolysis within the cell 
(Lafontan and Berlan 1995).
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Figure 1.9: Adrenoceptors in the adipocyte. Cyclic AMP (cAMP), 
stimulatory Gs Protein (Gs), inhibitory Gi proteins (Gi), Hormone 
sensitive lipase (HSL), Monoacylglycerol lipase (MGL), Protein kinase 
A (PKA), Phosphate (+P) and Triacylglycerol (TG). Adapted from Volk 
(1998).
The G-coupled protein adrenoceptors, link with G-proteins just inside the cell 
membrane. The G-proteins consist of three subunits with different binding and 
characteristic effects. This is commonly called the G-protein effector system. When 
either of the catecholamines binds to an adrenoceptor on the adipocyte, it causes a 
conformational change that activates one or more of these G-protein subunits. 
Specificity of the hormonal response is regulated by one of the subunits coupling to 
different effector molecules within the cell. This specific coupling activates a 
cascade of signals within the cell leading to a physiological response. The two 
families of the G-proteins that are involved with control of lipolysis are stimulatory 
Gs and inhibitory Gi proteins, p-adrenoceptors couple with the Gs protein and thereby
activate adenylyl cyclase (AC), the key enzyme which produces cAMP. This will
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activate protein kinase-A (PKA) leading to phosphorylation of HSL and thereby 
increase lipolysis i.e. breakdown of TGs (Amer et al. 1988). Phosphorylation of 
HSL by PKA is accompanied by the translocation of HSL from the adipocyte cytosol 
to the surface of the lipid droplet and also by phosphorylation of perilipin (Frayn et 
al. 2003). Perilipin is a protein that coats the lipid droplet in adipocytes and protects 
it from the cell lipases, such as HSL. In 1991, Greenberg et al. found that rat 
epididymal adipocytes contain a prominent phosphoprotein which was specific for 
adipocytes, and it was called perilipin. Following p-adrenergic receptor activation, 
perilipin is hyper-phosphorylated by PKA and phosphorylated perilipin changes 
conformation, exposing the stored lipids to HSL-mediated lipolysis (Clifford et al. 
2000). Although PKA also phosphorylates HSL, which can increase its activity, the 
more than 50-fold increase in fat mobilization is primarily due to perilipin 
phosphorylation (Kershaw et al. 2006). Immunocytochemical studies with specific 
antisemm shows that the perilipin is closely associated with the periphery of lipid 
storage droplets in cultured adipocytes. Given its adipocyte specificity, acute 
regulation by hormones, and subcellular location, it has been speculated that perilipin 
plays a role in the specialized lipid storage function of adipocytes (Granneman and 
Moore 2008). Sztalryd et al (2003) demonstrated that in the absence of expression of 
fully phosphorylated perilipin-A, translocation of HSL fails.
Mottagui-Tabar et al. (2003) studied human subcutaneous fat cells of obese and non- 
obese women, and found that the perilipin protein content decreased significantly by 
50% in adipocytes of the obese women. In subjects matched for BMI and fat-cell 
volume, a high rate of lipolysis was associated with a low adipocyte content of 
perilipin. Adipocyte content of perilipin was inversely correlated with the circulating
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concentrations of glycerol and NEFA. Perilipin seems important for the regulation of 
lipolysis in human fat cells and could be a factor behind impaired lipolysis in insulin- 
resistant conditions. More than a 50-fold increase in fat mobilisation stimulated by 
adrenaline is primarily due to perilipin phosphorylation (Holm 2003).
Activation of the ai-adrenoceptor diminishes the production of cAMP by its 
inhibition of AC. The exact mechanism of this inhibition is not clearly understood. 
Several theories have been presented; the currently accepted one is that there is 
dissociation of the subunits of the proteins from the Gi-protein complex, thereby 
inhibiting further transduction of the signal to AC which decreases the production of 
cAMP and leads to a de-phosphorylation of HSL which will decrease lipolysis 
(Smith and Wood 1992, Limbard et al. 1995). Insulin and the catecholamines are the 
main regulatory hormones of lipid mobilization (Bums et al. 1981). Insulin inhibits 
HSL by promoting the dephosphorylation and, hence, inactivation of the enzyme 
(Champe et al. 1987) (Figure 1.10).
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Figure 1.10: Hormonal regulation of triacylglycerol (TAG) degradation in 
adipocyte. Adenosine diphosphate (ADP), Adenosine triphosphate (ATP), cyclic 
adenosine monophosphate (cAMP), hormone sensitive lipase (HSL), phosphate 
(P) and protein kinase A (PKA). Adapted from (Champe et al. 1987).
1.6 Insulin in Lipid Metabolism
Adipose tissue is an important site of insulin-stimulated glucose uptake (Amer 
2005). Although insulin is an important hormone for regulating glucose mtabolism, it 
is also a key hormone regulating lipid mtabolism (Figure 1.11).
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Figure 1.11: The regulation of metabolism by insulin in the liver, adipocyte and 
muscle cells. Green arrows illustrate the direction of processes facilitated by 
insulin; red arrows illustrate the direction in the absence of insulin. Black 
arrows show non-insulin dependent processes. (Saltier and Kahn 2001).
In adipose tissue, insulin stimulates lipogenesis i.e. fat storage (from glucose 
providing the substrate glycerol 3-phosphate for TG synthesis) and decreases the 
level of circulating fatty acids by inhibiting the activity of HSL (inactivation of the 
enzyme possibly by dephosphorylation), thus inhibiting lipolysis of TGs to glycerol 
and NEFAs (McTeman et al. 2002) . Insulin also enhances the formation of NEFAs 
from glucose in the liver.
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Figure 1.12 demonstrates that, in the fed state, plasma glucose levels rises 
stimulating insulin release from the pancreas. Circulating insulin activates the 
enzymes acetyl-CoA carboxylase and fatty acid synthase by inducing their 
phosphorylation. Insulin enables entry of glucose into the adipocytes via induction of 
glucose transporter activity. In the adipocyte, glucose is metabolized to glycerol 3- 
phosphate. Insulin stimulates the estérification process within the adipocyte, where 
three NEFA chains combine with a glycerol molecule to form TG. The primary 
action of insulin as an antilipolytic hormone involves dephosphorylation of HSL, 
which deactivates the enzyme and decreases production of cAMP which in turn 
results in an inhibition of eAMP-dependent PKA. This is a very potent and rapid 
effect, it responds to a relatively low concentration of insulin and occurs within
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minutes of raising the insulin concentration (Frayn 2010). This suppression of 
lipolysis lowers the rate of NEFA delivery to the liver and to peripheral tissues. The 
consequence of reduced NEFA delivery to the liver is a reduction in ketoacids 
production and TG synthesis. Insulin also stimulates the use of ketoacids by 
peripheral tissues, preventing an accumulation of these acids in the blood. Therefore, 
insulin not only promotes fat storage but it also restricts fat mobilization.
Adipocytes are very sensitive to the antilipolytic action of insulin. Insulin binds to 
tyrosine kinase receptors on adipocytes causing tyrosine phosphorylation and thus 
activation of insulin receptors as shown in Figure 1.13. Interactions with signal 
proteins ‘Insulin like Receptor Substrate’ (IRS-1 and IRS-2) activates the 
phosphadityl inositol 3-kinase complex leading to phosphorylation and activation of 
phosphodiesterase 3A (Degerman et al. 1998). Phosphodiesterase 3A catalyses 
cAMP breakdown to inactive 5’AMP so that the level of cAMP is decreased which 
leads to inactivation of protein kinase A and HSL.
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1.7 Adipose Tissue Insulin Resistance
Figure 1.14 below summarises insulin action and impairment due to the presence of 
insulin resistance in different sites. The defective ability of insulin to inhibit lipolysis 
in insulin resistant AT leads to an increased NEFA release. In addition, decreased 
glucose uptake in the AT may also contribute to elevated serum NEFA levels. This is 
explained by a blunted conversion of glucose to TGs with later intracellular NEFA 
accumulation (Virtanen et al. 2003).
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Figure 1.14: Insulin action and impairment due to the presence of insulin 
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Engfeldt et al (1988) found that chronic insulin exposure inhibited the lipolytic 
response to a p-adrenergic agonist in cultured adipocytes. Insulin exposure may 
cause a specific interaction with p- but not ai-adrenoceptors in human fat cells. It 
has been shown to reduce P-adrenoceptor number without changing the affinity of 
the p-adrenoceptor.
As reported by Benjamin and Clayton (1978), and observed by Greenberg et al 
(1991) insulin increases the incorporation of radioactive phosphate into perilipin. 
However, further studies are necessary to determine if the insulin effect represents 
increased phosphate content or increased turnover of phosphate at the constitutive 
site secondary to phosphatase activation. It is clear that these various hormone- 
stimulated phosphorylation changes underlie an important regulatory role for 
perilipin in adipocyte metabolic processes (Greenberg et al. 1991).
1.8 Caveolln
Adipose tissue lipolysis is a complex phenomenon involving not only enzymes and
hormones but also some proteins associated with the lipid droplets (Brasaemle et al.
2004). These include structural proteins, lipid modifying enzymes and proteins
which regulate enzyme activities (Londos et al. 1999). In 1968 Bums and Palade
described a morphological investigation of the endothelial cell membrane .They
identified and named plasmalemmal vesicles which appeared to transport molecules
into and out of the cell. Later, the term caveolae was used by Yamada in 1968 to
describe a small cave, pocket or vesicle communicating with the outside of the cell in
the gallbladder epithelium. The term caveolae then became synonymous with the
terms “flask-shaped” or “omega-shaped” specialised regions of the cell membrane
most commonly found in terminally differentiated cells (Figure 1.15). They range
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from 50 to 100 nm in size (Cohen et al. 2004). Caveolin was the first structural 
transmembrane protein discovered for caveolae (Rothberg et al. 1992), then when 
this specialized membrane domain was purified, it was found that caveolae contain a 
variety of signal transduction molecules. In addition to the protein caveolin, it was 
discovered that caveolae also contain a variety of signal transduction molecules 
which includes G protein-coupled receptors, G proteins and AC, molecules involved 
in the regulation of intracellular calcium homeostasis, and their effectors including 
the endothelial isoform of nitric oxide synthase, multiple components of the tyrosine 
kinase-mitogen-activated protein kinase pathway, and numerous lipid signalling 
molecules (Shaul and Anderson 1998).
a
Figure 1.15: Caveolae and caveolin-1 in the mature adipocyte. Cholesterol 
{yellow symbols), glycosphingolipids {green symbols), perilipin {green 
circles), adipose differentiation-related protein (blue triangle) and tail 
interacting protein-47 PAT domain-containing proteins (pink squares). 
Adapted from Garg and Agarwal (2008).
Caveolin exists as three subtypes, caveolin-1, 2 and 3. They are highly expressed in 
tissues such as the endothelium, adipose tissue and muscles. The role of caveolin-1
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has been demonstrated using caveolin-1 null mice (Cohen 2004). It was observed 
that caveolin-1 null mice have attenuated lipolysis in their white adipose tissue. 
During fasting they failed to show the normal increase in serum NEFA. Results from 
this study indicated that caveolin-1 is necessary for PKA phosphorylation as well as 
PKA-mediated phosphorylation of perilipin, and thus contributes to increased 
lipolysis. Therefore, caveolin-1 plays a dual role in lipid droplet mtabolism, affecting 
both lipid droplet accumulation and breakdown. Loss of caveolin-1 leads to a 
decrease in lipid accumulation and consequently, adipose tissue atrophy. Cohen et al. 
(2004) also showed that caveolin-1 null mice were also insulin resistant due to a 
-90% decrease in insulin receptor expression in adipose tissue. Figure 1.15 also 
describes a mechanism illustrated by (Garg and Agarwal 2008) where Caveolae are 
formed from lipid rafts on the cell surface, which include cholesterol, 
glycosphingolipids, and caveolin-1. Caveolae can be endocytosed and can form 
caveolin-1-containing vesicles. Caveolin-1 has also been found to be associated with 
lipid droplets in adipocytes. However, whether caveolin-1-containing vesicles 
directly merge with lipid droplets or caveolin-1 is incorporated directly within the 
endoplasmic reticulum (ER) during formation of lipid droplet still remains unclear. 
Shown also on the lipid droplets in Figure 1.14 are various PAT (perilipin, adipose 
differentiation-related protein, tail interacting protein-47) domain-containing proteins 
that decorate the lipid droplet.
Clifford et al. (2000) compared adipocyte lipolysis with HSL/perilipin subcellular 
distribution and perilipin phosphorylation. Under basal conditions, HSL resided 
predominantly in the cytosol and un-phosphorylated perilipin upon the lipid droplet. 
Upon lipolytic stimulation of adipocytes isolated from young rats with the p-
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adrenergic agonist, isoproterenol, HSL translocated from the cytosol to the lipid 
droplet, but there was no movement of perilipin from the droplet to the cytosol; 
however, perilipin phosphorylation was observed. By contrast, upon lipolytic 
stimulation and perilipin phosphorylation in cells from more mature rats, there was 
no HSL translocation but a significant movement of perilipin away from the lipid 
droplet. Adipocytes from younger rats had markedly greater rates of lipolysis than 
those from the older rats. Thus high rates of lipolysis require translocation of HSL to 
the lipid droplet and translocation of HSL and perilipin can occur independently of 
each other. A loss of the ability to translocate HSL to the lipid droplet probably 
contributes to the diminished lipolytic response to catecholamines with age. 
(Mottagui-Tabar et al. 2003) studied human subcutaneous fat cells of obese and non- 
obese women, they found that the perilipin protein content significantly decreased 
50% in adipocytes of the obese women. In subjects matched for body mass index and 
fat-cell volume, a high rate of lipolysis was associated with a low adipocyte content 
of perilipin. Adipocyte content of perilipin was inversely correlated with the 
circulating concentrations of glycerol and NEFA. Perilipin seems important for the 
regulation of lipolysis in human fat cells and could be a factor behind impaired 
lipolysis in insulin-resistant conditions.
1.9 Autocrine, Paracrine and Endocrine Role of Adipose Tissue
As mentioned before, adipose tissue produces adipokines which has autocrine, 
paracrine and endocrine activity. This activity influences many aspects of mtabolism. 
In obesity, adipose tissue has an increased production of most adipokines which has 
impacts on multiple physiological functions such as appetite and energy balance.
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immunity, insulin sensitivity, angiogenesis, blood pressure, lipid mtabolism and 
haemostasis, all of which are linked with cardiovascular disease (Ronti et al. 2006)
1.9.1 Leptin
In 1994 Friedman and colleagues showed that a single gene mutation leading to 
obesity was in a gene coding for a previously unknown protein, now known as leptin 
(from the Greek leptose, thin) and is highly expressed in WAT (Frayn 2010b). Leptin 
is produced primarily by differentiated adipocytes and exerts its influence on the 
central nervous system (CNS), suppressing energy intake (by reducing appetite i.e. 
anorexogenie) and stimulating energy expenditure (Munzberg 2010). The larger an 
adipocyte, the more leptin it produces, consequently, the more adipocytes present in 
the body the more leptin is produced. When obese mice {ob/ob mice) were injected 
with leptin (produced by bacterial DNA recombinant) their food intake was reduced 
and their energy expenditure was increased, and they became lean. Leptin was 
initially identified as an anti-obesity hormone, acting as a negative feedback 
adiposity signal to control energy homeostasis by interacting with its receptors in the 
hypothalamus (Bjorbaek et al. 1998). Leptin reduces intracellular lipid levels in 
skeletal muscle, liver and pancreatic beta cells, thereby improving insulin sensitivity 
(Ronti et al. 2006). Consequently, leptin was suggested as an obesity treatment, but 
conversely, obese individuals often have increased leptin concentrations (Rosicka et 
al. 2003). The high leptin levels associated with obesity are thought to be caused by 
leptin resistance, similar to the high insulin levels in type 2 diabetic patients are a 
consequence of insulin resistance. Leptin resistance may occur at several levels, 
including impaired transport of leptin across the blood brain barrier, reduced function
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of the leptin receptor, and defects in leptin signal transduction (Frayn 2010b) (Figure 
1.16).
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Figure 1.16: (a) Leptin inhibits lipogenesis. (b) Lipid mobilisation is 
stimulated by leptin. Adapted from (Marcelin and Chua 2010).
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1.9.2 Other Adipokines
The discovery of leptin has led to great progress in adipose tissue research signifying 
a more active role for the adipocyte in energy regulation. Besides leptin, however, 
the adipose tissue also secretes other proteins such as angiotensinogen, adipsin, 
acylation-stimulating protein (ASP), adiponectin, retinol-binding protein (RBP), 
tumour necrosis factor (TNF-a), interleukin 6, (IL-6) and plasminogen activator 
inhibitor-l(PAI-l). Some of these proteins are inflammatory cytokines, some play a 
role in lipid mtabolism, while others are involved in vascular haemostasis or the 
complement system (i.e. the innate immune system, the ability of antibodies and 
phagocytic cells to clear pathogens from an organism) (Trayhum and Beattie 2001). 
Some of them influence peripheral fuel storage, mobilization and oxidation, as well 
as energy homeostasis (Mohamed-Ali et al. 1998). Enhanced activity of the TNF-a 
and IL-6 are involved in the development of obesity-related insulin resistance (Ronti 
et al. 2006).
Adiponectin is an important adipokine, specifically secreted by adipocytes, that 
circulates at relatively high levels in the bloodstream (Goldstein and Scalia 2004). 
Increasing attention has been paid to the direct vascular effects of adiponectin, which 
exhibits potent anti-inflammatory and anti-atherosclerotic effects and insulin- 
sensitizing effects in glucose and lipid mtabolism (Goldstein and Scalia 2004). In 
humans, recent studies have demonstrated that the adiponectin level is a good 
predictor of developing type 2 diabetes and coronary artery disease (Arita et al. 1999 
and Weyer 2001). Decreasing levels of adiponectin are caused by the interaction 
between genetic factors, such as single nucleotide polymorphisms in the adiponectin 
gene, and environmental factors, such as high-fat diet. Adipocyte-derived
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adiponectin is insulin-sensitizing and it is (at least in physiological concentrations) 
insulin sparing as it stimulates p-oxidation of fatty acids in skeletal muscle (Ronti et 
al. 2006). Replenishment of adiponectin levels in animal models reversed insulin 
resistance (Yamauchi et al. 2001). Researches which are studying agents that 
increases the blood level of adiponectin or enhance the actions of adiponectin is a 
growing field of research in medicine for insulin resistance and type 2 diabetes 
treatment. In addition to its insulin-sensitizing effects in tissues involved in glucose 
and lipid mtabolism, adiponectin exhibits potent anti-inflammatory, anti- 
atherosclerotic and athero-protective responses in vascular tissue. Thus, the reduced 
circulating levels of adiponectin in visceral adiposity are now known to contribute 
not only to insulin resistance and dysglycemia, but also to the endothelial vascular 
dysfunction that is characteristic of the metabolic syndrome (Hara et al. 2005). In 
contrast to the dramatic increase in plasma levels of several of the adipokines 
observed in visceral adiposity, the plasma levels of adiponectin are markedly 
reduced. Thus, adiponectin levels correlate negatively with percent body fat, central 
fat distribution, fasting plasma insulin, and oral glucose tolerance and positively with 
glucose disposal during euglycaemic insulin clamp (Goldstein and Scalia 2004). 
Resistin is an adipose tissue-specific factor which is reported to induce insulin 
resistance, linking diabetes to obesity (Trayhum and Beattie 2001). In addition to the 
regulation of energy mtabolism, adipose tissue also influences steroid conversion and 
sexual maturation (Turgeon et al. 2006). Figure 1.17 demonstrates the suggested 
association between overproduction of adipocyte-derived factors and 
pathophysiological changes and complications (Fmhbeck et al. 2001).
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Figure 1.17: Overproduction of adipocyte-derived factors and associated 
pathophysiological complications. (Frühbeck et al. 2001)
1.10 Lipoprotein Lipase
Several proteins which play an important role in lipid and lipoprotein mtabolism are 
released from adipose tissue (Trayhum and Beattie 2001). The earliest recognised 
protein secretory product of adipocyte was the enzyme lipoprotein lipase.
Lipoprotein lipase LPL was first described in humans by Havel and Gordon (1960) 
in post heparin plasma from patients with severe forms of genetic hyperlipidemia
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who were unable to clear chylomicrons (CMs) from the bloodstream. CMs are the 
lowest density lipoproteins which transport dietary cholesterol and TGs from the 
intestine to the liver and other tissues. This finding established the crucial 
requirement of LPL in CM catabolism. The key to this observation was the use of 
CMs to assess lipolytic activity. Consequently, later studies using artificial emulsions 
discovered that LPL-deficient patients had significant TG lipolytic activity in their 
post heparin plasma; this led to the discovery of hepatic lipase (HL). Brunzell et al. 
(1973) followed patients with elevated TG levels and showed that elevations of 
VLDL resulted in chylomicronemia, an observation that led to LPL’s activity 
importance. Human LPL is a glycoprotein enzyme with a molecular weight of 61 
kDa (Ikeda et al. 2002). LPL is synthesized in parenchymal cells (e.g. adipocytes and 
muscle fibres) and then secreted and translocated to functional binding sites on the 
luminal side of the capillary endothelial cells (Frayn 2010). There, it is non- 
covalently bound to highly negatively charged glycosaminoglycan chains, such as 
heparin sulphate. This interaction can be blocked by heparin.
The endothelium-bound enzyme catalyses the hydrolysis of TG-rich lipoprotein 
particles. The exogenous dietary TGs are packaged into CMs by the intestine, whilst 
endogenously synthesised TGs are secreted by the liver as VLDL particles. Both 
classes of lipoprotein are hydrolysed by LPL to produce NEFAs which may be taken 
up into tissues for re-esterification and storage in adipose tissue (Nilsson-Ehle et al. 
1980) or oxidation for energy in muscle tissue or released bound to albumin (Braun 
and Severson 1992). This can happen only if the particles contain apo-lipoprotein 
Cn (apo CII). Shrinking of the particle core of CMs by lipolysis leaves excess 
surface residues, which break off as disks of emerging high-density lipoprotein
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(HDL). These newly formed particles acquire cholesteryl ester (CE) via lecithin- 
cholesterol acyltransferase reaction, becoming spherical HDL particles (Figure 1.18).
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Figure 1.18: hydrolysis of triglyceride (TG) in chylomicrons (CM) and by 
endothelial lipoprotein lipase (LPL) in presence of apoproteins (apoA, B, C 
and E) to produce monoglyceride (MG) and free fatty acids (FFA). FFA are 
taken up by tissue or released into circulation where they to albumin (ALB). 
Nascent high-density lipoprotein (HDL) acquires cholesteryl ester (CF) using 
lecithin-cholesterol acyltransferase (LCAT) to form spherical HDL particles.
Therefore, LPL plays a major role in fat accumulation and distribution (Ferrara et al. 
2002) and has a central role in the mtabolism of both TG-rich particles (CM and 
VLDL) and HDL, and it is one determinant of both serum TG and HDL 
concentrations (Merkel 2002). LPL is considered the rate limiting enzyme in TG -  
rich lipoprotein mtabolism. LPL can be assayed in both post heparin plasma (PHP) 
(Henderson et al. 1993) and tissues (Ceme et al. 2007). LPL exhibit different levels 
of activity (and consequently the TG storage into the adipose tissue) depending on 
several factors (Table 1.2).
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Table 1.2: Physiological factors that affect LPL activity. Adapted (Frayn, 
2010b)
Age LPL Activity decreases with age
Nutritional LPL activity decreases during fasting and rises in the fed 
status state
Gender LPL activity in females during fertile life is higher and 
tends to accumulate fat favorably in the femoral region 
compared to the abdominal, which is difficult to mobilize.
Pathology LPL activity is decreased in insulin resistance and type 2 
diabetics, the mechanism is unclear
Hormones Insulin stimulates LPL of adipose tissue and inhibits LPL 
of muscle.
Catecholamines, growth hormone and testosterone inhibit 
LPL activity
Also, different hormones regulate LPL synthesis and activity. Insulin stimulates the 
synthesis and activity of LPL in AT over a relatively long time (a few hours). In 
muscle insulin slightly suppresses LPL activity but its activity is increased by 
exercise (Frayn 2010). Catecholamines, growth hormone and testosterone inhibit 
LPL (Braun and Severson 1992). Differences in LPL activity partially account for 
regulation of AT distribution in various sites. This may partly explain the typical 
diversity in AT deposition in regional deposits and between the two genders (e.g. 
upper body versus lower body, visceral versus subcutaneous deposits). Deficiency in 
LPL plays an important role in hyperlipidemia in several clinical conditions; the 
most common one is poorly controlled diabetes (Simsolo et al 1992). Figure 1.19 
shows the LPL control in AT and muscles. LPL activity is decreased in insulin 
resistance and type 2 diabetics. The mechanism is unclear.
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1.11 Hepatic Lipase
Hepatic lipase (HL) is a glycoprotein enzyme which belongs together with LPL to 
the same family as pancreatic lipase, the principal enzyme of intestinal fat digestion 
(Frayn 2010). Human HL has a molecular mass around 65 kDa (Perret et al. 2002). 
It is synthesized by hepatocytes (liver cells) and found localized at the surface of 
liver sinusoid capillaries; it is also expressed in the adrenals and ovaries. In humans, 
HL is mostly bound onto heparin sulphate proteoglycans at the surface of 
hepatocytes and also of sinusoid endothelial cells. It is structurally related to LPL but 
has different characteristics and it does not require apo CII for activity. HL has 
significant phospholipase as well as TG lipase activity and more affinity to smaller
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lipoprotein particles such as low density lipoprotein (LDL) and high density 
lipoprotein (HDL) (Lewis et al. 2004). Peinado-Onsurbe et al. (1992) suggested that 
synthesis and post-translational processing of both enzymes are under separate 
control in the neonatal rat liver. Deeb et al. (2003) found that high HL activity is 
associated with small, dense LDL particles and with reduced HDL2 (large HDL) 
cholesterol levels. In addition, they found that HL activity is lower in premenopausal 
women, and is increased by visceral obesity with insulin resistance. HL activity is 
also affected by dietary fat intake (Campos et al. 1995) and certain medications 
(Chatteqee and Sparks 2011). Cell cholesterol content and hormonal status regulate 
HL activity (Lambert et al. 2000). Dyslipidemia with high HL activity is a 
potentially proatherogenic lipoprotein profile in the metabolic syndrome, in Type 2 
diabetes, and in familial combined hyperlipidemia.
1.12 Type 2 Diabetes
The major characteristics of type 2 diabetes are insulin resistance and pancreatic p- 
cell dysfunction. Insulin resistance is marked by defects in glucose transport into 
muscle and AT and overproduction of glucose by the liver (Saltiel and Kahn 2001). 
In AT from type 2 diabetic subjects, defective glucose transport has been shown to 
result from a reduced complement of insulin-stimulated glucose transporter GLUT4 
in intracellular pools as well as reduced translocation of GLUT4 cells to the plasma 
membrane (Ciaraldi et al, 2002).
The aim of treating diabetes is to help patients to achieve good control of their blood 
glucose level and minimise the risk of developing diabetic complications. Oral 
hypoglycaemic agents (OHA) are prescribed for patients if lifestyle changes are not
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effective at lowering blood glucose levels. There are several different types of oral 
hypoglycaemic agents used to treat type-2 diabetes, which work by different 
mechanisms. For example sulphonylureas directly stimulate insulin release whereas 
metformin enhances peripheral glucose uptake and reduces hepatic glucose output 
(Pickup and Williams 1991). Type-2 diabetes tends to get worse over time - it is 
usually necessary to increase the dose of OHA, add new treatments or combine 
different types of OHAs. When normal fasting blood glucose values cannot be 
obtained with a combination of OHAs, glycaemic control can be achieved by using a 
long-acting insulin preparation. The UK Prospective Diabetes Study (UKPDS) 
showed that intensive control of blood glucose, using sulphonylurea or insulin - and, 
for overweight people, metformin - could reduce the risk of diabetic complications 
substantially (Holman et al 2008). In addition, the UKPDS showed that type-2 
diabetes is characterised by a constant decrease in pancreatic beta cell function with 
time, which leads to increasing hyperglycaemia even with OHA. To compensate for 
this, most people with type-2 diabetes will eventually need insulin therapy.
1.13 Insulin Treatment in Type 2 Diabetes
In normal physiology insulin is released from the pancreas into the portal circulation 
which flows directly to the liver. The liver extracts up to 60% of the insulin 
delivered to it with the remainder dispersed into the systemic circulation. In 
consequence hepatocytes are exposed to insulin concentrations 3-4 times higher than 
the other major targets for insulin (adipose tissue and muscle). Insulin therapy is 
delivered in the periphery i.e. into a subcutaneous depot and is absorbed into the 
systemic circulation through which it is distributed in approximately equal 
concentrations throughout the body. The normal portal/peripheral insulin gradient is
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lost resulting in a relative peripheral hyperinsulinaemia. Peripheral 
hyperinsulinaemia may lead to abnormalities in adipocyte mtabolism which could 
then cause weight gain. This is illustrated in Figure 1.20 below.
The normal physiological role of insulin
Peripheral
Insulin
The therapeutic role of insulin injections
Figure 1.20: The physiological difference between normal insulin 
distribution and distribution with therapeutic insulin injection.
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1.14 NPH Insulin
Delaying insulin absorption was done primarily by adding zinc and/or protamine to 
stabilise insulin hexamers. Neutral protamine hagedom (NPH) insulin was the first 
effective type of insulin capable of prolonging the effect of the insulin. Protamine 
insulin is a combination of protamine -  a fish protein -  and insulin. The extension of 
the insulin action was chiefly to lessen the insulin’s solubility at neutral tissue fluid 
pH. Proteolytic enzymes break down the protein when injected subeutaneously, 
allowing for the insulin to be absorbed. Peak of action of NPH insulin action is 
around 3-8 hours after injection, with duration of 14±3 hours. Day to day variation of 
absorption can be affected by factors such as dosage size, volume injected, 
concentration of insulin and changes in blood flow to the tissue surrounding the area 
of injection (Hordern et al. 2005). Two injections of NPH insulin are required daily 
to attain insulin cover for 24 hours. Injecting before bed may lead to over 
insulinisation in the middle of the night, meaning a higher risk of hypoglycaemia and 
insufficient residual insulin levels, causing fasting hyperglycaemia (Lepore et. al. 
2000). Variability of effects is worsened more so due to irregularities in re­
suspension prior to injection (Havelund et al. 2004). Recently, insulin analogues 
have been altered to increase the desired molecular properties without affecting 
immunogenicity (Heller et al. 2007). The European Medicines Agency (EMEA) 
approved insulin lispro, the first insulin analogue, in 1996 and was also given 
approval by the Food and Drug Administration (FDA) in June 1996. Insulin lispro 
can be rapidly absorbed fi*om subcutaneous tissue and possesses an increased 
dissociation rate-constant. The prandial peaks of insulin secretion of ordinary 
physiology can be imitated when it is given before meals. Two different categories of
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insulin analogues exist today: rapid acting insulin analogues (insulin lispro, insulin 
aspart and insulin glulisine) and long acting insulin analogues (insulin glargine and 
insulin detemir).
1.15 Insulin Detemir
Insulin detemir is similar to human insulin. It is soluble, with a 14-carbon fatty acyl 
group. It is linked to the lysine at position B29, and the B30 tyrosine is removed ( 
Havelund et al. 2004). The molecular change is required to give detemir a high 
affinity for albumin to prolong its biological effects and has been reported to be 98% 
bound to albumin in circulation (Plank et al. 2005). The fatty acid residue is 
associated with the FFA binding sites on albumin in interstitial fluid and plasma ( 
Kurtzhals et al. 1995). The action period is up to 24 hours. If two doses of insulin 
detemir are taken twice daily, steady state will occur after 2 to 3 doses. For doses in 
the interval of 0.2-0.4U/kg, detemir uses more than 50% of its maximum effect from 
3-4 hours and up to approximately 14 hours after dose administration. Maximum 
concentration of the insulin is achieved between 6 and 8 hours after administration. 
As shown in Figure 1.20, in healthy subjects insulin is released from the pancreas in 
to the hepatic portal vein so that the liver is exposed to a much higher concentrations 
of insulin than peripheral tissues. When insulin is administered subeutaneously in 
diabetic patients, this situation is reversed with peripheral tissues being exposed to 
higher concentrations of insulin than liver. Figure 1.21 shows the most common 
insulin regimens used to treat diabetes and their onset, peak and duration.
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Insulin Onset Peak Duration
Aspart, lispro, glulisine 10-15 mins 60-90 mins 4-5 hrs
Regular 30-60 mins 2-4 hrs 5-8 hrs
NPH 1-3 hrs 5-8 hrs 12-18 hrs
Detemir (Levemir) 90 mins Relativelypeakless 12-24 hrs
Glargine (Lantus) 90 mins Peakless 24 hrs
Aspart^ lispro, glulisine
Regular
NPH
"5
V
e
3wG
Detemir
Glargine
n
E
rt
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2 4 6 8 12 14 180 20 22 2410
Hours
Figure 1.21: The most common insulin regimens used to treat diabetes. 
Adapted from (Tonyolac et al. 2010).
The mechanisms behind the weight-sparing effect of insulin detemir are still 
unidentified. Reduced risk of hypoglycaemia with insulin detemir, coupled with a 
more consistent and reliable delivery of the required dose than is available with 
traditional basal insulin, such as NPH, has been proposed to minimise protective 
snacking by patients, and may help to limit weight gain (Hermansen and Davies
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2007). However, there is little evidence for this and even if this was proven, it would 
be unlikely to fully explain the weight-sparing effect of insulin detemir.
Figure 1.22 shows an illustration of suggested mechanisms of different insulin 
treatments. A study in healthy subjects suggested that when compared to an 
equipotent dose of NPH, detemir had a greater effect on glucose mtabolism in the 
liver than in peripheral tissues (muscles and adipose) (Hordern et al. 2005). This 
reduced effect of insulin detemir on peripheral tissues was confirmed by the fact that 
it was less effective in reducing NEFA concentrations than NPH. This suggests that 
detemir may be hepatoseleetive. Detemir may have the potential to restore the 
physiological insulin gradient, which may be an alternative explanation for the 
reduced weight gain.
R apid A nalog  (m o n o m e r)  P eak  T im e: 
1 -2  H ours  _
Insulin  G largine
(h o u rs )
Insulin D etem ir
In su lin  D e tem ir
0  3  6  9  12  15  18  21  24
Figure 1.22: Illustration of suggested absorption of different insulin 
treatments. UK Diabetes 2009.
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1.16 Study Aims
1. To develop sensitive and reproducible methods to measure a) basal lipolysis 
rate, b) rates of isoproterenol and adrenaline stimulated lipolysis c) rates of 
insulin-inhibited lipolysis in AT biopsies.
2. To develop methods to measure, LPL activity and mass and lipolysis in 
healthy subjects and subjects with type 2 diabetes.
3. To develop methods for cell size measurements.
4. To compare between SCAT and OMAT cell size and lipolysis in patients 
with type 2 diabetes with non-diabetic participants.
5. To apply the developed methods in patients with type 2 diabetes in a study 
of NPH versus insulin detemir.
Aim 5 forms part of a larger project examining the physiology that underpins the 
clinical observation of reduced weight gain with insulin detemir.
1.17 Hypothesis
a) For aim 4, lipolysis will be higher in OMAT than SCAT in subjects with type 
2 diabetes and non-diabetic subjects. In both fat depots adipocyte size and 
lipolysis will be higher in T2D than non-diabetic subjects.
b) Insulin detemir may have a lesser effect than NPH insulin on peripheral 
tissues; this may lead to lower LPL activity and higher lipolysis. This could 
lead to less weight gain. In order to investigate this hypothesis the effect of 
treatment with insulin detemir on adipocyte physiology was studied.
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CHAPTER TWO: METHOD DEVELOPMENT
2.1 Validation of the Methodology to Measure Human AT 
Metabolism
This chapter explains the validation of the methodology to measure human adipose 
tissue mtabolism. This includes adipose tissue digestion and adipocytes isolation, 
mature adipocyte measurements (count and size), LPL mass and activity 
determination of adipose tissue biopsies.
2.1.1 Materials
Unless otherwise stated the chemical materials used in this work were obtained from 
Sigma-Aldrich Ltd (Gillingham, Dorset, UK), Fisher Scientific UK Ltd 
(Loughborough, Leicestershire, UK), Bio-Rad Laboratories (Richmond, CA, USA) 
and BDH Laboratories Supplies (Poole, England).
For each experiment an intra-assay and inter-assay coefficient of variation (CV) was 
determined. CV values of < 10% were considered aeeeptable.
2.1.2 Source of AT Samples
Until ethical approval for this study was obtained from the Surrey Research Ethics 
Committee and the University of Surrey Ethics Committee (Appendix 1.2), 
epididymal fat pads were obtained from rats, mice and guinea pigs (which had been 
left over from other animal studies). They were used to establish the methodology in 
the laboratory.
When the Ethics Committees approved the protocols, human adipose tissue samples 
were used. Subjects were recruited through the elective surgery schedule of the
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surgery unit at the RSCH. Males and females > 1 8  years of age were included; 
pregnant women and any subject with mental incapacity, unwillingness or a language 
barrier precluding adequate understanding or co-operation were excluded.
If the subjects were suitable, then the investigator met them the day before the 
surgery. Subjects who agreed to participate were required to sign and date an 
informed consent form (Appendix 3). All subjects were provided with a copy of the 
patient information sheet (Appendix 4) and of their own signed and dated informed 
consent form. Another copy of the consent form was kept in their medical file and 
the surgeon and surgical team were informed to take the fat biopsy during surgery. 
All subjects were fasted overnight prior to surgery. .Five grams of omental adipose 
tissue (OMAT) and 5 grams of subcutaneous adipose tissue (SCAT) were collected 
at the site of surgical incision (Figure 2.1). The sampling site was kept the same for 
all participants. The samples were immediately carried to the laboratory in a Krebs- 
Ringer-Bicarbonate buffer solution (KRB) (Appendix 5) pH 7.4 and kept at 37°C. 
All solutions were prepared using deionized water and all apparatus used for this 
procedure was thoroughly cleaned. The KRB can be prepared several days in 
advance and stored at room temperature.
Adipose tissue digestion and adipocyte isolation were performed with a portion of 
the fresh biopsy. The remaining tissue was immediately frozen in liquid nitrogen and 
stored at -80°C for lipoprotein lipase activity measurements.
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Figure 2.1: Freshly extracted (~5 g) human visceral adipose tissue from 
elective abdominal surgery, washed with and kept in KRB solution at 
room temperature ready for laboratory processing.
All measurements were in triplicate to establish the reproducibility of each test on the 
day. The lipolysis results of each experiment (on the same day) were used to 
calculate the intra-assay CV to examine the method’s reproducibility in different cell 
isolation preparations. It was not possible to estimate inter-assay (on different days) 
CV as the adipose tissue samples had to be prepared freshly on the day of the 
measurements.
2.1.3 Adipose Tissue Digestion and Adipocyte Isolation
Adipocyte isolation was performed immediately using a modified version of the
Rodbell’s method (Boivin et al. 2007). Fresh tissue samples were cut into small
pieces with very sharp scissors and tissue tearing was avoided to preserve the
adipocytes. The paste like tissue was digested to separate adipocytes from stromal
cells and collagen fibres by treatment in a shaking water bath (Stuart, Barloworld
Scientific) with 200 strokes/ min at 37°C for 45-60 minutes with collagenase in KRB
solution supplied with 5% FFA free bovine serum albumin (BSA). The adipocyte
dense suspension was filtered through a nylon mesh (300 micron, monofilament
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filter cloth, (Cadisch Precision Mesh Ltd) to eliminate any debris. The adipocyte 
suspensions were washed 3 times with KRB, by floating to eliminate blood and 
collagenase (McTeman et al. 2002). At the last wash, the suspension was 
centrifuged, (Jouan BR4i multifunction centrifuge. Thermo Electron Corporation) at 
500 rpm (1400 g) at 25°C for 2 min. The infranatant was discarded and only the thick 
adipocyte suspension was used. Any oil layer which appeared on the top of the 
adipocyte suspension was aspirated with a pipette and discarded. The adipocyte 
suspension was then diluted (500 pi of cell suspension in 2.5 ml of buffer). To get a 
good homogeneous suspension, the diluted adipocyte suspension was placed in a 
plastic tube with a tiny magnetic flea (Spin-bar, Sigma) on a stirrer (Mini MRl BS2, 
IKA Labortechnik) at fixed low speed for all experiments.
2.1.4 Collagenase Type Validation
Three different types of collagenase Typel from Worthington Biochemical Corp. 
(S5K8219, 47N9985 and 46S9287, Lakewood, California, USA), were investigated 
for their ability to release viable adipocytes, initially from rat epididymal fat pads, 
then from human adipose tissue. The effect of collagenase digestion on the 
morphological characteristics and metabolic activity of adipocytes was examined. 
Figure 3 shows that, collagenase 46S9287 was the best collagenase to use compared 
with S5K8219 and 47N9985 due to the highest stimulated lipolysis activity at the 
same concentration of isoproterenol. This was repeated in triplicates and the intra­
assay CV was 3.4%.
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Figure 2.2: Validation of different types of collagenase (Worthington) at
0.5 mg/ml, on in-vitro isoproterenol-stimulated lipolysis (10'^-10'^ mol/1) 
in freshly isolated mature human adipocytes in the presence of adenosine 
deaminase. Results are presented as means of triplicates ±SEM.
2.1.5 Collagenase Concentration Validation
Three different concentrations of collagenase Type 1/46S9287 were validated; 2 
mg/ml, 1 mg/ml and 0.5 mg/ml in KRB solution with 5% fatty acid free bovine 
serum albumin (BSA). Figure 2.3 shows that higher collagenase concentration (2 
mg/ml) appears to cause adipocyte destruction, which was clearly observed from the 
increased oily droplets released on the top of the adipocyte floating layer, and the CV 
of the assay which was 14%. A comparison between 1 mg/ml and 0.5 mg/ml showed 
that the latter was the best concentration to use due to the lower basal and higher 
stimulated lipolytic activity at the same concentration of isoproterenol (p=0.04). The 
CV of this assay was 1.6%.
78
s
I
■o
i
Ia
I
500 n
200  -
150 -
100
-9 -8 -7 -6
Isoproterenol cone. (Log[M])
- ^ 2  mg/ml -B—1 mg/ml -A—0.5 mg/ml
Figure 2.3: Validation of the effect of different collagenase concentrations 
(2, 1 and 0.5 mg/ml) on adipose tissue digestion, evaluated by measuring 
glycerol release of in-vitro isoproterenol-stimulated lipolysis (10'^-10'^ 
mol/1) in freshly isolated mature human adipocytes. Results are presented as 
means of triplicates ±SEM.
2.1.6 Adipocyte Measurements
In initial experiments, adipocytes were isolated from rat epididymal pads and 
injected into a glass haemacytometer (improved Neubauer, HAWKSLEY Medical 
and Laboratory Equipment, Lancing, Sussex, UK) (Figure 2.4 and Figure 2.5). For 
human adipocyte samples, it was difficult to inject the cell suspension into the glass 
haemocytometer. It gave a non-homogeneous distribution, which affected the 
accuracy of cell measurements.
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Figure 2.4: Improved Neubauer glass haemaeytometer. Hawksky 
Medical and Laboratory Equipment, Lancing, Sussex, UK.
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Figure 2.5: Sizing and counting lOpl suspension of isolated mature 
rat epididymal adipocytes (stained with oil red O, using an improved 
Neubauer glass haemacytometer and microscope with Tucsen 
software).
An alternative method, plastic fast read 102 counting chambers (Immune Systems 
Ltd, UK) as therefore used for cell measurements (Figure 2.6). A sample of ~10 pi of 
human adipocyte suspension was homogeneously distributed into the counting 
chamber.
§
Figure 2.6: Plastic fast read 102 counting chambers (Immune Systems Ltd).
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The number of adipocytes per chamber was variable from person to person due to the 
variability in adipocyte size. Adipocytes have 95% lipid content and are spherical in 
shape therefore their size can be estimated from the diameter. For precise cell size 
measurements, mature adipocyte suspensions were visualized using a contrast 
microscope attached to a camera (Tucsen microscope camera, Fuzhou Tuesen 
Imaging Technology Co. Ltd. China) and computer interface. This produced a 
permanent visual photomicrographie record that could be analysed using TS view Cx 
Image Application software (Tucsen Imaging Technology Co. Ltd. China). A 
calibration was performed previously. Using the line tool, the diameters of 
adipocytes in the chamber were manually drawn and individually measured and 
counted (Figure 2.7). Cells <35 pm diameter were excluded because they were 
immature multilocular adipocytes (Tchoukalova et al. 2008). The digital images of 
cell suspensions were imported and analysed, where the output of the measured 
diameters was transferred to an Excel programme (Microsoft Windows 2003, USA).
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Figure 2.7: Freshly isolated human adipocytes using Plastic fast 
read 102 counting chambers, at magnification (160x).
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The mean diameters and standard error of means were calculated and histograms 
were created (Figure 2.8). The intra-assay CV value of the cell counting procedure 
was 1.6%, and for cell sizing was 5.4 % (n=10).
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Figure 2.8: A histogram of freshly isolated mature human adipocytes 
measurements in one subject, total cell count in the sample =247 cells /lO 
pi. Results are presented as % of mature adipocyte size range of the total 
cell count.
2.1.7 Adipocyte Staining
For an enhanced view, several modified cell staining techniques were investigated
i.e. Oil Red O, trypan blue and methylene blue.
2.1.7.1 Oil Red O
Oil Red O, (saturated 0.25-0.5 % in isopropanol) was diluted with distilled water 3:2 
(v/v). Then, the solution was allowed to stand for 5-10 min and filtered with a 
micropore filter (Minisart plus, Millex Millipore, Livingston, UK) to eliminate any 
impurities. Four drops of Oil Red O solution were placed in a small plastic vial. In 
another vial, 4 drops of Mayers Haemalum were placed to stain the nuclei. With a
8 2
pipette, 200pl of adipocyte suspension were placed into the two vials containing the 
stains and left for 10 min. Then ~10pl of stained cell suspension was injected into a 
haemocytometer to be viewed under the microscope. Lipid droplets appeared as a 
bright red colour and the nuclei as a distinct blue colour (Figure 2.9).
m
€
Figure 2.9: Freshly isolated human adipocytes using 
Rodbell’s method, stained with Oil red O, at 
magnification (160x).
2.1.7.2 Trypan Blue
Trypan blue is a dye that is used to estimate the viability of the cell. Living cells 
exclude the dye, whereas dead cells will take up the blue dye. The blue stain is easily 
visible, and cells can be counted using a light microscope. The exposure of cells to 
trypan blue for a period longer than 30 min was avoided due to trypan toxicity which 
may lead to cell death. 0.4% (w/v) of trypan blue solution was prepared in KRB 
solution. One hundred pi of the cell suspension was placed in a screw cap test tube 
and 20 pi of trypan blue solution was added, mixed well, and allowed to stand for 5 
min at room temperature. Then -10 pi of stained cell suspension was injected into a 
haemocytometer to be viewed under the microscope (Figure 2.10).
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Figure 2.10: Freshly isolated mature human adipocytes 
stained with Trypan blue, at magnification (160x).
2.1.7.3 Methylene Blue
Methylene blue is used for staining cell nuclei. It has a relatively low toxicity. 0.02 g 
of methylene blue powder was dissolved in a solution of 10 ml of 2% BSA and 
filtered using a micropore filter. A sample of 50-150 pi from the cell suspension was 
placed in a screw cap test tube; 450pl of methylene blue solution was added, mixed 
well, and incubated for 10-15 min at 37°C. The mixture was allowed to stand for 5 
min at room temperature then -10 pi of stained cell suspension were injected into the 
haemocytometer to be viewed under a microscope (Figure 2.11).
Figure 2.11: Freshly isolated mature human adipocytes stained 
with Methylene blue, at magnification (160x).
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2.1.8 In-vitro Lpolysis of Freshly Isolated Adipocytes
Lipolytic activity of the isolated adipocytes was tested using two stimulating lipolytic 
agents, B-adrenergic receptor agonist isoproterenol (Isoproterenol hydrochloride, 
16504, Sigma) and adrenaline (Epinephrine hydrochloride, E4642, Sigma). Insulin 
(Actrapid, Biosynthetic human insulin 100 lU/ml, Novo Nordisk limited, Denmark) 
was used as an anti-lipolytic agent, all with and without the presence of adenosine 
deaminase (Type IX: from calf spleen. Sigma). Addition of 5 pi of 2 pg/ml 
adenosine deaminase eliminates traces of adenosine, which may interfere with the 
antilipolytic effects that are mediated through adrenergic receptors and insulin in the 
current incubation medium (Lofgren et al. 2005).
Lipolysis experiments were conducted by incubating 100 pi of the homogenous 
suspension of isolated adipocytes in KRB with 5% (BSA) solution into labelled 
plastic tubes (LP4, Fisher Scientific, Leicestershire, UK) in a gentle shaking water 
bath with 100 strokes/minute at 37°C for 90 min with and without:
5 pi of B-adrenergic receptor agonist isoproterenol at 10'  ^to 10'  ^mol/1, with 5 pi of 2 
pg/ml adenosine deaminase (Appendix 6) in the presence and absence of 5 pi of 10'  ^
mol/1 human insulin.
5 pi adrenaline at 10'  ^to 10'  ^mol/1 with 5 pi of 2 pg/ml adenosine deaminase in the 
presence and absence of 5 pi of 10'  ^mol/1 human insulin. (Appendix 7).
After 90 min, the reaction was stopped by putting all tubes on ice for 10 min 
(Visentin et al. 2003). Then 30 pi of the infranatant were taken for glycerol assay to 
determine the lipolytic index, taking extra care to avoid the fat cells residues on the 
surface.
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Initially, adipocytes from rat epididymal pads were used to establish the method. 
Then, human adipocytes from patients undergoing elective abdominal surgery were 
tested. To ensure reproducibility, the same experimental conditions were established 
for all experiments, i.e. the same type and concentration of collagenase, buffer, 
temperature and time. Subsequently, adipose tissue metabolic activity was measured 
in samples from patients with type 2 diabetes.
2.1.8.1 Measurement of Glycerol Release as an Index of Lipolysis
Glycerol release was used as an index of lipolysis. It is well identified that, the
hydrolysis of one molecule of triglyceride produces one molecule of glycerol and
three molecules of fatty acids. Some fatty acids are re-utilized by the fat cells, mostly
as re-esterification to new triglycerides whereas, very little glycerol is re-utilized
because adipocytes contain very low levels of glycerol kinase (Langin 2006).
Initially, the glycerol concentration was measured in the cell-free infranatant using
ABX Mira Plus analyser (Roche diagnostic Ltd. UK) using the assay kit glycerol
colorimetric method (Randox Laboratories, UK). This kit is intended to be used for
the quantitative in-vitro determination of glycerol in serum and plasma and is
successfully used in Diabetes and Metabolic Medicine laboratories. It is a
colorimetric procedure utilizing a quinoneimine chromogen system in the presence
of glycerol kinase, peroxidase and glycerol phosphate oxidase. For this study, this
method was found not sensitive enough to detect the glycerol released in the media
from the stimulated lipolysis in isolated adipocyte suspension. The glycerol readings
were unstable and much lower than controls. The normal concentration of glycerol in
plasma is 70 pmol/1. In this experiment, it was found that glycerol concentration in
deionised water was 10 pmol/1, in saline was 11 pmol/1 and in plasma samples it was
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83 pmol/1, in control samples it was 660 pm ol/l,whereas in the cell free adipocyte 
infranatant sample was 13 pmol/L
Subsequently, another method of bioluminescence was tested to detect glycerol 
release in the cell free infranatant. This assay is a nicotinamide adenine dinucleotide- 
linked bacterial luciferase assay (Kather et al. 1982 and Tchemof et al. 2006). This 
technique was found to be not feasible because the luminometer was not sensitive 
enough for this assay. In addition, this method uses sodium arsenate, a highly toxic 
substance, which is essential to make one of the key enzymatic reactions irreversible. 
This made it difficult to try other luminometers in other laboratories in the university 
because of the danger of arsenate contamination.
An alternative method was successfully validated to measure glycerol concentration 
using the free glycerol determination kit (FGOlOO, Sigma) and a glycerol standard 
solution (G7793, Sigma) (Gauthier et al. 2008). In this method, free glycerol is 
measured using coupled enzyme reactions (Figure 2.12). Glycerol is phosphorylated 
by adenosine-5’-triphosphate forming glycerol-1-phosphate and adenosine- 5’- 
diphosphate in the reaction catalysed by glycerol kinase. Glycerol-1-phosphate is 
then oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate and 
hydrogen peroxide. Peroxidase catalyses the coupling of H2O2 with 4- 
aminoantipyrine and sodium 7V-ethyl-A-(3-sulfopropyl) m-anisidine to produce a 
quinoneimine dye that shows an absorbance maximum at 540 nm. The increase in 
absorbance at 540 nm is directly proportional to the free glycerol concentration of the 
sample.
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Figure 2.12: Glycerol Assay Enzymatic Reactions. (ATP: Adenosine-5 
triphosphate, GK: glycerol kinase, G-l-P: glycerol-1-phosphate, ADP: 
adenosine- 5’-diphosphate, GPO: glycerol phosphate oxidase, DAP: 
dihydroxyacetone phosphate, 4-AAP: 4-aminoantipyrine, ESPA: sodium 7V- 
ethyl-A-(3 -sulfopropyl) w-anisidine.
Glycerol measurement was undertaken in 96 clear well microplates (Nunc-Immuno™ 
Modules, Roskild, Denmark). A series of duplicate 30 pi of blanks (2% BSA, fatty 
acid free), glycerol standards and samples were set in a 96 well plate. Then, 200 pi of 
the free glycerol reagent was pipetted in each well. The microplate was gently 
shaken and left to stand at room temperature for 15 -20 min at 37°C. A 
spectrophotometer (OP Sys, Dynex Technologies Inc, Worthing, UK) was used to 
measure the absorbance at 540 nm. The read cycle time was < 10 seconds. 
Windows® Revelation Quick link"^  ^ software (Dynex Technologies Inc, Worthing, 
UK) was used to read the results.
Using this data, a standard curve was plotted (Figure 2.12). A glycerol standard 
curve was generated every time an assay was run. Each standard curve had a 
minimum of 4 data points, the CV of this assay was 5.3 %.
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Figure 2.13: Glycerol standard curve using free glycerol reagent and glycerol 
standard solution (Sigma) in a 96 well microplate and a spectrophotometer 
(OP Sys, Dynex Technologies Inc, UK) at 540 nm. The increase in 
absorbance is directly proportional to the free glycerol concentration of the 
sample.
The following equation was used to convert absorbance data obtained from the 
spectrophotometer into concentrations.
Glycerol content (ppmol) = (A b so rb a n e e ^ ^ ^ -  AbsorbancCy|^^ ) x 1000
Slope
This equation gives glycerol concentrations in pmoles, then data were normalised to 
cell number i.e. 1 0  ^cells or to the lipid content of 1 0 0  pi of adipocyte cell suspension
i.e. mg lipid during the incubation time (90 min). Basal lipolysis i.e. spontaneous 
glycerol release can be used to convert concentrations to glycerol release expressed 
as fold over basal (by dividing concentration values of stimulated lipolysis with the 
concentration value of basal lipolysis).
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2.1.8.2 Measurements of Total Lipid Content
As mentioned before adipocytes have 95% lipid, the lipid content per mg of adipose 
tissue is an important method to express the lipolytic activity of adipocytes. This was 
determined using Dole’s method for lipid extraction for each experiment. This will 
be presented later in this chapter.
There is a diversity of methodologies for lipid extraction and determination because 
biological tissues are diverse when considering their structure, texture, sensitivities 
and lipid contents. In the Diabetes and Metabolic Medicine department laboratory 
the use of the Folch method has been validated and used frequently for lipid 
extraction in plasma samples. The Dole extraction method was used to determine 
lipid content in other adipose tissue studies (Sengenès et al. 2000). Determination of 
the total lipid content is crucial to normalise the lipolysis measurement values of 
glycerol release in adipocyte cell suspension as well as the enzyme activity in 
adipose tissue samples. The choice of lipid extraction method in both adipose tissue 
biopsies and adipocyte cell suspension needs to be validated to obtain reliable results. 
Therefore, two basic procedures, Foleh (Folch et al., 1957) and Dole (Dole and 
Meinertz 1960) extraction methods have been validated in both adipocyte suspension 
and adipose tissue biopsies. The small amount of extracted lipids and the highly 
sensitive methods required the use of very pure solvents and clean glassware. Also, 
all lipids have been protected against degradation due to oxidation by solvent, 
oxygen, enzymes, temperature and light. Therefore, for solvent evaporation a gentle 
stream of oxygen free nitrogen (OFN) (NitroFlow® basic mobile, Parker Filtration 
and Separation, The Netherland) was used all the time.
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The total lipid content present in the adipocyte cell suspension (used in in-vitro 
lipolysis experiments) was measured for each sample. Lipids from 100 pi adipocyte 
suspension were extracted overnight with a 4-fold volume of ice-cold chloroform- 
methanol solution 2:1 (vol %) at 4°C. Then samples were centrifuged (Jouan BR4i 
multifunction centrifuge, Thermo Electron Corporation, Waltham, Massachusetts, 
USA) at low speed (2000 x g) for 5 min at 25°C to separate the solvent from the 
aqueous layer. The infranatant was transferred to a pre-weighed clean sample tube 
using a glass Pasteur pipette. The supernatant was re-extracted with a further 2-fold 
volume of ice-cold chloroform-methanol 2:1 (vol: vol) at 4°C for at least 1 hour and 
again centrifuged at (2000 x g) at 4°C for 30 mins. The solvent extracts were then 
combined. A quarter of the volume of all the solvent extracts used to extract the 
lipids of potassium chloride (0 .8 8 % w/vol %) was then added to the solvent 
extraction and the sample was re-centrifuged at 4°C (2000 x g) for 30 mins. The 
aqueous layer was discarded and 1 0 0  pi of ethanol was added to the solvent phase. 
The solvent was evaporated using a gentle stream of OFN. The weight of the lipid 
extracted in mg was obtained from the weight of tubes before and after lipid 
extraction. The CV value of this assay was 15.35% which is considered non- 
satisfactory (> 10%). Due to the high variability in the Folch method, it was 
necessary to try another reliable method. The Dole extraction method has been 
frequently used in adipose tissue research (Lafontan et al. 2008). The Dole extraction 
reagent consists of isopropanol (40 ml), heptane (10 ml) and IM H2SO4 (1 ml). For a 
measured volume of adipocyte suspension, a 2  ml glass tube was used and heptane ( 1  
ml), water (1 ml) and Dole extraction reagent (1 ml) were added. The mixture was 
vortexed vigorously for 2 min and left for 5 min for the two layers to settle and
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separate. From the top layer, 800 pi was placed in a pre-weighed clean glass tube and 
left to dry under a gentle stream of OFN. The extracted lipid was weighed and 
recorded. The value of the CV of this assay was satisfactory (2.12 %). In addition, it 
has been observed after extraction that Dole extraction method has produced much 
higher fat yield than Folch’s method of extraction, from the same volume and source 
of adipocyte homogenous suspension sample.
2.1.8.3 Lipolysis Data Normalization
Data normalization is a critical factor to obtain sensitive and reproducible results and
in results interpretation. There are different ways to normalise and express lipolysis
results, the results can be normalised by either the cell count (glycerol release in
pmol/1 0  ^ cells/ time of incubation) or the lipid content of the sample (glycerol
release in pmol/mg lipid/time of incubation). Cell protein concentration is a very
common way for normalization but it is not suitable in this experiment, because the
vast majority of the protein in a typical adipocyte suspension is contributed by the
BSA added to protect the cells, whereas the protein contributed by the cells will be a
small fraction of the total protein present. Therefore, the most efficacious ways to
normalize lipolysis data is by either cell number or lipid content. Despite
methodological variations and different ways of expressing data, previous studies on
lipolysis have been remarkably equivocal (Carpéné et al. 1999, Sengenes 2000,
Barakat et al. 2002, Lofgren 2002, Visentin et al. 2003, Tchemof et al. 2006 and
Viswanadha and Londos 2008)). In this study the results were normalised by cell
count obtained from 10 pi of cell suspension (glycerol release in pmol/10^ cells/ 90
min). They were also normalised by the lipid content of a 1 mg of wet adipose tissue
sample/ 90 min. Coefficient of variation was used to determine variability between
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data of the two ways of expression. It has been found that variability using lipid 
content is less than the per cell count (50% and 80% respectively), the mean was 
estimated with the greater level of precision. Lipolytic stimulation and inhibition 
were also expressed as fold of stimulation over basal and decrease of inhibition under 
stimulated.
2.1.9 Lipoprotein Lipase Activity and Mass Measurements in 
Adipose Tissue Samples
Initially, rat epididymal pads also were used to establish this method. Then, human 
adipose tissue biopsies from patients undergoing elective abdominal surgery were 
used. To ensure reproducibility, the same experimental conditions were established 
for all experiments, i.e. the same tools, buffer, temperature and time. Successively, 
adipose tissue LPL activity was measured in samples from subjects with type 2 
diabetes on either insulin detemir or NPH.
2.1.9.1 Adipose Tissue Preparation and Homogenisation
First, the frozen tissue was weighed (wet weight in mg) then homogenised in order to 
solubilise all the LPL present in the tissue sample in combination with the presence 
of heparin in the medium. A glass homogeniser (Duall 20, Kontes Glass Co, Fisher 
Scientific UK Ltd, Leicestershire, UK) was used to break up the tissue physically. 
This kind of homogeniser is suitable for small sized of samples i.e. 50 mg tissue or 
less. All steps of homogenisation were undertaken on ice and using ice-cool 
homogenising buffer to prevent loss of any lipase activity. An eppendorf tube was 
weighed and about 50 mg of biopsy was added to the tube and the precise weight of 
tissue was recorded. I found that using an ice-cool glass homogeniser, to break up the
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sample inside the eppendorf tube with the gradual addition of ice-cool homogenising 
buffer to wash the glass apparatus is efficient in avoiding any loss of the sample. 
The appropriate amount of buffer was added (according to the recorded mass of the 
sample) for every 5 mg of tissue sample 100 pi of buffer was added (Ceme et al. 
2007). The homogenising buffer contained 100 mM Trizma base, 150 mM NaCl, 4 
mM KCl, 3 mM CaCl2 .2 H2 0 , 2 mM MgSO4 .7 H2 0 , 10 g/1 BSA, and 5 IU/1 heparin 
(heparin ammonium salt fi*om porcine intestinal mucosa. Sigma) at pH of 7.4 
adjusted with HCl. Once homogenised, the tubes were capped and incubated in a 
shaking water bath at 37°C for an hour. They were then centrifuged for 30 min at 
4000 X g at 4°C. The clear infranatant was immediately extracted for use in the assay 
and kept on ice to prevent any further loss of activity.
Initially, a continuous fiuorometric lipase test (Confiuolip Total Lipase Test Progen, 
Biotechnik GmbH, Germany) was used to measure lipoprotein lipase activity. This 
kit is successfully used to measure total lipase in plasma samples in the laboratory of 
Diabetes and Metabolic Medicine Department in University of Surrey, but it was not 
sensitive enough to measure total lipase activity in adipose tissue homogenate. This 
may be due to the small amount of the released lipase in tissue homogenate in 
presence of heparin in-vitro compared with in vivo post-heparin plasma. Another 
reliable assay was needed to be validated to measure lipase activity in tissue samples. 
An assay containing substrate emulsion and pre-hydrolysed substrate (Roar 
Biomedical LPL Activity assay kit. New York, USA) was used to measure lipase 
activity in tissue homogenate samples (Ceme et al. 2007). This measures total lipase 
activity by fluorescence intensity readings, in which the substrate emulsion 
fluoresces on hydrolysis in the presence of lipase enzymes.
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First, the pre-hydrolysed substrate (included in the assay kit) was used to standardise 
and calibrate the assay. This was repeated in eaeh assay preformed. The pre- 
hydrolysed substrate had a concentration of 75.7 pmoles/ml. Firstly a 1:2500 dilution 
was made followed by two 1:10 serial dilutions. One pi of each dilution of substrate 
was added to 200 pi of assay buffer. The assay buffer alone was used as a blank 
sample. They were placed in the 96 wells black plate (FIA-plate, black, flat bottom, 
medium binding, Greiner Bio-one, Neuburg, Germany) and the fluorescence was 
read in the fluorimeter (DTX880 multimode detector, Beckeman Coulter, Germany). 
The calibration plots were constructed using fluorescence unit (RFU) against 
concentration of the standards (pmol/1). The molecular fluorescence of the substrate 
emulsion is required for the calculation of the concentration of the unquenched 
substrate which accumulates over time. Molecular fluorescence of the unquenched 
product is the slope of the straight line obtained with the pre-hydrolysed standards. It 
can be calculated from the calibration curve using the difference of the fluorescence 
intensities RFU (Y2-Y1) and the difference of the corresponding standard 
concentration (X2-X1) values. The calculation is as follow:
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Figure 2.14: The standard curve of lipoprotein lipase activity 
measurement fluorescence assay (Roar Biomedical LPL Activity assay 
kit, New York, USA). Fluorescence was measured using 96 a well black 
plate in the fluorimeter (DTX880 multimode detector, Beckeman 
Coulter, Germany) at excitation 370 nm and emission 450 nm.
2.1.9.2 LPL Activity Measurement
Two pi of LPL substrate emulsion was diluted with 400 pi of assay buffer and 200 pi 
of this was incubated with the LPL preparation from the tissue samples. As each well 
required 2 0 0  pi of substrate emulsion, enough substrate was made according to the 
number of samples to be tested. The kinetic lipase assay started with addition of 20 
pi of each sample to the wells in a 96 well plate independently. Substrate emulsion 
( 2 0 0  pi) was then added to the wells with care using a multipipette and the plate was 
placed in the fluorimeter equipped with incubator at 37°C for 15 min. The plate was 
read at 370 nm excitation and 450 nm emission according to the kit manufacturer’s 
advice. Kinetic measurement started after 2-3 min and was measured for 6-10 min. 
The molecular fluorescence calculated from the standards and the released 
fluorescence over time from the substrate by the action of the lipase, were used to
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calculate lipase activity. Fluorescence of the substrate over time represents the slope 
of the linear curve. It is calculated from the difference between the corresponding 
time points. The unit will be RFU x m in '\ The lipase activity was calculated as the 
change in fluorescence/ change in time obtained from the kinetic measurement, and 
the molecular florescence constant obtained from the standard curve. Lipase activity 
unit will thus be pmolxml'^xmin'\ Enzyme activity is presented as relative activity 
normalized to wet tissue weight. Softmax Pro software (Molecular devices, 
Sunnyvale, California, USA) was used to set the wavelengths, and time readings. A 
human post heparin plasma sample (1:80 dilutions) was used as a quality control for 
this experiment and was run with each batch of test samples. The inter-assay and 
intra-assay CV values gained for this assay were 6.1% 5.5%, as both CV values were 
under 10%, they were deemed satisfactory. The increasing fluorescence of the 
samples was monitored every 5 min, to identify samples with unusual kinetic 
behaviour. All measurements were made in duplicate and paired samples (before and 
after treatment with detemir or NPH for the same subject) were always analysed in 
the same batch. Results were standardised to the amount of tissue and extraction 
buffer used. Enzyme activity was expressed in units of pmoles /mg tissue/min.
2.1.9.3 LPL Mass Measurements
An enzyme-linked immunosorbent assay (ELISA) kit was used to measure LPL mass
in tissue homogenates (Markit-M LPL assay kit, DS Pharma Biomedical Co., Ltd,
Tokyo, Japan). This assay uses microplate wells that are coated with the first anti-
LPL antibody (mouse). Samples or standards were pre-treated with stabiliser solution
and then added to the wells containing anti-LPL antibody. This was washed to
remove any excess LPL. A labelled anti-LPL antibody was then added to sandwich
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the bound LPL between the two antibodies, followed by another wash procedure.
Substrate was then added which caused the release of a chromatic product in 10 min
which was read by the microplate reader (SPECTRA max GEMINI XS Microplate
spectrofluorometer, Molecular Devices, Inc, Sunnyvale, USA) at 492 nm. Six
standards were provided in the assay kit (standard: 0, 25, 50, 100, 200, and 300), 0.5
ml of purified water was added to each of the standard vials and then mixed gently.
A substrate tablet (provided -  containing o-phenylenediamine dihydrochloride) was
added to the substrate diluent buffer and gently mixed. Wash buffer concentrate was
added to 900 ml of double distilled water. To obtain a standard curve for this assay,
25 pi of each standard was added to the microplate for dilution in duplicate and 100
pi of stabiliser solution was then added to the wells. Then 100 pi was taken from
each well and put in the LPL antibody-coated wells. The plate was agitated for 30
seconds and then incubated between 15-25° C for 30 min. Using 300 pi of wash
buffer the plate was washed 3 times and then 100 pi of LPL antibody-enzyme
conjugate was added to each well and agitation, incubation and washing was
repeated as before. Then 100 pi of substrate solution was added to each well and
incubated as before. The reaction was stopped using 100 pi of stop solution and then
agitated for 30 seconds. Using the microplate reader, absorbance was read at 492 nm
(as main wave length) and 620 nm (as a reference wave length). A standard curve
was plotted and used for calculating LPL mass in the tissue homogenates (Figure
2.15). A human post heparin plasma sample (1:80 dilutions) was used as a quality
control for this experiment. The intra-assay CV value detected for this assay was 2.5
%, which is deemed satisfactory. As the manufacturer has stopped production of this
kit due to high cost, there was only one kit available for use (only one plate
provided), it was not possible to repeat the measurements on other days to validate
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inter -assay measurements. Samples were obtained from tissue homogenates 
produced as the method described for LPL activity measurement. Samples were 
tested according to the manufacturer’s procedure and in the same way the standard 
curve was determined by replacing the standards with samples. LPL concentration 
was determined using the concentration corresponding to the absorbance on the 
standard curve, where the value directly indicated the concentration in ng/ml/mg wet 
tissue.
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Figure 2.15: The standard curve of the enzyme-linked immunosorbent assay 
kit, Markit-M LPL (DS Pharma Biomedical Co., Ltd, Japan) for LPL mass 
measurements. Absorbance of the microplate was read using (SPECTRA max 
GEMINI XS Microplate spectrofluorometer. Molecular Devices, Inc, 
Sunnyvale, USA) at 492.
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CHAPTER THREE: METHODS FOR LIPOLYSIS,
REGIONAL DIFFERENCES AND DIFFERENT INSULIN 
TREATMENT
3.1 Adipose Tissue Metabolism in OMAT and SCAT in 
Subjects with Type 2 Diabetes and Non- diabetic Subjects
In order to compare the differences in adipose tissue mtabolism in healthy
subjects and subjects with type 2  diabetes, subjects were recruited through the
elective surgery schedule of the surgery unit at the RSCH. Suitability of the
subjects was assessed first with their doctors based on the criteria shown in
(Table 3.1). All subjects were age and BMI matched. All methods which were
validated to study adipose tissue mtabolism in the previous chapter i.e.
adipocytes size and count, in-vitro lipolysis and LPL mass and activity were
applied in this study to investigate the differences between SCAT and OMAT in
healthy subjects and subjects with type 2  diabetes on oral hypoglycaemic agent
(T20H).
1 0 0
Table 3.1: The inclusion and exclusion criteria for comparison between 
SCAT and OMAT in healthy and participants with T20H.
Inclusion criteria
Subjects with the  following were included:
> Males and females > 18 years of age.
> Fasting blood glucose < 7 mmol/l for control group and > 7 
mmol/l for subjects with Type 2 diabetes on metformin.
> Normal blood pressure <140/90 mmHg.
Exclusion criteria
Subjects with the following were excluded:
> Type 2 diabetes trea ted  with, insulin, thiazolidinediones (TZDs), 
sulphonylureas, Gliptins, or thiazolidinediones.
> Impaired hepatic or renal functions.
> Clinical history of cardiovascular disease.
> Cancer (or undergoing chemo- or radiotherapy)
> Uncontrolled endocrine disease
> Hypertension > 140/90 mmHg and on any of the following 
trea tm ents  p-blockers, Fibrates
> Mental incapacity, unwillingness or a language barrier precluding 
adequate understanding or co-operation.
> Pregnancy and breast-feeding.
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3.2 Investigation of The Effect of Insulin Detemir on Adipose 
Tissue Metabolism in Patients With Type 2 Diabetes.
All methods which were validated to study adipose tissue mtabolism in the
previous chapter i.e. adipocytes size and count, in-vitro lipolysis and LPL mass
and activity were used in this study to investigate the effect of insulin detemir on
adipose tissue mtabolism in patients with type 2  diabetes.
3.2.1 Clinical Protocol
For the detemir study, the clinical research team in the Centre of Endocrinology 
and Diabetes Research (CEDAR) at the RSCH were responsible for recruitment 
of patients, screening, medical follow up and biopsies extraction. The author was 
responsible for the handling and analysis of the biopsies in the laboratory.
Before screening has taken place subjects have been provided with verbal and 
written information about the trial and the procedures involved. The subjects 
have been fully informed of their responsibilities and rights while participating 
in the trial, as well as of possible disadvantages in being treated with the trial 
products. They have been given the opportunity to ask questions and ample time 
to consider participation. Subjects who agreed to participate in the trial were 
required to sign and date an informed consent form prior to any trial-related 
activities taking place. All subjects have been provided with a copy of the 
patient information sheet (Appendix 8 ) and of their own signed and dated 
informed consent forms (Appendix 9).
The detemir clinical trial was a single-eentre, 24 weeks, randomised parallel 
group trial in 24 subjects. Table 3.2 shows the inclusion and exclusion criteria of 
the detemir study.
1 0 2
Table 3.2: The inclusion and exclusion criteria of participants in the 
detemir clinical trial.
Inclusion criteria
> Males > 18 years of age and postmenopausal females.
> BMI range 27-40.
> With Type 2 diabetes, HbAlc > 8.0%.
> Able and willing to  perform self-blood glucose monitoring.
> Able and willing to  maintain consistent eating habits 
throughout the entire trial period.
> Able and willing to maintain consistent physical activity level 
throughout the entire trial period.
Exclusion criteria
> Patients on sulphonylureas or thiazolidinediones.
> Impaired hepatic or renal functions.
> Cardiac problems.
> Uncontrolled hypertension (treated or untreated).
> Proliferative retinopathy tha t has required acute trea tm ent 
within the last six months.
> Mental incapacity, unwillingness or a language barrier 
precluding adequate understanding or co-operation.
All participants were on metformin and were already on treatment with long- 
acting or intermediate insulin treatment. Subjects who were on sulphonylureas or 
thiazolidinediones (giltazones) were excluded. Because treatment with 
sulphonylureas will promote insulin release from pancreatic p-cells (Frayn 
2010a) and treatment with thiazolidinediones which enhances AT insulin 
sensitivity causing increased AT ability to store excess fat as TG, thus
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circulating FA concentrations is reduced and muscle tissue can utilize more 
glucose because of reduced substrate competition (Frayn 2010a). Most patients 
with Type 2 diabetes in the UK are treated with twice daily insulin mixtures, a 
minority will be on basal bolus regimen. Subjects were assessed at base line. 
Then they received insulin treatment with twice daily NPH insulin + insulin 
aspart. After insulin dosage was optimised for 8  weeks (with set targets for 
fasting and pre-supper glucose levels) they were randomised by the clinical 
research doctor using a computer programme to receive either insulin detemir or 
continue with NPH insulin as basal insulin for a further 16 weeks. At the end of 
the 8  week optimisation period and at the end of the 16 week treatment period 
fat and blood biopsies were taken (Figure 3.1).
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Participants have been required to avoid alcohol consumption and vigorous exercise 
the night before the biopsies were taken. If the subject was felt unwell on the day the 
biopsies were due to be taken, they were rescheduled to a later date. After an 
overnight fast, one to two grams of subcutaneous abdominal adipose tissue biopsy 
were obtained from a 4 cm subcutaneous incision under ~5 ml local anaesthesia (2% 
Lidocain Hydrochloride 40 mg/2 ml, Hameln Pharmaceuticals Ltd, Gloucester, UK) 
in the lower back region. The biopsy specimens were placed and transported 
immediately to the laboratory in a vessel containing KRB solution pH 7.4 and kept at 
37°C to measure adipocyte size and the response of lipolysis to stimulation and 
inhibition. An additional 50 mg of subcutaneous adipose tissue was placed in a tube 
and immediately (snap) frozen in liquid nitrogen for LPL activity determination. All 
validated methods mentioned in chapter two were followed to undertake the AT 
measurements.
3.2.2 Plasma Metabolites Measurements
After an overnight fast blood biopsies were taken at the end of the 8  weeks 
optimisation period and at the end of the 16 weeks treatment period. Blood samples 
were obtained with sterile syringes and collected in sterile vacutainers containing 
different anticoagulants. Samples were mixed immediately by inverting the tubes 8 - 
10 times and kept on ice. Samples for plasma TG, NEFA and glycerol concentration 
were collected in tubes containing lithium heparin. All samples were centrifuged 
immediately, and plasma was separated at 2500 rpm (1440 x g) for 10 min at 4°C. All 
consumables and reagents/ chemicals in used in metabolites measurements were 
supplied by Alpha laboratories, UK unless otherwise stated for specific analysis.
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3.2.2.1 Measurements of Plasma TG
Plasma TG concentration was measured using an ABX Mira Plus analyser (Roche 
diagnostic Ltd. UK) using the enzymatic assay kit ABX Pentra Triglycerides CP 
(Horiba, ABX, Northampton, UK). The analysis was based on colorimetric method 
and the absorbance was measured biochromatically at 500 nm wavelength. The 
reagent included ATP, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate 
oxidase and peroxidase. Figure 3.2 shows the assay reaction.
TPT
TG + H2O--------- > Glycerol + Fattyacids
Glycerol + ATP — >Glycerol- 3 - phosphate + ADP
Glycerol-S-phosphate^O, Glycerol~3 - phosphateoxidase
2H2O2+4—AAP+p-Chlomphenol— >Quinoneimine + 4H2O2
Figure 3.2: The enzymatic reaction of the colorimetric assay ABX Pentra 
Triglycerides CP (Horiba, ABX, Northampton, UK) for serum TG 
measurements. (LPL: lipoprotein lipase, ATP: adenosine 5-triphosphate, 
ADP: adenosine 5-diphosphate, DHAP: dihydroxyacetone phosphate, 4-AAP: 
4-aminoantipyrine).
The colorimetric indicator quinoneimine was detected by colorimetry. The assay 
quality control (QC) included a low QC (mean concentration 1.18 mmol/l, range 
from 1.14 to 1.23 mmoFl) and a high QC (mean concentration 2.02 mmol/l, range 
from 1.98 to 2.06 mmol/l). These QCs were assayed after each calibration, the low 
QC and high QC intra-assay CVs were 6.65% and 6.83% respectively.
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3.2.2.2 Measurements of Plasma NEFA
Quantification of Plasma NEFA concentration was achieved by using an ABX Mira 
Plus analyser (Roche diagnostic Ltd. UK) using the enzymatic colorimetric assay kit, 
NEFA-HR(2) (Wako Chemicals GmbH, Germany). The principle of this assay 
depends on the conversion of NEFA in serum to the three compounds, Acyl-CoA, 
AMP and pyrophosphoric acid by the action of Acyl-CoA synthetase, under 
coexistence with coenzyme A and adenosine 5-triphosphate disodium salt. Oxidation 
of Acyl-CoA yields 2,3 -trans-enoyl-CoA and hydrogen peroxide by the action of 
Acyl-CoA oxidase. In the presence of peroxidase, the hydrogen peroxide formed 
yields a blue purple pigment by quantitative oxidation condensation with 3-Methyl- 
N-Ethyl-N-(E-Hydroxyethyl)-Aniline and 4-amino-antipyrine. Non-esterified fatty 
acids concentration is obtained by measuring absorbance of the blue purple colour by 
colorimetry at wavelength 550 nm. The assay QC (mean concentration 0.799 mmol/l, 
range from 0.788 to 0.794 mmol/l) was assayed after each calibration and the intra­
assay CV was 6.65%.
3.2.2.3 Measurements of Plasma Leptin and Adiponectin
Adiponectin was measured by radioimmunoassay (Millipore, Corp. Billerica, MA, 
USA). The Millipore Adiponectin RIA assay utilizes ^^^I-labelled Murine 
Adiponectin and a Multi-species Adiponectin Rabbit antiserum to determine the 
level of Adiponectin in the plasma by the double antibody/polyethylene glycol (PEG) 
technique. The Adiponectin Standard is prepared using recombinant human 
adiponectin and can be used to determine the circulating levels of adiponectin in 
human plasma samples. The kit contain a ready-made QC which was a purified 
recombinant adiponectin lyophilized for stability.
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3.2.2.4 Measurements of Plasma Glucose
Plasma glucose concentration was determined enzymatically using Trinder method 
wwith the presence of glucose oxidase (Kit ref: A11A01668; Horiba ABX, UK). The 
absorbance of the quinoneimine dye was quantified biochromatically at a wave 
length of 500 nm. Intra-assay CVs was for the QC.
3.2.2.5 Measurements of Plasma Insulin
Plasma insulin was measured by radioimmunoassay (RIA). It had four basic 
requirements:
1 . a specific antiserum to the antigen to be measured
2 . the availability of a radioactive labelled form of the antigen
3. a method whereby antibody-bound racer can be separated 
from the un-bound tracer, and
4. finally, the RIA to count radioactivity (Kit ref: HI-IAK;
Merck Millipore, MA, USA).
A standard curve was set up. The Millipore Human Insulin assay (Merck Millipore,
MA, USA) utilised 1251-labelled Human Insulin and Human Insulin antiserum to 
determine the level of insulin in plasma using the double antibody/PEG technique.
3.2.2.6 Measurements of HOMA
The Homeostasis Model Assessment (HOMA) estimates steady state p-cell function 
(%B) and insulin sensitivity (%S), as percentages of a normal reference population. 
The HOMA Calculator used in this measurements was downloaded from the 
University of Oxford website (Oxford 2004). The HOMA Calculator uses the 
H0MA2 model to estimate P-cell function (%B) and insulin sensitivity (%S) for an 
individual from simultaneously measured fasting plasma glucose and fasting plasma
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RIA insulin values. The H0MA2 model is calibrated to give %B and %S values of 
1 0 0 % in normal young subjects when using a suitable insulin assay.
3.3 Statistical Analysis
All results presented in the text, tables and figures as mean ± SEM unless otherwise 
stated. Paired t tests were used to compare between the two groups in their adipocyte 
size, LPL activity, and lipolysis activity. ANOVA was used when the Levene’s test 
(p<0.05) revealed unequal variance. All variable that were not normally distributed 
according to a significant Shapiro-Wilk test (p<0.05) were normalised and 
transformed for analysis when necessary using the Statistical Package for the Social 
Sciences (SPSS) version 19 (IBM Corporation, New York, USA). When normality 
could not be reached a non-parametric Wilcoxon test was used. A linear mixed 
model was run with tissue type (subcutaneous vs. omental), condition (healthy and 
T20H) and tissue*condition interactions as fixed effects and subject as a random 
effect using the statistic programme SAS 9.1.3 (SAS Institute Inc. North Carolina, 
USA) to look at the differences between the effect of different condition on the 
lipolytic measurements of different AT depots. All measurements were made in 
duplicate and paired samples (before and after treatment with detemir or NPH for the 
same subject) were always analysed in the same batch.
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CHAPTER FOUR: THE INVESTIGATION OF ADIPOSE TISSUE 
METABOLISM IN HEALTHY PARTICIPANTS AND 
PARTICIPANTS WITH TYPE 2 DIABETES ON ORAL 
HYPOGLYCAEMIC TREATMENT
Obesity, metabolic syndrome and type 2 diabetes are all characterised by insulin 
resistance and in most cases large intra-abdominal fat stores. Insulin resistance is 
associated with the dysregulation of adipose tissue (AT) mtabolism including a reduced 
effectiveness for insulin to suppress lipolysis.
Methods were developed to measure cell sizes, in vitro basal, stimulated and insulin 
inhibited lipolysis and lipoprotein lipase (LPL) activity in AT biopsies. These methods 
were then applied to invistigate the mtabolism of subcutaneous AT (SCAT) and 
omental AT (OMAT) biopsies from twelve participants, seven non-diabetic subjects and 
five patients with type 2 diabetes treated with metformin (T20H) undergoing elective 
abdominal surgery.
This chapter shows the results of this investigation. Lipolysis was expected to be 
higher in OMAT than SCAT in both groups. Also, adipocyte size was expected to be 
larger in T2D than non-diabetic participantss and their lipolytic activity was expected to 
be higher in both fat depots. LPL activity was expected to be higher than healthy 
participantss.
4.1 Results
Table 4.1 shows the characteristics of participants of the two groups. There was no 
significant difference in age or BMI between groups.
I l l
Table 4.1: Characteristics of participants of the two groups, healthy and 
withT20H(n=12).
Healthy T20H
Number of participantss 7 5
Female: Male (ratio) ............ ............... 2:3 "
Age 59 ±2.3 61 ±1.9
! BMI 29 ± 0.2 31 ±0.6
4.1.1 Cell Measurements
There was no significant difference in adipocyte count between SCAT and OMAT 
within each group or between the two groups (Table 4.2). But the size of the adipocytes 
from participants with T20H were significantly larger than adipocytes from healthy 
participants in both SCAT and OMAT, (p<0.001 and ^<0.05 respectively, ANOVA) 
(Figure 4.1). Within each group there was no significant difference between the 
adipocytes size in the two depots (Figure 4.2).
1 1 2
Table 4.2: Adipocyte count and diameter size in SCAT and OMAT fat depots in 
the two groups.
Healthy
n=7
T2 OH 
n=5
Significance
Mean SC adipocyte count per 
1 0  pi cell suspension
192 ±17.8 175 ±18 NS
Mean OM adipocyte count per 
1 0  pi cell suspension
193 ±17.7 171 ±31.4 NS
Mean SC adipocyte size (pm)
median
Range
130±18
115
[105-177]
240 ±22 
245 
[199-283]
;;<0 . 0 0 1
Mean OM adipocyte size (pm)
median
Range
153 ±18 
152 
[142-198]
225 ±22- 
209 
[195-264]
;?<0.05
Values presented as mean+SEM and analysed using ANOVA.
;?<0.05D<0.001
% 200
u 150
& 100
SCAT OMAT
□ Healthy T20H
Figure 4.1: Size measurements of freshly isolated mature adipocyte 
from both SCAT and OMAT in healthy participants: n=7 and patients 
with T20H: n=5. Results are mean ± SEM and analysed using 
ANOVA.
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Figure 4.2: Comparison of mean size of freshly isolated SC and 
OM adipocytes within each group. Healthy participants: n=7, 
patients with T20H: n=5. Results are mean ± SEM, differences 
between the two depots in the two groups (p<0.05, the linear mixed 
modle) NS: not significant.
4.1.2 I n  v i tr o  Lipolysis of Freshly Isolated Mature Adipocytes
Basal lipolysis is the unstimulated or spontaneous hydrolysis of the intracellular TG to 
FF A and glycerol. In this study, basal lipolysis was stimulated using isoproterenol (10" 
-^10"^  mol/1) and adrenaline (10" -^10"  ^ mol/1). Human insulin (10"  ^ mol/1) was used to 
examine the inhibitory effect of insulin on stimulated lipolysis. In this chapter, the 
results of the stimulatory effect of both isoproterenol and adrenaline on basal lipolysis 
was expressed as fold change over basal. While the inhibitory effect of insulin on 
stimulated lipolysis was expressed as decrease below stimulation. All values were 
proprtionate considering all single values of lipolysis results of all participants.
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4.1.3 Isoproterenol and Adrenaline
Both isoproterenol and adrenaline enhanced lipolysis, but lipolysis was inhibited as the 
concentration was increased (10'^ mol/1). At maximal enhancement of lipolysis with 
isoproterenol (10‘^  mol/1), lipolysis was increased 1.5 ± 0.6 fold change whereas with 
adrenaline (10'^ mol/1) it was increased by 0.5 ± 0.2 fold change (p<0.005). At the 
higher concentration of isoproterenol and adrenaline ( 1 0 '^  mol/1) lipolysis was inhibited 
to a similar degree. Lipolysis with adrenaline was very similar to lipolysis with 
isoproterenol but at a reduced degree (Figure 4.3).
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Figure 4.3: Comparison between the effect of adrenaline and 
isoproterenol (lO'^^-l 
mean ± SEM, n= 12.
10 10'^ mol/1) on SCAT in-vitro lipolysis. Values are
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4.1.4 The Effect of Isoproterenol and Adrenaline Stimulation and 
Insulin Inhibition on AT in  v i t r o  Lipolysis in Healthy 
Participants
Table 4.3: In-vitro lipolysis in freshly isolated mature human adipocytes in 
healthy participants.
Healthy participants, n=7 SCAT OMAT p value
Basal lipolysis 51.2+11 82.5 ± 14 p<0.01
Stimulated lipolysis with (10'  ^mol/1) 
isoproterenol 147.4 ±25 266 ± 33 j9<0.005
Inhibited isoproterenol lipolysis with ; 
(10'  ^mol/1) insulin 108.1 ±18 160 ±19 p<0.05
Stimulated lipolysis with (10'  ^mol/1) 
adrenaline 78.2 ± 1 6 112.9 ±17
NS
p=0.06
Inhibited adrenaline lipolysis with 
(10'  ^mol/1) insulin 61 ±  12 99.6 ±16 p=0.05
Results are presented as mean ± SEM (pmoEmg lipid/min), n=7, differences 
between the two tdepots (p<0.05, un-paired t-test), NS; not significant.
In healthy participants, lipolysis in SCAT was significantly increased by 2.3±0.7 fold 
change due to isoproterenol stimulation (p<0.01, paired t-test). Insulin inhibition caused 
0.2±0.1 decrease change below stimulation in stimulated lipolysis however it did not 
reach significance (p=0.08, paired t-test). The healthy participants’ OMAT exhibited 
almost the same pattern where a significant 3.6±1.3 fold change increase by 
isoproterenol stimulation took place (p<0.01, paired t-test) and a significant inhibition 
with insulin decreased stimulated lipolysis by 0.4±0.1 decrease change below 
stimulation (p<0.05, paired t-test) (Table 4.3) and (Figure 4.4).
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Figure 4.4: In-vitro lipolysis in SCAT and OMAT of healthy participants. 
Basal, isoproterenol (10'^ mol/1) stimulation and insulin (10'^ mol/1) 
inhibition. Results are mean ±SEM, n=7, differences in lipolytic activity 
within healthy group (p<0.05, paired t-test). NS: not significant.
OMAT had higher basal lipolytic activity, a higher isoproterenol stimulation response 
and higher lipolysis with insulin inhibition than SCAT (p<0.01, /7<0.001and ^<0.05, 
ANOVA) (Figure 4.5).
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Figure 4.5: Comparison of in-vitro lipolysis between SCAT and OMAT of 
healthy participants. Basal, isoproterenol (10’^  mol/1) stimulation and insulin 
(10'^ moFl) inhibition. Results are mean ±SEM, n=7, differences between 
the two depots (p<0.05, ANOVA).
Using adrenaline to stimulate in vitro lipolysis in healthy participants caused a trend of 
increased lipolysis by 0.7±0.3 fold change in SCAT but it was not significant (p=0.09, 
paired t-test). Insulin inhibition caused 0.2+0.3 decrease below stimulated lipolysis 
however it did not reach significance (p=0.07, paired t-test). Their OMAT exhibited 
almost the same trend with adrenaline stimulation by 0.6+0.2 folds increase and it was 
also not significant and a lower non-significant inhibition by 0.1+0.04 decrease with 
insulin (Figure 4.6).
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Figure 4.6: In vitro lipolysis in SCAT and OMAT of healthy participants. 
Basal, adrenaline (10'^ mol/1) stimulation and insulin (10'^ mol/1) inhibition. 
Results are mean ±SEM, n=7, differences in lipolytic activity within healthy 
group (p<0.05, paired t-test). NS: not significant.
OMAT had higher basal lipolytic activity (p<0.01, ANOVA) and a higher adrenaline 
stimulation response than SCAT, however the latter was not significant. The inhibitory 
effect of insulin on adrenaline stimulated lipolysis in OMAT was significantly higher 
than SCAT (p<0.05, ANOVA) (Figure 4.7).
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Figure 4.7: In vitro lipolysis of SCAT and OMAT in healthy participants. 
Basal, adrenaline (10'^ mol/1) stimulated and insulin (10'^ moEl) inhibited. 
Results are mean ±SEM, n=7, differences between the two depots (p<0.05, 
ANOVA).
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4.1.5 The Effect of Isoproterenol and Adrenaline Stimulation and 
Insulin Inhibition on AT Lipolysis in Participants with Type 2 
Diabetes
Table 4.4 shows the in vitro lipolysis results in participants with T20H.
Table 4.4: In-vitro lipolysis in freshly isolated mature human adipocytes in 
participants with type 2 diabetes.
Participants with T20H, n=5 SCAT OMAT p value
Basal lipolysis 78.1+23 44+11 NS
Stimulated lipolysis with (lO'^moFl) 
isoproterenol 146.5 + 36 84.5 ± 20 p<0.05
Inhibited isoproterenol lipolysis with 
(10'  ^mol/1) insulin 119.2+12 63 ±12 NS
Stimulated lipolysis with (lO'^moFl) 
adrenaline 98 ±  16 114 ±20 NS
Inhibited adrenaline lipolysis with 
(10‘^  mol/1) insulin : 77 ±  18 89 ±18 NS
Results are presented as mean ± SEM (pmol/mg lipid/min), n=5, differences 
between the two depots (p<0.05, ANOVA). NS: not significant.
In participants with T20H, basal lipolysis in SCAT was significantly augmented by 
1.1+0.5 fold change due to isoproterenol stimulation (p<0.05, paired t-test). OMAT 
showed a similar response to SCAT with isoproterenol, with a 1+0.2 fold change 
increase over basal (p<0.01, paired t-test). Insulin inhibition had no significant effect on 
both depots (Figure 4.8).
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Figure 4.8: In vitro lipolysis in SCAT and OMAT of patients with T20H. 
Basal, isoproterenol (10'^ mol/1) stimulation and insulin (10'^ mol/1) 
inhibition. Results are mean ±SEM, n=5, differences in lipolytic activity 
(p<0.05, paired t-test). NS: not significant.
In a comparison between the two depots in patients with T20H, SCAT had a 
significantly higher response to isoproterenol stimulation than OMAT (p<0.05, 
ANOVA). However the difference in their basal and insulin inhibition did not reach 
significant (Table 4.4) and (Figure 4.9).
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Figure 4.9: In vitro lipolysis of SCAT and OMAT in patients with T20H.
Basal, isoproterenol (10'^ mol/1) stimulated and insulin (10'^ mol/1) inhibited. 
Results are mean ±SEM, n=5, differences between the two depots (p<0.05, 
ANOVA). NS: not significant.
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In SCAT of patients with T20H, adrenaline stimulated basal lipolysis by 0.5+0.3 fold 
change over basal, however, this was not significant. Lipolysis was reduced with insulin 
by 0.2+0.1 decrease below stimulation which was not significant as well. In OMAT 
adrenaline stimulated lipolysis with 1.3+0.3 fold increase over basal (p<0.05) and 
insulin diminished lipolysis by 0.3+0.1 decrease below stimulation but it was not 
significant (Figure 4.10).
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Figure 4.10: In-vitro lipolysis of SCAT and OMAT in participants with 
T20H. Basal, adrenaline (10'^ mol/1) stimulation and insulin (10"  ^mol/1) 
inhibition. Results are mean +SEM, n=7, differences in lipolytic activity 
(p<0.05, paired t-test), NS: not significant.
Although SCAT basal lipolysis was greater than OMAT, this difference did not reach 
significance (p=0.07, ANOVA). There was no significant difference in lipolytic activity 
between the two depots in response to stimulation by adrenaline or inhibition by insulin 
in patients with T20H (Figure 4.11).
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Figure 4.11: In-vitro lipolysis of SCAT and OMAT in patients with 
T20H. Basal, adrenaline (lO'^moFl) stimulated and insulin (10'^ mol/1) 
inhibited. Results are mean ±SEM, n=5, differences between the two 
depots (p<0.05, ANOVA), NS: not significant.
4.1.6 Differences in Lipolytic Activity of SCAT and OMAT in the Two
Groups (Healthy vs. T20H).
A statistical linear mixed model was used to look at the differences between the effect 
of different conditions (healthy vs. T20H) on the lipolytic measurements of the two 
different tissues (SCAT and OMAT) using tissue*condition interaction as a fixed 
effects and subjects as a random effect. Figure 4.12 shows the SCAT in-vitro lipolysis 
results of the two groups, the healthy and patients with T20H; where the basal lipolysis 
of patients with T20H was higher than healthy participants but did not reach 
significance (p=0.1, linear mixed model). There were no significant differences in the 
stimulated or inhibited lipolysis of SCAT between healthy participants and patients with 
T20H.
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Figure 4.12: Comparison of SCAT in vitro lipolysis between healthy 
participants and patients with T20H. Basal, isoproterenol (10'^ mol/1) 
stimulation and insulin (10'^ mol/1) inhibition. Results are mean ±SEM, 
(p<0.05, the linear mixed model), NS: not significant
Figure 4.13 shows the OMAT lipolysis results where basal, isoproterenol stimulated and 
insulin inhibited lipolysis were significantly higher in the healthy group compared to 
T20H (p<0.05, ^ <0.001 andp<0.01 respectively, the linear mixed model).
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Figure 4.13: Comparison of OMAT in-vitro lipolysis between healthy 
participants and patients with T20H . Basal, isoproterenol (10'^ mol/1) 
stimulation and insulin (10'^ mol/1) inhibition. Results are mean ±SEM, 
NS: not significant
124
SCAT did not show any significant differences in the adrenaline stimulated and insulin 
inhibited lipolysis between healthy participants and patients with T20H (Figure 4.14).
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Figure 4.14: Comparison of SCAT in vitro lipolysis between healthy 
partieipants and participants with T20H. Basal, adrenaline (10'^ mol/1) 
stimulation and insulin (10'^ mol/1) inhibition. Results are mean ±SEM, 
regional differences in two depots in two different groups (p<0.05 was 
considered significant, the linear mixed model), NS: not significant
In OMAT basal lipolysis was lower in the T20H than healthy participants (p<0.05, the 
linear mixed model). Adrenaline stimulated and insulin inhibited lipolysis were not 
significantly different between healthy group and T20H group (Figure 4.15).
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Figure 4.15: Comparison of OMAT in vitro lipolysis between healthy 
participants and patients with T20H. Basal, adrenaline (10'^ mol/1) 
stimulation and insulin (10'^ mol/1) inhibition. Results are mean ±SEM, 
regional differences in two depots in two different groups (p<0.05, the 
linear mixed model), NS: not signifieant NS: not significant
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4.1.7 LPL activity in AT Homogenate in Different Depots
In the healthy and T20H participants LPL activity in OMAT was significantly 
higher than in SCAT, (p<0.001 andp< 0.05, ANOVA) (Figure 4.16).
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Figure 4.16; LPL aetivity of two different fat depots SCAT and 
OMAT in the healthy participants, n=7 and patients with T20H, 
n=5. Results are mean ±SLM, (p<0.05, ANOVA).
Figure 4.17 shows the comparison of LPL activity between the two groups, LPL 
activity in SCAT in T20H was significantly higher than the healthy group(p<0.005, 
the linear mixed modle). LPL activity in OMAT was not significantly different in 
healthy participants and T20H patients.
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Figure 4.17: LPL activity in two different fat depots, SCAT and OMAT 
in healthy participants, n=7 and patients with T20H, n=5. Results are 
mean ±SEM, (p<0.05, ANOVA).
The correlations between mean adipocyte size and other measurements are presented 
in (Table 4.5).
Table 4.5: Pearson’s correlation test for the relation between mean adipocyte 
size in SCAT, OMAT, lipolysis and LPL activity.
Healthy T20H
BMl vs. OMAT cell size NS NS
BMI vs. SCAT cell size r=0.87 r=0.64^<0.005, /?<0.01,
Basal lipolysis vs. OMAT cell size NS NS
Basal lipolysis vs. SCAT cell size NS NS
Stimulated lipolysis vs. OMAT cell size NS NS
Stimulated lipolysis vs. SCAT cell size NS r=0.83
;?<0.05
Inhibited lipolysis vs. OMAT cell size NS NS
Inhibited lipolysis vs. SCAT cell size NS r=0.77
;?<0.05
LPL activity vs. OMAT cell size NS
LPL activity vs. SCAT cell size NS NS
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In this study, adipocyte size of SCAT and OMAT from healthy participants did not 
correlate with either basal, isoproterenol stimulated, adrenaline stimulated or insulin 
inhibited lipolysis. Adipocyte size of SCAT from healthy participants and patients 
with T20H correlated significantly with BMI (r=0.87, /?<0.005 and r=0.64, /?<0.01 
respectively, Pearson’s) (Figure 4.18) but did not correlate in OMAT.
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Figure 4.18: Pearson’s correlation between SCAT adipocyte size 
and BMI in the healthy participants: n=7, patients with T20H: 
n=5
In T20H there was a correlation between BMI and adipocyte size from SCAT, also a 
significant correlation between adipocyte size and both isoproterenol stimulated 
(r=0.83, /?<0.05, Pearson’s) and insulin inhibited (r=0.77, ^<0.05, Pearson’s) 
lipolysis was found (Figure 4.19). There was no correlation found between adipocyte 
size and LPL activity in the two groups.
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Figure 4.19: Pearson’s correlation between mean size of SCAT 
adipocyte and in-vitro lipolysis (isoproterenol stimulated lipolysis 
and insulin inhibited lipolysis) in patients with T20H , n=5.
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4.2 Discussion 
4.2.1 Adipocyte Measurements: Adipocyte Count
It is well established that with obesity, insulin resistance and type 2 diabetes adipose 
tissue secretes cytokines which stimulate pre-adipocyte proliferation and the 
adipocyte number increases (Trayhum 2005). However, in this study there was no 
statistically significant difference in adipocyte count in either SCAT or OMAT and 
between the healthy participants and patients with type 2 diabetes. The healthy 
participants were BMI matched with the patients with type 2 diabetes, so their 
adipocytes are expected to be similar.
4.2.2 Adipocyte Measurements: Adipocyte Size
Adipocyte size is an important determinant of adipocyte function (Tchemof et al.
2006) where large adipocytes tend to synthesize more TGs than smaller adipocytes 
and release more Jfiee fatty acids through lipolytic pathways (Edens et al. 1993). 
Laurencikiene et al. (2011) examined fi*eshly isolated SC adipocytes and compared 
between small and large adipocytes (from the same participants) in healthy 
participants and concluded that large adipocytes have increased lipolytic capacity, 
perhaps due to the increase of regulatory proteins in the lipolytic cascade. Increased 
lipolytic ability may relate adipocyte hypertrophy to the risk of developing type 2 
diabetes.
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4.2.3 Adipocytes in Different Depots and Different Population 
SCAT and OMAT
Reports of adipocyte size between SCAT and OMAT in different populations is 
inconsistent between various studies (O’Connell et al. 2010, Pasarica et al. 2009, 
Wajchenberg 2000). One study which investigated the differences between SCAT 
and OMAT in type 2 diabetes (O’Connell et al. 2010) measured freshly isolated 
adipocyte size in both SCAT and OMAT in twenty morbidly obese participants 
(BMI range 40-71, males and females); six out of the twenty had type 2 diabetes. It 
was found that males had larger subcutaneous adipocytes than females; however 
subcutaneous adipocytes were larger than omental adipocytes regardless of gender 
difference or presence of diabetes. However, in the current study no significant 
difference was found in adipocyte size between different depots within each group, 
but there was a significant difference between the healthy participants and those with 
T20H . The mean size of subcutaneous adipocytes of patients with T20H was 
significantly larger than the healthy participants. These adipocytes might be more 
resistant to insulin increasing lipolysis. In agreement, omental adipocytes in the 
patients With T20H were also found significantly larger. O’Connell et al. (2010) 
also found that obese patients with type 2 diabetes have larger omental adipocytes 
than obese participants without diabetes, although did not reach significance. In 
addition, the findings of the current study agree very well with the study by Pasarica 
et al. (2009) who compared SCAT of patients with type 2 diabetes with BMl- 
matched healthy obese participants; they found that patients with type 2 diabetes had 
lower adipocyte number but greater mean adipocyte size which may have been due
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to an increased size of the very large adipocytes, suggesting that type 2 diabetes is 
accompanied by hypertrophy rather than hyperplasia of adipocytes.
4.2.4 Adipocyte Size and Correlation with Other Parameters
The correlation between subcutaneous adipocyte mean size and BMI in healthy 
participants but not in T20H was also reported by Pasarica et al. (2009). O’Connell 
et al. (2010) have found no correlation between BMI and adipocyte size in healthy 
obese participants or patients with type 2 diabetes. However, they found that omental 
adipocyte size correlated with IR, plasma TG concentration and TG/HDL ratio 
although subcutaneous adipocyte size did not correlate with these measurements. It 
found that both depots correlate positively with fatty liver.
4.2.5 I n  v i t r o  Lipolysis (Basal, Stimulated and Inhibited)
As will be discussed later, a great variation in lipolytic activity of human adipose 
tissue has been reported previously in different depots and different populations. This 
variation is perhaps due to several factors. Amer (2005) reported that these factors 
could be age, gender, hormones, physical activity, general health, and medication. 
Also, the variability could be due to differences in AT biopsy site, obesity and 
ethnicity.
Discrepancies between studies, may be the result of methodological variations such
as small sample size, different methods of sample analysis, i.e., in-vivo, in-vitro,
isolated adipocytes, tissue explants, cell culture, in-situ microdialysis, open surgery,
needle biopsy and different assays to measure glycerol or FFAs. Also, using different
units to express the results (per adipocyte cell count, per lipid content or per cell
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surface) and different parameters, namely glycerol release of basal lipolysis, 
responsiveness to catecholamine stimulation, adipocyte sensitivity, percentage 
response of stimulation or inhibition may cause these discrepancies.
All participants in this study had either been treated with local anaesthesia or 
undergone general anaesthesia for elective abdominal surgery. Lattermann et al.
(2001) and Schricker et al. (2001) proposed that anaesthesia and surgery trauma can 
affect lipolysis measurements. A very similar study to the current study by Large et 
al. (1997) obtained fat samples from eleven obese but otherwise healthy participants, 
was undertaken. Samples were obtained from the abdominal subcutaneous region 
during both local anaesthesia (using lidocaine) and during gastric banding under 
general anaesthesia (propofol) immediately after skin incision. Isolated fat cells were 
incubated in the presence or absence of increasing concentrations of different 
lipolysis agents, acting at the adrenoceptor. Glycerol release to the incubation 
medium was measured as an index of lipolysis. All agonists caused a concentration 
dependent increase or inhibition of glycerol release. The comparison of data from 
local and general anesthesia procedures showed no statistical difference in glycerol 
response for any of the drugs used. Therefore, adrenergic regulation of lipolysis is 
not influenced by the mode of sampling, at least not in subcutaneous fat cells of 
obese participants obtained during local anesthesia with lidocaine as compared to 
general anesthesia with propofol.
Therefore, in this thesis, to avoid great variation, only the most comparable human 
studies were used to discuss and interpret the results.
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4.2.6 Regional Differences in Lipolytic Activity of SCAT and 
OMAT
It is well established through in-vivo and in-vitro investigations that there are 
regional variations in the lipolytic activity of human AT but the results of these 
studies have been inconsistent. It is very important to emphasise that catecholamines 
stimulate lipolysis via pi-, P2- and pg-adrenoceptors, but also have inhibitory effects 
on lipolysis that are mediated via a 2-adrenoceptors (Amer et al. 1987, Lafontan and 
Berlan 1995). The presence of a large population of a 2- adrenoceptors in human fat 
cells has been confirmed in preparations of plasma membranes of human adipocytes 
(Wright and Simpson 1981).
In the current study, healthy participants had high basal lipolysis in OMAT than 
SCAT. Most studies using fi*esh AT (isolated adipocytes or tissue explants) from 
different populations (males and females, lean and obese, pre- and post-menopausal 
women) have shown higher basal lipolysis in SCAT than OMAT (Ostman et al. 
1979, Richelsen et al. 1991, Hellmer et al. 1992, Fried et al. 1993, Edens et al. 1993, 
Mauriège et al. 1995, Van Harmelen et al. 1997).
Many studies carried out by Amer et al. have extensively investigated the regional 
differences of AT looking at different populations and different aspects of adipose 
tissue mtabolism. Ostman et al. (1979) looked at the differences between two 
different sites of SCAT (femoral and hypogastric: below stomach) and found that 
differences exist between different regions of adipose tissue in their lipolytic 
responsiveness to noradrenaline, which seems related to the balance between a- and 
p-adrenergic receptor response. Later, Hoffstedt et al. (1997) looked at obese and
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non-obese males and found that in obese participants OMAT had higher 
noradrenaline induced lipolysis and higher noradrenaline sensitivity than SCAT. 
Van Harmelen et al. (1997) compared three different fat depots, SCAT, OMAT and 
mesenteric AT in healthy non-obese participants. They found that the two visceral fat 
depots showed no difference in adrenoceptor function but that Ps-adrenoceptor action 
was enhanced and ai-adrenoceptor action was decreased in both mesenteric and 
omental adipocytes as compared to subcutaneous adipocytes.
Hellmer et al. (1992) studied healthy non obese participants; they found that 
regardless of gender differences catecholamines were 5 to 10 times more lipolytic in 
omental cells than in SC fat cells. Furthermore, Marin et al. (1992) found that 
omental adipocytes showed a higher lipolytic sensitivity and responsiveness to 
catecholamines than subcutaneous adipocytes. Busetto et al. (1993) looked at 
lipolytic activity of omental and subcutaneous AT of visceral and epigastric (above 
stomach) obese participants, males and females. They observed similar basal 
lipolysis but higher adrenaline and isoproterenol stimulated lipolysis in the OMAT 
than SCAT in both types of obesity but this was higher in the visceral obese than 
epigastric. In comparison with SCAT, OMAT demonstrates greater catecholamine 
stimulated lipolysis in obese men and women (Edens et al. 1993 and Van Harmelen 
et al. 1997), catecholamine stimulated lipolysis and inflammation in men (Fried et al. 
1993) and in IR obese women (Liu et al. 2009). Therefore, metabolic activity was 
lowest in the gluteofemoral area followed by the abdominal subcutaneous deposits 
then the visceral. Catecholamines were most active in the visceral area, followed by 
the subcutaneous abdominal and gluteofemoral areas.
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Most studies suggest that in OMAT there is a greater lipolytic response to 
catecholamine stimulation than SCAT. This was supported by the current study.
Hellmer et al. (1992) and Richelsen et al. (1991) suggested that the increased 
catecholamine stimulated lipolysis in OMAT was due to the increased number and 
fiinction of p-adrenoceptors and decreased number and function of ai-adrenoceptors 
in OMAT and increased number and function of az-adrenoceptors in SCAT. The 
difference in p- and ai-adrenoceptor function might explain why noradrenaline 
induced lipolysis is increased in visceral fat depots, as compared to the subcutaneous 
fat depot.
In addition, other studies suggested that these regional variations are partially due to 
differences in adrenoceptor populations as well as blood supply (Bouchard et al. 
1993 Ramsay 1996). Bjomtorp (1990) put forward the portal vein theory; 
emphasizing the specific characteristics and anatomical location of visceral (mainly 
omental) AT and its venous drainage by the portal vein system. It is generally 
believed that visceral adipose tissue is drained by the portal vein and has direct 
access to the liver. So, activity is highest in the visceral region where more fat is 
mobilized during times when there is a need for fast energy supply, such as during 
physical exercise.
On the other hand, a study by Tchemof et al. (2006) investigated the regional 
differences in AT mtabolism and the effect of obesity and body fat distribution in 
healthy women with a range of body fat (19.6-47.5%). The study showed that 
subcutaneous adipocytes were larger in size and were more lipolytic (basal and 
isoproterenol stimulated) than omental adipocytes. However, the response (fold
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increase over basal) of omental adipocytes to the lipolytic stimuli was greater than in 
SCAT. This finding was consistent across the range of body fat percentage studied.
In the healthy group OMAT expressed higher basal lipolysis (/?<0.005), higher 
isoproterenol stimulated lipolysis (p<0.001) and higher response to insulin 
antilipolytic activity (p<0.05). Also, healthy participants showed higher response to 
insulin antilipolytic activity in SCAT compared with OMAT (p<0.05). This data 
(stimulated lipolysis OM>SC) suggests that FFA are more readily mobilized from 
OMAT than from SCAT.
4.2.7 Regional Difference in Lipolysis in T20H
Although there were clearly regional differences in lipolysis in the non-diabetic 
participants this was not the case in patients with T20H since they did not reveal 
any significant regional differences. In other words, healthy participants showed 
regional differences in basal, isoproterenol stimulated lipolysis and insulin inhibited 
lipolysis, while patients with T20H did not show any regional differences.
Abate et al. (1995) reported that men with type 2 diabetes (non-insulin treated) do 
not have excess intraperitoneal fat, but their fat distribution favours more truncal and 
less peripheral subcutaneous fat when compared with obese men without diabetes. 
Moreover, subcutaneous truncal fat plays a major role in obesity-related insulin 
resistance in men, whereas intraperitoneal fat and retroperitoneal fat have a lesser 
role.
Between the two groups, this study has not found significant regional differences in
basal lipolysis. However, percentage increase in lipolysis due to isoproterenol
stimulation in OMAT in healthy participants was significantly higher than in patients
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with T20H. The difference in total percentage increase within OMAT was even 
higher in between the two groups. With adrenaline stimulation in both depots 
however, the difference between the rates of lipolysis between the two groups was 
not as substantial.
The adrenoceptor theory can be applied to explain this case, this variation between 
the two groups may be due to the enhanced adrenergic responsiveness with a 
parallel decrease in p-adrenergic responsiveness in patients with diabetes (Lafontan 
2008).
4.2.8 Responsiveness to Insulin Inhibition Within Each Group
In this study, the percentage decrease in isoproterenol stimulated lipolysis due to 
insulin inhibition in OMAT was greater than in SCAT in the healthy group. This was 
not significantly different in patients with T20H . Likewise, Marin et al. (1992) also 
found that in healthy men with a wide variation of total body fat, OMAT showed a 
lower sensitivity to antilipolytic effect of insulin than subcutaneous. In contrast, 
Bolinder et al. (1983) found that in non-obese males SCAT has higher insulin 
receptor affinity and higher insulin action and 3 folds higher responsiveness than 
OMAT, and insulin dissociation rate was more rapid in OMAT than SCAT. This 
contradiction in the results could be due to the difference in the population. The 
current study included overweight healthy participants and obese participants with 
T20H (BMI= 29 and 31 respectively) who may show more insulin resistance in 
their SCAT than OMAT.
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4.2.9 Responsiveness to Isoproterenol and Adrenalin Stimulation of 
Lipolysis
In this study it was observed that both isoproterenol and adrenaline enhanced 
lipolysis, but lipolysis was inhibited as the concentration of the lipolytic agent was 
increased. Also, glycerol release with isoproterenol stimulation produced higher 
values than adrenaline. Wright and Simpson (1981) elucidated that, although 
isoproterenol is a P-adrenergic agonist presumably at higher concentration (10^ 
mol/1) it binds with low affinity to ai-adrenergic receptors which may mediate an 
antilipolytic effect. Simultaneously, adrenaline is a mixed a ] -  and p-adrenergic 
agonist once it binds to p-receptors it will start enhancing lipolysis but at higher 
concentration (10'^ mol/1) it started to bind to the a 2-receptor where the inhibitory 
action started. Mauriege et al. (1987) found that adrenaline always has a higher 
affinity for ql2 adrenoceptors than for p-adrenoceptors in the subcutaneous and 
omental depots. They suggested that, the differences in the lipolytic responses to 
adrenaline in adipocytes from different sites are linked to a variable a 2 inhibiting 
effect (and a 2 adrenoceptors number) rather than to a modified P-adrenoceptors 
driven increase in lipolysis initiated by the physiological amine. The net lipolytic 
action of adrenaline could be expected to be less than that of isoproterenol.
Additionally Bums et al. (1981) found that the rate of lipolysis stimulated by
adrenaline in freshly isolated human subcutaneous adipocytes was much less than the
rate of isoproterenol-stimulated lipolysis. Wright and Simpson (1981) also reported
that there was an increased subcutaneous adipocytes binding capacity for a -
adrenergic ligands which was found seven times higher than the binding capacity for
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p-adrenergic ligands. This may provide an explanation for the relatively small 
stimulation of lipolysis by adrenaline compared to isoproterenol. In the current study, 
it was not possible to expand the experiments to look more extensively at a i-  p-and 
adrenergic ligands due to the small sample size.
In 1983, Bolinder et al. investigated SCAT and OMAT in healthy non obese 
participants and found that SCAT has higher insulin receptor sensitivity and 3 times 
higher responsiveness than OMAT. It was suggested that these findings were due to 
higher insulin receptor affinity in SCAT and higher insulin dissociation rate in 
OMAT even if no difference in insulin receptor number existed.
Most studies suggest that OMAT is poorly responsive to inhibition by insulin than 
SCAT. Marin et al. (1992) looked at men with a wide variation of total body fat 
content and found that omental adipocytes had less sensitivity to the antilipolytic 
effects of insulin than subcutaneous adipocytes.
4.2.10 Effect of High BMI on Stimulated AT Lipolysis
All participants in this study were overweight (obese) with an average BMI of 29-31 
Kg/m^. Amer (2005) reported a number of abnormalities of catecholamine-induced 
SCAT lipolysis in obesity. Although the basal lipolysis was higher than in lean 
participants, the lipolytic effect of catecholamines was decreased and HSL 
expression was decreased in mature subcutaneous adipocytes (Langin 2006). Lofgren
(2002) suggested that, this was due to at least three defects: increased ai-antilipolytic
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function, decreased p2-adrenoceptor lipolytic function and/or decreased ability of 
cAMP to activate lipolysis.
4.2.11 The Effect of Metformin on AT Lipolysis
In this study metformin was not added into the in vitro lipolysis medium however all 
participants with type 2 diabetes were being treated with metformin (as the only 
OHA for patients with T20H ). The two main mechanisms by which metformin 
lowers blood glucose level are by either enhancing the sensitivity of tissue to insulin 
or by acting on the liver and decreasing hepatic glucose output (Bailey and Turner 
1996). Although the exact mechanisms by which metformin acts at the molecular 
level remains unknown, it has been shown that the drug inhibits a step in the 
mitochondrial respiratory-chain (Viollet et al. 2012). Zhang et al. (2009) looked at 
the effect of metformin on lipolysis in primary rat adipocytes. They found that 
metformin acts on adipocytes and suppresses the lipolysis response to 
catecholamines. They examined metformin at 250-500 pM and found that it 
attenuated NEFA and glycerol release from the adipocytes stimulated with IpM 
isoproterenol. They elucidated that during isoproterenol stimulated lipolysis, 
metformin decreased cellular cAMP production, reduced activity of protein kinase A 
(PKA) and mitogen-activated kinase (MAPK 1/3), and attenuated the 
phosphorylation of perilipin. This antilipolytic effect could be a cellular basis for 
metformin decreasing plasma NEFA levels and improving insulin sensitivity.
This effect of metformin on adipocytes may explain the lower responsiveness to 
isoproterenol stimulation and similar responsiveness to insulin inhibition in both AT
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depots of patients with T20H (treated with metformin) compared to healthy 
participants in this study (Table 4.5).
Zulian et al. (2011) examined the effect of metformin on adiponectin expression and 
secretion in subcutaneous and visceral adipose tissue in lean and obese participants, 
they found that in both in-vitro and in-vivo experiments, the treatment with 
metformin increased the expression and secretion of adiponectin in SCAT, but not in 
VAT. This suggest there may be a regional difference in the effect of metformin on 
AT.
4.2.12 LPL Activity
Tchemof et al. (2006) investigated the regional differences in AT mtabolism and the 
effect of obesity and body fat distribution in healthy women. The study showed that 
subcutaneous adipocytes have higher LPL activity and more lipolytic than omental 
adipocytes. The LPL activity results from the current study is opposing, this may be 
due to insulin resistance and lower LPL in SCAT.
Ohira et al. (2007) found that after three months treatment with metformin in patients 
with type 2 diabetes, their pre-heparin plasma LPL mass was increased significantly. 
They suggested that metformin may diminish insulin resistance and increased LPL 
production. Is there a regional difference of the effect of metformin on AT? Our 
results suggest that metformin may affect SCAT more than OMAT.
143
4.3 Conclusion
Methods were validated for adipocyte isolation, adipocyte count and size 
measurements and lipolytic activity. Adipocyte size of SCAT and OMAT was 
significantly larger in T20H than healthy participants (p<0.001,/><0.05 respectively, 
the linear mixed modle). In healthy subjects OMAT had higher basal, isoproterenol 
stimulated and insulin inhibited lipolysis than SCAT (p<0.01, ^<0.001, /><0.05 
respectively, the linear mixed modle). In participantss with T20H, stimulated 
lipolysis with isoproterenol in SCAT was significantly higher than OMAT, but there 
was no significant difference between in basal and insulin inhibited lipolysis. There 
was no significant difference between healthy and T20H in SCAT lipolytic activity, 
but OMAT has higher basal, isoproterenol stimulated and insulin inhibited lipolysis 
than SCAT (p<0.05, /><0.001, /><0.01 respectively, the linear mixed model) in 
healthy participants. LPL activity in OMAT was significantly higher than SCAT in 
both healthy and T20H group (p<0.001, /><0.05 respectively, the linear mixed 
modle).
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CHAPTER FIVE: COMPARISON BETWEEN THE EFFECT 
OF DETEMIR AND NPH ON SCAT METABOLISM IN 
PATIENTS WITH TYPE 2 DIABETES.
The mechanisms behind the weight-sparing effect of insulin detemir are still 
unidentified. Reduced risk of hypoglycaemia with insulin detemir, coupled with 
a more consistent and reliable delivery of the required dose than is available with 
traditional basal insulin, such as NPH, has been proposed to minimise protective 
snacking by patients, and may help to limit weight gain (Hermansen and Davies
2007). However, there is little evidence for this and even if this was proven, it 
would be unlikely to fully explain the weight-sparing effect of insulin detemir. 
This part of this thesis forms part of a larger project examining the physiology 
that underpins the clinical observation of reduced weight gain with insulin 
detemir. It is hypothesised that detemir may have the potential to restore the 
physiological insulin gradient, which may be a possible explanation for the 
reduced weight gain.
This chapter demonstrates the results of the comparison between the effect of 
insulin detemir and NPH on SCAT mtabolism in patients with type 2 diabetes. 
The detemir clinical trial was a 24 weeks, randomised parallel group trial. 
Insulin dosage was optimised for 8 weeks with NPH insulin then participants 
were randomised to receive either insulin detemir or continue with NPH insulin 
as basal insulin for a further 16 weeks. At the end of the 8 week optimisation 
period and at the end of the 16 week treatment period fat and blood biopsies 
were taken. The in-vitro lipolytic activity of the isolated mature adipocytes was 
measured, LPL mass and activity were detemiined and plasma lipid profile was
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analysed. It is postulated that insulin detemir may have a lesser effect than NPH 
insulin on peripheral tissues; this may lead to lower LPL activity and higher 
lipolysis. This could lead to less weight gain.
5.1 Results
Twenty-two type 2 diabetic patients (14M, 8F, aged 60.4 ±8.1 yrs), BMI (32.3 
±3.6 Kg/m^) (mean±SD) were recruited for this study. In a sub-set, 12 
participants (6M, 6F, aged 58.5 ±2.9 yrs), BMI (33.1±0.9 Kg/m^) basal and 
stimulated lipolytic activity and LPL activity in a SCAT biopsy was compared 
between NPH (n=5) and detemir (n=7).
Fasting plasma measurements
Table 5.1 shows fasting plasma measurements for both groups after both 
optimization period (week 8) and after the 16 week treatment period (week 24). 
Fasting plasma NEFA concentration significantly increased after the 16 week 
treatment period with NPH (p<0.05, paired t-test). Although with detemir NEFA 
concentration decreased but it was not significant (p=0.09, paired t-test). The 
change in NEFA concentration between the two groups was significant (p<0.05, 
ANOVA) (Figure 5.1). TG concentration did not show significant changes either 
within the groups or between groups. Fasting plasma adiponectin or leptin was 
not different with either detemir or NPH treatment. HbAlc also was not different 
between the two groups (Table 5.1).
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Figure 5.1: Changes in fasting plasma NEFA concentration between 
the two groups after the 16 weeks treatment period, detemir group n=7 
and NPH group n=5, (p<0.05, ANOVA).
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5.1.1 Body Composition and Adipose Tissue
During the 8 week optimization period both groups gained weight (detemir
0.49±0.7Kg p=OA and NPH 1.24±0.7 Kg />=0.08, paired t-test). At 24 weeks 
there was a further increase in body weight with NPH (p=0.03, paired t-test) 
with no change with detemir, the difference between the two groups was 
significant (p<0.05, ANOVA) (Table 5.2).
The total fat mass decreased significantly with detemir (p<0.04, paired t-test) 
and increased with NPH but did not reach significance. Fat free mass did not 
change in the two groups. The detemir group had decreased level of both SCAT 
and visceral adipose tissue at 24 weeks but this did not reach significance 
(p=0.06, j9=0.1, paired t-test) respectively. On the other hand, NPH group gained 
visceral fat (p<0.01, paired t-test) but not SCAT, Table 5.2 and Figure 5.2 
summarise these changes. At a cellular level the count and size of mature 
adipocytes in the two groups were not significantly changed.
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5.1.2 Lipolytic Activity of SCAT Biopsies
5.1.2.1 I n - v i t r o  Lipolysis (Basal, Stimulated and Inhibited)
Basal adipose tissue lipolysis was reduced in the detemir group after 16 weeks treatment 
(p<0.05, paired t-test). There was a trend of decreased stimulated and inhibited lipolysis with 
detemir but this did not reach statistical significance (Figure 5.3).
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Figure 5.3: Changes in in-vitro lipolysis of SCAT of patients on detemir treatment, 
week 8: after the optimization period; week 24: after the 16 weeks treatment period; 
stimulated lipolysis with isoproterenol (10'^ mol/1), inhibited lipolysis with insulin 
(10'^ mol/1) n=7. Results are expressed as mean±SEM, n=12, differences between 
week 8 and week 24 (p<0.05, paired t-test), NS: not significant.
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In the NPH group there was a trend of increased basal, stimulated and inhibited lipolysis after 
the 16 week treatment period but it did not reach significance (Figure 5.4).
□ week 8 
■ week 24
i>> 10
Basal Stimulated Inhibited
Figure 5.4: Changes in in-vitro lipolysis of SCAT of patients on NPH treatment, week 
8: after the optimization period; week 24: after the 16 week treatment period; stimulated 
lipolysis with isoproterenol (10'^ mol/1), inhibited lipolysis with insulin (10^ mol/1) n=5. 
Results are expressed as mean±SEM, n=12, differences between week 8 and week 24 
(p<0.05, paired t-test), NS: not significant. NS: not significant.
5.1.2.2 LPL Activity SCAT Homogenate
LPL activity increased significantly after 16 weeks treatment in the detemir group (p=0.05, 
paired t-test) and significantly decreased in the NPH group (p=0.02, paired t-test). Figure 5.5 
shows the LPL activity changes in the two groups.
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Figure 5.5; LPL activity changes in SCAT biopsies (homogenate) within each group. 
Week 8: after the optimization period and week 24: after the 16 week treatment 
period, detemir group n=7 and NPH group n=5. Results are expressed as 
mean±SEM, differences between week 8 and week 24 (p<0.05, paired t-test).
LPL mass exhibited the same change pattern, it increased significantly with detemir (p=0.02, 
paired t-test) and decreased with NPH treatment but did not reach statistical significance 
(p=0.06, paired t-test) (Figure 5.6).
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Figure 5.6: LPL mass changes in SCAT biopsies (homogenate) within each group. 
Week 8: after the optimization period and week 24: after the 16 week treatment period, 
detemir group n=7 and NPH group n=5. Results are expressed as mean±SEM, 
differences between week 8 and week 24 (p<0.05, paired t-test).
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The change in LPL activity and LPL mass over the 16 week treatment period was 
significantly different between the two groups (p=0.006, p=0.005, ANOVA) respectively 
(Figure 5.7 and Figure 5.8).
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Figure 5.7: LPL activity changes in SCAT biopsies (homogenate) in the two groups 
after the 16 week treatment period, detemir group n=7 and NPH group n=5. Results 
are expressed as mean±SEM, differences between the two groups (p<0.05, paired t- 
test)
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Figure 5.8: LPL mass changes in SCAT biopsies (homogenate) in the two groups 
after the 16 week treatment period, detemir group n=7 and NPH group n=5. Results 
are expressed as mean±SEM, differences between the two groups (p<0.05, paired t- 
test)
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There w as a strong positive correlation betw een LPL m ass and LPL activity (Figure 5.9).
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Figure 5.9: Pearson’s correlation between LPL activity and LPL mass of 
SCAT homogenates from 12 patients with type 2 diabetes on different insulin 
treatment, n=24 (biopsies at 8 and 24 weeks).
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5.2 Discussion
5.2.1 Insulin Treatment
In people with type 2 diabetes the elevated serum NEFA levels have previously been 
attributed to adipose tissue insulin resistance due to the insulin failure to suppress 
lipolysis (Swislocki et al. 1987). Insulin therapy is administered as a subcutaneous 
injection and absorbed into the systemic circulation through which it is distributed in 
approximately equal concentrations throughout the body. In normal physiology 
hepatocytes are exposed to insulin concentrations 3-4 times higher than the other 
major targets for insulin (adipose tissue and muscle). Thus with subcutaneous insulin 
delivery the normal portal/peripheral insulin gradient is absent resulting in a relative 
peripheral hyperinsulinaemia and lower insulinisation of the liver. This metabolic 
imbalance is expected with most present insulin preparations and may contribute to 
both acute and chronic complications of diabetes.
It is well established that over-insulinisation results in down regulation of the insulin 
receptor, thus contributing to insulin resistance (Okabayashi et al. 1989 and 
Goodyear et al. 1995). Over-insulinisation may also be responsible for weight gain 
with insulin treatment. An in-vitro study by McTeman et al. (2002) showed that 
chronic hyperinsulinaemia of adipose tissue induced increased rates of lipolysis in 
contrast to its acute effects. This was the first report to address the long-term effects 
of insulin on human adipocyte lipid mtabolism, and their findings were consistent 
with a clinical observation of the association of hyperinsulinaemia with increased 
lipolytic rate and fat accumulation in type 2 diabetes (Large and Amer 1998).
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Previous studies found that people with type 2 diabetes had a reduced weight gain 
when treated with insulin detemir compared to NPH (Raslova et al. 2004 and Haak 
et al. 2005), and they suggested that it may be related to lower within-person 
variation in plasma glucose, which may reduce the need for defensive snacking to 
avoid hypoglycemia. Later, a multinational observational study looked at the effect 
of a long-term (52-week) treatment with insulin detemir, NPH and glargine in people 
with type 2 diabetes and they found the same results of achieving better glycaemic 
control with less/no weight gain (Meneghini et al. 2007 and Marre et al. 2009).
It has been established that the weight sparing effect of insulin detemir compared to 
NPH insulin is not explained by the reduction in hypoglycemia episodes (Davies et 
al. 2008). Two theories have been put forward. The first one suggests that detemir 
which has a novel method of prolonging action via acylation and albumin binding, 
where it is 98-99% reversibly bound to plasma albumin which produces a bigger 
molecule (Jones and Patel 2006) limits its access to peripheral adipose and skeletal 
tissues through the endothelial barrier, while allowing full access to hepatocytes via 
the large sinusoidal fenestrae in hepatic capillary membranes, thus effectively 
suppressing hepatic glucose output. Such a shift in target tissue distribution would 
produce a more physiological profile of action, reducing FFA deposition and glucose 
uptake thus reducing lipogenesis in the periphery (Hordern et al. 2005 and Smeeton 
et al. 2009). The second theory suggests that insulin detemir may be more effective 
than NPH in communicating satiety signals within the central nervous system. The 
latter theory is beyond the scope of this PhD thesis.
The data in the current study showed that insulin detemir treatment significantly 
decreased NEFA levels, suggesting that adipose is more insulin sensitive after 16
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weeks treatment with insulin detemir than insulin NPH. Stumvoll et al. (2000) has 
shown that lipolysis is very insulin sensitive. Since body weight did not significantly 
change with detemir treatment, the decrease in NEFA suggests a direct effect of 
detemir to improve adipose tissue sensitivity to insulin’s anti-lipolytic action. 
Although there was a trend for lower basal lipolytic activity in the adipose tissue 
biopsies with insulin detemir statistical significance was not attained. LPL is also 
highly regulated by insulin, with insulin increasing LPL activity in adipose tissue 
(Raynolds et al. 1990). Thus, increased adipose tissue LPL activity is also associated 
with an improvement in insulin sensitivity (Maheux et al. 1997). In chronically 
insulin-treated patients with good control, the enzyme activity in postheparin plasma 
is increased. In untreated Type 2 diabetic patients, the average enzyme activity in 
adipose tissue and postheparin plasma is normal or subnormal (Taskinen 1987).
The current findings showed a significant increase in SCAT LPL mass and activity 
with insulin detemir compared with NPH which supports an improvement in AT 
insulin sensitivity. Since there was no significant weight loss with detemir, this 
indicates the improvement in insulin sensitivity was not due to weight changes but 
was a direct effect of the insulin analogue itself.
5.3 Study Limitation
• Human studies are limited by relatively small sample sizes, short exposure 
durations, and reliance on participants compliance and outcome measures 
with unknown relevance to chronic adverse effects.
• The relative small adipose tissue sample size, fragile nature of the tissue.
• The variability of tissue biopsies fi*om person to person.
• The gender imbalance, which may cause variation in lipolysis measurements.
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• In the detemir study, the differences in the time of taking the biopsies (not 
exactly week 8 or week 16).
5.4 Conclusion
Weight change over the treatment period was -0.62 ± 0.84 kg with detemir and 
+2.19 ± 1.03 kg with NPH (p=0.049). There was no difference in HbAlc, energy 
intake, total, visceral or subcutaneous adipose tissue. Fasting non-esterified fatty 
acids (NEFA) decreased significantly with detemir compared to NPH (p=0.046). 
Basal lipolysis in the fat biopsies showed a significant reduction with detemir 
treatment (from 36.8+ 8.9 to 10.66+ 1.93 pmol glycerol released/mg lipid, /><0.05) 
with no significant change following NPH treatment (16.01+4.34 to 17.02+6.36 
pmol glycerol released/mg lipid). LPL mass and activity increased significantly after 
16 weeks treatment with detemir compared to NPH (p=0.006, />=0.005). No 
significant differences were observed on stimulated lipolysis or adipocyte size 
following either of the treatments.
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CHAPTER SIX: THE EFFECT OF DIETARY EXTRINSIC 
SUGARS ON BODY COMPOSITION AND LIPID METABOLISM 
IN MEN AT RISK OF METABOLIC SYNDROME 
6.1 Introduction
6.1.1 The Metabolic Syndrome
Metabolic syndrome (known previously as syndrome X) is a cluster of metabolic 
abnormalities including central (abdominal) obesity and insulin resistance, so it is 
also known as insulin resistance syndrome. A joint conference of the American Heart 
Association (AHA), the National Heart, Lung and Blood Institute (NHLBI) and the 
American Diabetes Association (ADA) identified the major components of the 
syndrome as abdominal obesity, insulin resistance with or without glucose 
intolerance and atherogenic dyslipidemia and hypertension (Grundy et al. 2004). 
Also, other accepted clinical criteria for metabolic syndrome diagnosis were 
produced by the World Health Organization (WHO), the European Group for the 
Study of Insulin Resistance (EGER), and the National Cholesterol Education Program 
-  Third Adult Treatment Panel (NCEP ATP III) (WHO 1999 and NCEP 2001). All 
groups agreed on the core components of the metabolic syndrome: obesity, insulin 
resistance, dyslipidaemia and hypertension.
The WHO suggests a definition for the metabolic syndrome (Stipanuk 2006), if the 
person has insulin resistance i.e. hyperinsulinemia, where fasting plasma insulin 
>25% quartile and at least two of the following components:
■ Abdominal obesity: waist/hip ratio for men >0.9 and for women >0.85; 
or BMI >30 kg/m^.
■ Glucose intolerance: fasting plasma glucose >6.0 mmol/1
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■ Arterial blood pressure: > 149/90 mmHg (or on antihypertensive 
medical treatment)
■ Dyslipidaemia: elevated fasting TG >2.1 mmol/1 and/or reduced fasting 
HDL cholesterol <1.0 mmol/1 (or on cholesterol lowering medical 
treatment)
However, according to the new international diabetes federation (IDF) definition, for 
a person to be defined as having the metabolic syndrome they must have central 
obesity (defined as waist circumference with ethnicity specific values i.e. if BMI is 
>30 Kg/m^, central obesity can be assumed and waist circumference does not need to 
be measured) plus any two of the following four factors:
1. Raised triglycerides >150 mg/dl (1.7 mmol/1) or specific treatment for this 
lipid abnormality.
2. Reduced HDL cholesterol < 40 mg/dl (1.03 mmol/1) in males < 50 mg/dl 
(1.29 mmol/1) in females or specific treatment for this lipid abnormality.
3. Raised blood pressure systolic BP > 130 or diastolic BP > 85 mm Hg or 
treatment of previously diagnosed hypertension.
4. Raised fasting plasma glucose (FPG) >100 mg/dl (5.6 mmol/1), or previously 
diagnosed type 2 diabetes. If above 5.6 mmol/L or 100 mg/dl, OGTT is 
strongly recommended but is not necessary to define presence of the 
syndrome.
The prevalence of the metabolic syndrome varies with country, race and the 
definition used. Using the NCEP Adult Treatment Panel III criteria. Ford et al. 
(2002) found that 24%, increasing to 44% in the over-60s have metabolic syndrome 
in the USA. Using the IDF’s definition of metabolic syndrome, a recent study in 
Leicester, UK reported that the prevalence of metabolic syndrome in 3099
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participants aged 40-75 years, was high in both south Asian and white European 
(34.2% and 34.5% respectively) (Khunti et al. 2010). It is very well established that, 
metabolic syndrome is highly associated with increased risk for both cardiovascular 
and cerebrovascular disease and type 2 diabetes (Olefsky et al. 1985, Reaven 1995, 
Lebovitz 2001 and Amer 2003). The IDF reported that, people with metabolic 
syndrome are twice as likely to die from, and three times as likely to have a heart 
attack or stroke compared with people without the syndrome (IDF 2006). In addition, 
people with metabolic syndrome have a five-fold greater risk of developing type 2 
diabetes.
6.1.2 Insulin Resistance
Insulin resistance (IR) is defined as the decreased responsiveness of target tissues, 
such as liver, adipose tissue and muscles to the normal circulating concentration of 
insulin (Champe et al. 1987). Insulin resistance can be divided into states in which 
there is a shift in the dose response to the hormone but the maximal response remains 
normal (decreased insulin sensitivity) or states in which the dose response is normal 
but the maximal response is decreased ( decreased responsiveness) or a combination 
of the two (Kahn and Saltiel 2005). IR occurs both in disease states such as T2DM, 
obesity, hypertension, polycystic ovarian syndrome, and a variety of genetic 
syndromes and in physiologic conditions such as puberty, pregnancy, stress and 
infections, also it presents secondary to some treatments especially glucocorticoids 
(Kahn and Saltiel 2005). IR can occur at multiple levels (pre-receptor, receptor or 
post-receptor) and be either acquired or genetic. It has been recognised that, in 
T2DM and obesity, there are decreases in insulin receptor concentration, receptor 
kinase activity, insulin receptor substrate IRS-1 and IRS-2 concentration and
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phosphorylation, PI 3-kinase activity, and in glucose-transporter translocation, as 
well as defects in activity of intracellular enzymes (Caro et al. 1989 and Cusi et al. 
2000). Several recent reviews have looked extensively at insulin signal transduction 
and its relevance to systemic insulin sensitivity (Goldstein 2002, White 2002, 
Mauvais-Jarvis et al. 2002 and Kitamura et al. 2003).
IR is characterised by uncontrolled hepatic glucose production and decreased glucose 
uptake by muscle and adipose tissue. It has been found that in obese type 2 diabetes, 
IR increases with weight gain and equally diminishes with weight reduction (Fukuda 
et al. 1989). Several studies suggest that fat accumulation is a key factor in 
developing IR and have proposed adipose tissue as the primary site of IR. The effect 
of the increased amount of adipose tissue may be due to two different reasons, first is 
the effect of changes in regulatory substances (cytokines) released from adipose 
tissue such as TNF-a, leptin, resistin and adiponectin (Smith et al. 1999, Hotamisligil 
2000, Trayhum and Beattie 2001, Amer 2003, and Savage et al. 2007). Secondly, 
the elevated levels of free fatty acids that are associated with obesity have 
implications in the development of IR (Amer 2002). NEFA are also released fi*om 
abdominal adipose tissue, and are absorbed via the portal vein and thus have direct 
access to the liver (Champe et al. 1987). Visceral adipose tissue has been specifically 
identified as a main contributor to IR and its related syndrome (Bergman et al. 2001). 
Furthermore, visceral depots are much more strongly linked to T2DM and CVD than 
are subcutaneous fat depots ( Amer 1997). The reason for this is poorly understood.
6.1.3 Lipoproteins
TGs are hydrophobic and thus insoluble in plasma. In order to circulate in the plasma 
cholesterol and TGs are associated with polar phospholipids and proteins in the form
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of lipoproteins. Figure 6.1 illustrates the structure of a lipoprotein particle. Increased 
release of NEFA from adipose tissue results in an increase in their delivery to the 
liver which may result in increased TG synthesis. The majority of NEFA delivered to 
the liver are derived from subcutaneous AT, by far the largest AT depot. Even in 
viscerally obese adults NEFA delivered to the liver from the systemic circulation 
provide more than 50-60% of the hepatic NEFA supply (Nielsen et al. 2004).
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Figure 6.1: The general structure of a lipoprotein particle.
(Université Laval. 2012)
Lipoprotein particles are heterogeneous within classes, within each patient and 
between patients. Particle composition, determines its metabolic function. Figure 6.2 
illustrates the classification of major lipoproteins according to their density and 
particle size. The TGs, cholesterol, and cholesterol esters are combined with 
phospholipids and proteins (apoproteins) to form the lipoprotein particles (nascent 
chylomicrons in the intestinal mucosa and nascent VLDL in the liver). Once these 
nascent lipoproteins enter the plasma, they pick up additional apolipoproteins from 
circulating HDLs to be mature. These mature chylomicrons and VLDLs become
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smaller and denser in the plasma after losing TGs from their core. Chylomicrons 
become chylomicron remnants. VLDL are hydrolysed to intermediate density 
lipoproteins (IDL), known as VLDL remnants and then LDL (Danishefsky 1980). 
LDLs have a distinguishing feature in that they contain about 75%-80% lipid which 
is principally cholesterol; whereas VLDLs and chylomicrons consist primarily of 
TGs associated with small amounts of protein, cholesterol and phospholipids. 
Consequently, the main function of chylomicrons is to transport absorbed dietary 
TGs from the intestine. The main function of VLDL is to carry endogenous TGs, 
whereas, LDL major role is to transport cholesterol and phospholipids to the 
peripheral tissues and regulate de novo synthesis of cholesterol at these sites. HDL 
(originally synthesised in the gut and the liver) is responsible for the removal of 
excess cholesterol from peripheral tissues and its return to the liver (Yaqoob et al. 
2005).
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Figure 6.2: Classification of major lipoproteins according to 
their density and particle size (Dayspring and Pokrywka 
2010).
In the plasma lipoproteins vary according to their lipid-to-protein ratios and in the 
composition of the lipid and protein content (Danishefsky 1980). Classification of
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lipoproteins is based on two principal modes, their electrophoretic mobility and on 
their density. Electrophoresis of serum proteins results in their separation into 
albumin and a-, P- , and y-globulins. These fractions are not homogeneous proteins 
but mixtures containing certain amounts of lipoproteins. Analysing separated protein 
using lipid stains reveals the presence of lipoproteins in the ai- and p-globulin 
sections; pre-P-lipoproteins can be observed as well. These lipoproteins differ from 
each other in the percentage and composition of lipids, and in the nature of the 
protein components. The lipid contents in lipoproteins effectively decrease the 
densities of the total macromolecules. Lipoprotein classes can be separated by 
ultracentrifugation on the basis of their density using different density solutions by 
modifying the density. These fractions are classified as chylomicrons (CM), very low 
density lipoproteins (VLDL), low density lipoproteins (LDL) and high density 
lipoprotein (HDL). These fractions can be further characterised by 
ultracentrifugation analysis. Table 6.1 shows the general composition of each major 
class of plasma lipoprotein. The protein fraction of lipoproteins consists of several 
components, called apoproteins or apolipoproteins; they are designated as apoA, 
apoB, apoC, apoD and apoE. Some apoproteins can be classified into subgroup 
denoted by numerals, e.g., ApoA-I, apoA-II, apoC-I and apoC-II. Each lipoprotein 
has a different apoprotein content and proportion.
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Table 6.1: Major classes of plasma lipoprotein. Adapted from Yaqoob et al. (2005).
Properties and 
composition
Chylomicrons VLDL IDL LDL HDL
Mr (10^ kDa) 400 10-80 5-10 2.3 175-0.36
Density (g/ml) <1.006 1.006-1.019 1.02-1.063 1.064-1.21
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12
% Protein 1.5-2.5 5-10 15-20 20-25 40-55
% TG 84-89 50-65 22 7-10 3-5
% Phospholipid 7-9 15-20 22 15-20 20-35
% Free Cholesterol 1-3 5-10 8 7-10 3-4
% Cholesteryl esters 3-5 10-15 30 35-40 12
AI, All A I,A II,
B48 BIGG BIGG BIGG B48
Major apoproteins Cl, cii, cm Cl, CII, cm Cl, CII,
E cm. E cm, E
E
Turnover in plasma 4-5 min 1-3 h 1-3 h 45% /day 4 days
Lipid mtabolism is controlled by several hormones such as insulin, adrenaline, 
noradrenaline, glucagon, cortisol, thyroxine and growth hormone (Danishefsky 1980) 
(Table 5.2). Although insulin is classically associated with carbohydrate mtabolism 
and glucose uptake into the cells, it also has a major role in lipid mtabolism. In the 
postprandial state, insulin stimulates LPL in AT increasing NEFA uptake, supresses 
the intracellular lipolysis of stored TGs in AT by inhibiting HSL, thus minimising 
NEFA release in to the circulation. Also, insulin supresses VLDL release from the 
liver. Therefore, insulin controls both the lipolysis of stored TG and uptake of NEFA 
from dietary TG into AT. Tissue sensitivity (AT, liver and muscle) to insulin is 
critical to the maintenance of these effects.
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6.1.4 Atherogenic Lipoprotein Phenotype
The American heart association (AHA 2012) defines atherosclerosis as a type of 
arteriosclerosis (a general term for the thickening and hardening of arteries) which 
characterizes the process of building up of plaque (consists of fatty substances, 
cholesterol, cellular waste products, calcium and fibrin) in the inner lining of an 
artery which reduces the amount of blood and oxygen that is delivered to vital organs 
(Figure 6.3). Plasma lipoproteins play a major role in the deposition and removal of 
lipids that accumulate in atherosclerotic lesions. ApoB-containing lipoproteins and 
HDL have opposite effects on CAD; they are independent risk factors for CAD 
(Castelli et al. 1992). The atherogenic lipoprotein phenotype (ALP) describes a 
common collection of abnormalities in plasma lipoproteins which causes increased 
risk of coronary heart disease (CHD) in normal, healthy individuals (Griffin and 
Zampelas 1995). The ALP is characterized by a moderately increased level of serum 
TG, a low level of HDL and a prevalence of abnormally small, dense LDL and HDL 
particles. It is likely to develop due to a complex interaction between dietary factors 
and specific apolipoprotein gene expression which is susceptible to certain dietary 
stimuli. This atherogenicity may occur due to an impaired metabolic ability to 
eliminate TG-rich lipoproteins of dietary origin (CM and CM remnants) and of 
hepatic origin (VLDL) from the circulation, leading to their alteration into small, 
atherogenic cholesterol-enriched remnants and LDL.
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Figure 6.3; Formation of plaque, the effect of LDL 
and HDL. Adapted from (AHA 2012)
6.1.5 Dietary Carbohydrate (CHO)
Carbohydrates (CHO) are the major macronutrient in most human diets (Quezada- 
Calvillo et al. 2000). They are classified as monosaccharides (glucose, fructose and 
galactose), disaccharides (sucrose, lactose, maltose and trehalose), oligosaccharides 
(a breakdown product of polysaccharides as found in com symp), polysaccharides 
(starches) and sugar alcohols (sorbitol and manitol). Furthermore, the European food 
information council (EUFIC) divides sugars into "intrinsic" and "extrinsic" sugars. 
Intrinsic sugars are those present naturally within the cellular stmcture of food, these 
sugars are mainly found in fruits and vegetables. Extrinsic sugars are those which are 
present in food or added to it. Extrinsic sugars are further divided into milk sugars 
(lactose) and non-milk extrinsic sugars (NMES) that are honey and added sugars 
(EUFIC 2012). In the USA and Canada, carbohydrate represents 32-70% of energy 
from diet (McGrane 2000) and 47-50% in the UK (Henderson et al. 2003). All
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consumed carbohydrates are digested, absorbed, and transported through the body 
predominantly as glucose, although fructose and galactose are present as well.
6.1.6 Glucose in the Liver
The liver plays a central role in glucose homeostasis. The hepatocytes (parenchymal 
cells) of the liver can completely oxidise glucose for energy, store glucose as 
glycogen (glycogenesis), or can provide carbons for the biosynthesis of fatty acids or 
amino acids. De novo lipogenesis (DNL) is the synthesis of saturated fatty acids 
(SFAs) and TGs from non-lipid precursors (simple sugars mostly glucose) in the 
liver (Aarsland and Wolfe 1998 and Parks et al. 2008). This process is stimulated by 
insulin (by activation of the rate limiting enzyme acetyl-CoA carboxylase) (Frayn 
2010a). Fatty acids synthesis by DNL is low on a typical Western diet, but it may 
become more significant on a high-carbohydrate diet (Yaqoob et al. 2005).
The liver can also produce glucose from glycogen breakdown (glycogenolysis) and 
gluconeogenesis when blood glucose level is low. The hepatocytes like other cells 
can utilise glucose for NADPH production via the pentose phosphate pathway 
(McGrane 2000).
6.1.7 Glucose in Muscles
The skeletal muscle and cardiac muscle respond to blood glucose changes by altering 
their internal usage, but they don’t release glucose in the blood (Danishefsky 1980). 
In the muscle glucose can be completely oxidised or stored as glycogen.
6.1.8 Glucose in the Adipocytes
In adipocytes, glucose can be partially degraded by glycolysis to provide glycerol for
TG synthesis. It can be completely oxidised or can be metabolised to acetyl CoA and
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the acetyl moiety channelled to de novo fatty acid synthesis for storage (during high 
carbohydrate intake) (McGrane 2000). During conditions of energy deficiency, 
adipocytes supply the tissues with metabolic fuel in the form of fatty acids by 
hydrolysing the stored TGs (lipolysis).
6.1.9 CHO Induced Dyslipidaemia
(Seneff et al. 2011) Over the last several decades, medical advice has highlighted the 
concept that a low-fat diet is a healthy diet, and this has led to a modification towards 
an increased dietary intake in carbohydrates. However, this may increase the risk of 
metabolic syndrome. Recent studies by Forsythe et al. (2008) and Volek et al. (2009) 
have established that a low-carbohydrate diet can be used as an effective approach to 
improve features of metabolic syndrome and cardiovascular risk. A crossover clinical 
trial conducted by Lê et al. (2009) showed that a short-term (7 days) hypercaloric 
high-fructose diet, in 16 healthy male (offspring of patients with type 2 diabetes) lead 
to dyslipidaemia and ectopic lipid deposition, along with increased hepatic insulin 
resistance. Following the high-fructose diet both liver fat and VLDL TGs increased 
by over 75%. Lipids stored in skeletal muscles also increased significantly. In 
addition, whole-body insulin sensitivity decreased by 27%. Stanhope et al. (2009) 
assessed the relative effects of dietary sugars during sustained consumption. 
Overweight and obese subjects consumed glucose- or fructose-sweetened beverages 
providing 25% of energy requirements for 10 weeks. Their findings suggested that 
dietary fmctose specifically increases DNL, promotes dyslipidaemia, decreases 
insulin sensitivity, and increases visceral adiposity.
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6.1.10 Fatty Acid Metabolism
Fatty acids present in the body in two forms, non-esterified fatty acids (NEFAs) that 
are carried in the plasma bound to albumin. Alternatively, they may be liberated from 
TG in the plasma (associated in lipoprotein particles). There are different sources for 
F As for TG synthesis in the liver, this includes FAs returned to the liver by 
chylomicron remnants, of VLDL remnants, NEFAs delivered bound to albumin and 
FAs formed by DNL in the liver (Yaqoob et al. 2005). Fatty acid synthesis occurs in 
the cytosol, whereas fatty acid oxidation occurs in the mitochondria.
There are several possible mechanisms for NEFA uptake. It is possible that both 
diffirsion and carrier mediated transport are involved. Different cell membrane fatty 
acid transporter are involved in fatty acid transport, this includes fatty acid 
translocase (FAT), fatty acid transport protein (FATP) and fatty acid binding protein 
in plasma membrane (FABPpm) (Yaqoob et al. 2005). In addition, FABP also acts as 
an important intracellular carrier for fatty acids delivering them to mitochondria for 
oxidation. Before FAs can take part in any metabolic reaction, they are esterified to 
coenzyme A (CoA), forming acyl CoA in the presence of several acyl CoA 
synthetases. Fatty acid synthase is an enzyme complex which plays an important role 
in fatty acid synthesis and catalyses a series of reactions involving successful 
addition of 2-carbon units to a growing fatty acid chain using malonyl CoA. The end 
product of this reaction is palmitic acid, a saturated, 16-carbon fatty acid, which is 
cleaved fi*om the complex by an integral thioesterase. Elongation and/or desaturation 
of fatty acids after palmitic acid yield different fatty acids with different chain length 
in different tissues.
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Fatty acids act through nuclear receptors known as peroxisome proliferator activated 
receptor (PPARs) mainly to regulate fat oxidation and storage (Frayn 2010a). Fatty 
acid oxidation starts at the a-, p-, or cû-carbon; p-oxidation is the most 
physiologically important pathway. In p-oxidation, F As are degraded by the 
sequential liberation of acetyl CoA units. In addition to the mitochondria, the major 
site for P-oxidation, the peroxisomes also contain the enzymes for this reaction. This 
additional site is of great importance in the liver, where partial oxidation of very 
long-chain fatty acids takes place before it is completely oxidized in the 
mitochondria.
In the postabsorptive (fasting) state, the normal plasma NEFA concentration is 
approximately 0.5 mmol/1, the circulating NEFAs being derived from adipose tissue 
TG lipolysis by HSL (Yaqoob et al. 2005). In the absorptive (fed) state, the rise in 
blood glucose concentration and subsequent insulin concentration supresses HSL 
activity, therefore the plasma NEFA concentration will fall to < 0.1 mmol/1. The rate 
of oxidation of NEFAs by tissues depends mainly on the plasma concentration i.e. 
the higher the concentration the greater the rate of utilisation. The plasma NEFA 
concentration is normally an inverse reflection of the plasma glucose and insulin 
concentration.
6.1.11 Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) involves a spectrum of disease ranging
from simple hepatic-steatosis (accumulation of fat in the interstitial spaces of the
liver) or fatty liver disease which has a benign prognosis, to nonalcoholic
steatohepatitis (NASH) (Figure 6.5) which is associated with fibrosis and progression
of cirrhosis with increased risk of hepatocellular carcinoma which can lead to liver
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failure and ultimately liver transplantation (Byrne 2012). After hepatitis B, hepatitis 
C and alcohol, NAFLD has become the most common cause of chronic liver disease 
in the developed world, affecting up to a third of population (De Alwis and Day 
2008).
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Figure 6.4: Pathogenesis of non-alcoholic fatty liver disease (NAFLD) 
and non-alcoholic steatohepatitis (NASH) (Nobili et al. 2009)
NAFLD is now recognized as the hepatic component of the metabolic syndrome 
(Byrne 2012). Insulin resistance contributes to the excess accumulation of TG in the 
liver (Figure 6.4). Smith and Adams (2011) reported that T2DM and NAFLD are 
associated with adverse effects of the other; T2DM is a risk factor for progressive 
liver disease and liver-related death in patients with NAFLD, whereas NAFLD may 
be an indicator of cardiovascular risk and mortality in people with T2DM. The 
underlying mechanisms for the association of insulin resistance and obesity to 
hepatic steatosis remain unclear.
Bugianesi et al. (2010) suggest the mechanism contributing to the accumulation of 
fat in the liver may include excess dietary fat, increased delivery of NEFA to the 
liver, inadequate fatty oxidation, and increased DNL. Liver fat is highly correlated
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with all the components of the metabolic syndrome, independent of obesity, and 
NAFLD may increase the risk of type 2 diabetes and atherosclerosis. Overproduction 
of glucose, VLDL, C-reactive protein and coagulation factors by the fatty liver could 
contribute to the excess risk of cardiovascular disease.
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Figure 6.5: The role of insulin resistance in hepatic TG 
accumulation. Insulin promotes hepatic TG accumulation by 
increasing peripheral adipose tissue lipolysis and FFA influx as 
well as up-regulating levels of hepatic lipogenic transcription 
factors SREBPlc and ChREBP. Adapted from (Smith and Adams 
2011).
In six healthy males, Timlin et al. (2005) measured the contribution of NEFA, DNL,
and dietary F As to VLDL-TG in the fed state using stable isotopes and GCMS. A
liquid diet was administered by mouth or via a continuous feeding tube. Contribution
of NEFAs to VLDL-TG was similar under meal feeding and continuous feeding.
Lipogenesis achieved a higher level with meal feeding versus continuous feeding
supporting greater stimulation of DNL from increased glucose delivery rate. The
contribution of dietary fatty acids to VLDL-TG was also greater with meal feeding.
These data revealed for the first time in human studies the well-coordinated use of
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F As by the liver during the transition from the fasted to fed states and highlighted the 
overriding role of NEFAs for VLDL-TG synthesis in both states. In 30 participants 
who were biopsy-proven NAFLD patients with a BMl <30 Kg/m^, Marchesini et al. 
(2001) measured insulin sensitivity and normal glucose tolerance. Of those 30 
participants, 9 had simple fatty liver and 21 had evidence of steatohepatitis. They 
concluded that NAFLD, in the presence of normo-glycemia and normal or 
moderately increased body weight, is characterized by clinical and laboratory data 
similar to those found in diabetes and obesity. NAFLD may be considered an 
additional feature of the metabolic syndrome, with specific hepatic insulin resistance. 
Using stable isotopes in human participants with NAFLD, Diraison et al (2003) 
showed that enhanced DNL appears as a major abnormality of hepatic fat mtabolism 
which contribute to the accumulation of TGs in lipoprotein and hepatocytes. In 
another study using stable isotopes in human participants Donnelly et al. (2005) 
quantified the biological sources of hepatic and plasma lipoprotein TAG in 
participants with NAFLD who were obese with fasting hypertriglyceridemia and 
hyperinsulinemia. They were orally fed stable isotopes for 4 days to label and track 
serum NEFAs, dietary F As, and those derived from DNL pathway, present in liver 
tissue and lipoprotein TG. The quantitative metabolic results showed that both 
elevated peripheral F As and DNL contribute to the accumulation of hepatic and 
lipoprotein fat in NAFLD. Byrne (2012) proposed that fatty acid fluxes through the 
liver are crucial for the pathogenesis of NAFLD and for increasing IR. Therefore, 
strategies that aim to decrease liver fat and improve whole-body insulin sensitivity 
may both contribute to prevention of T2DM and to better glycaemic control in people 
who already have developed diabetes.
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In addition, it has been found that, liver fat is closely correlated with serum TGs and 
VLDL production (Adiels et ah, 2006 and Kotronen et ah, 2007). In addition to its 
role in the pathogenesis of T2DM, NAFLD may have an important role in the 
pathogenesis of CVD. Both Ryysy et al. (2000) and Seppala-Lindroos (2002) found 
that once the liver accumulate fat (becomes fatty liver) it develops insulin resistance 
and over produce glucose. Also, fatty liver over produce VLDL (Malmstrom et al. 
1997 and Adiels et al. 2006) leading to hyperglycemia, hypertriglyceridemia, and a 
low HDL cholesterol concentration which contribute to the excess risk of CVD. 
Donati et al. (2004) examined the hypothesis that fatty liver with normal liver 
enzymes occurs more frequently in arterial hypertensive patients and to establish 
whether this condition is associated with insulin resistance. They found that the 
higher prevalence of NAFLD in non-obese hypertensive patients with normal liver 
enzymes appears to be related to increases in insulin resistance and body weight. 
Kotronen and Yki-Jarvinen (2008) reported that in 1439 men and women aged 50 to 
75 years participating in the Hoorn Study in the Netherlands, the increased serum 
alanine-amino transferase (ALT, which is an indicator for fatty liver) at baseline 
increased the 10-year risk of CHD events even after adjustment for components of 
the metabolic syndrome and other CVD risk factors (glucose tolerance status, 
systolic blood pressure). On the other hand, many well-defined CVD risk factors 
play a major role in the pathophysiology of NAFLD.
Therapeutic actions aimed at decreasing hepatic lipogenesis would be the most 
appropriate in order to reduce hepatic TG synthesis and content and concemitantly 
will reduce CVD risks.
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6.1.12 NAFLD and Dietary Carbohydrate
Several human studies which looked at the effect of weight loss (due to low caloric 
intake with or without exercise) on liver fat have shown that even small reductions in 
body weight (as small as 3%, Kantartzis et al. 2009) result in significant decreases in 
liver fat (Colles et al. 2006, Larson-Meyer et al. 2006, Kirk et al. 2009 and Shah et 
al. 2009).
Sobrecases et al. (2010) have studied the effects of short-term (7days) overfeeding 
with fat, fructose, or a combination of both on liver fat content in humans. They 
found no significant differences in changes in liver fat content in response to the 
different diets, but the number of participants was relatively low (fructose, n=12, fat 
diet, n=10 and fructose fat diet, n=8). A different response was observed in serum 
VLDL triglycerides, which significantly increased during fructose and decreased 
during the fat overfeeding period, indicating that overfeeding with fructose but not 
with fat stimulates VLDL triglyceride production.
These findings were supported by a recent Finnish study by Sevastianova et al. 
(2012). It showed that, a short period of (3 weeks) carbohydrate overfeeding in 
overweight participants increased body weight and liver fat by 2% and 27% 
respectively. Furthermore, liver fat increase was proportional to the increase in DNL 
and long term weight loss (6 months) restored liver fat to normal. These data show 
that the fatty liver accumulates fat during carbohydrate overfeeding and support the 
role for DNL in the pathogenesis of NAFLD.
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6.1.13 Hepatic Lipase and Lipoprotein Lipase
Several human studies (Tan et al. 1999, Prenais 2001 and Berk-Planken et al. 2003) 
observed an association between the abnormalities in lipase (LPL and HL) levels and 
the plasma lipoprotein profile in people with impaired glucose mtabolism (T2DM) 
and with features of the metabolic syndrome, therefore, a relation between insulin 
resistance and lipase activities has been found. Thus, HL is involved in lipoprotein 
mtabolism and may contribute to the atherogenic lipid profile in type 2 diabetes (Bos 
et al. 2004).
(Tan et al. 1999) found that HL was significantly increased in both the male and 
female participants with type 2 diabetes compared to their controls. Also, plasma 
when LDL particles become enriched in TG they are then acted on by HL to produce 
lipid-poor sdLDL.
Bos et al. (2004) found a significant interaction between LPL activity and glucose 
mtabolism (p=0.03), indicating that glucose mtabolism is an effect modifier in the 
relationship between LPL activity and LDL size. Thus, higher LPL activity might 
protect against the development of small LDL size, especially in participants with 
type 2 diabetes, who have increased TG concentrations. Nevertheless, in the 
multivariate model containing plasma TG, LPL and CETP, HL activity did not 
contribute to LDL size in any of the glucose mtabolism groups. These findings may 
indicate that HL activity is not rate limiting in the formation of sdLDL in this 
population and suggest that further than TG concentration, lipolytic enzyme activities 
explain the differences in LDL size in both diabetic and non-diabetic people. LPL 
and HL also play an important role in abnormal HDL mtabolism in insulin resistance 
and metabolic syndrome (De Vries et al 2003). LPL hydrolyses TG in lipoprotein
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particles, thus providing lipids for HDL formation. In insulin resistance states, a 
decreased post-heparin plasma LPL activity contributes to the low HDL cholesterol;, 
increasing the risk for premature atherosclerosis as observed in in insulin resistance 
and type 2 diabetes.
However high HL activity is linked with low HDL cholesterol i.e. increased activity 
of HL reduces HDL particle size by hydrolysis HDL-TGs and phospholipids, 
Dyslipidemia eith high HL activity is potentially pro-atherogenic lipoprotein profile 
in the metabolic syndrome, in type 2 diabetes, and in familial combined 
hyperlipidaemia ( Deeb et al. 2003). Recently, Miksztowicz et al.(2012) found that 
patients with hepatic steatosis presented with higher HL activity , HOMA and dense 
LDL. HL correlated with a more atherogenic profile and remained higher in patients 
even after correcting for age, gender, body mass index, HOMA and adiponectin. The 
higher HL activity in NAFLD patients contributes to a more atherogenic profile 
linked to increased cardiovascular risk, beyond the insulin reisitance and the 
reduction in adiponectin.
6.1.14 Effect of Diet and Lipases
Animal studies by (Wang et al. 1987 and Bhattacharyya et al. 1989) showed that 
increased saturated fat and cholesterol intake cause an increase in both HL and LPL 
activity. All changes occurred simultaneously, suggesting metabolic relationships 
between plasma lipolytic activities, plasma lipids, and apolipoproteins.
Several human studies were undertaken to test whether LPL or HL activities are 
associated with lipoprotein subclasses, and to assess the effects of dietary 
manipulations on these associations. Campos et al. (1995) measured the enzyme 
activities in post-heparin plasma from healthy men who were randomly allocated to a
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low-fat or a high-fat diet for 6 weeks each in a cross-over study design. The high-fat 
diet significantly increased both LPL and HL activities. On both diets, HL activity 
was significantly positively correlated with plasma apoB concentrations, and with 
levels of sdLDL III, while LPL activity was inversely associated with levels of LDL 
III. The authors hypothesised that increased LPL activity induced by high-fat feeding 
may contribute to the accumulation of both large LDL I and small IDL in the plasma, 
whereas increased HL may increase sdLDL.
In an animal study which comparing a sucrose diet and with a starch diet, Sharma et 
al. (1986) markedly increased insulin levels compared to starch. Post heparin LPL 
activity was increased 2-3 fold more in the sucrose than in the starch diets. HL 
activity was increased more with the sucrose diet than the starch diet.
In a crossover clinical trial, Chen studied the effect of low-fat high-CHO diet for 6 
weeks in patients with non-insulin dependent diabetes. They found that low-fat high 
CHO led to higher plasma glucose, insulin, and TG concentrations, postprandial 
accumulation of TG-rich lipoproteins of intestinal origin; increased production of 
VLDL-TG; and increased post heparin LPL activity.
6.1.15 The Use of Stable Isotopes Technique to Measure Free Fatty 
Acid Kinetics
Investigation of lipid mtabolism and its regulation requires information about the 
rates of lipid absorption into the body (fi*om the intestine), production and transport 
within the body and utilization by different tissues. One of the most renowned 
methods to investigate lipid mtabolism in humans in vivo is the use of isotope- 
labelled tracers for the quantitative evaluation of major pathways of FA and TG
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mtabolism (Magkos and Mittendorfer 2009). The isotopes labelled tracers are used 
to study adipose tissue lipolysis and NEFA appearance in the plasma, FA tissue 
uptake and oxidation, and hepatic VLDL-TG production. An intravenous tracer 
infusion together with arterialized venous or arterial blood sampling provides data 
that reflects the physiology of the release by adipocytes of FF As into the venous 
circulation for delivery to tissues via the arterial circulation (Basu and Jensen 2005). 
The measurements from these kinds of studies and the interpretation of data can 
provide unique insights into human lipid mtabolism. A tracer is a compound that is 
administered (usually intravenously or orally) into the body to trace the mtabolism of 
the tracee (a specific compound of interest), therefore, the tracer must be 
metabolically indistinguishable from the tracee but distinct in some way that allows 
its detection (Wolfe 1992). Normally one or more naturally occurring atoms in the 
molecule of the tracee are substituted with one or more stable or radioactive isotopes 
of that atom. Although radioactive isotopes are used by some research groups, stable 
isotopes are now used in the majority of lipid kinetic studies. Stable isotopes of the 
same element (e.g., and ^H, and ^^ C) have the same number of protons and 
different number of neutrons in their nucleus; therefore they have the same chemical 
properties but different atomic mass, this property allows their detection. The major 
principle of using stable isotope tracers in metabolic investigation is that the 
metabolic fate of the tracer and the tracee are indistinguishable. An example of a 
stable isotope labeled tracer used in metabolic research is palmitic acid, where 1- 
^^Ci-palmitic acid (one carbon atom at position 1 is replaced with (Figure 6.6).
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palmitic acid
H,C
Molecular mass = 256
t.«C^-palmillc add
Molecular mass = 257
Figure 6.6: An example of a tracer labeled stable isotope used in 
metabolic research is, 1-^^Ci- palmitic acid where one carbon atom 
at position 1 is replaced with (Magkos and Mittendorfer 2009)
6.1.16 The Tracer Theory
Detection and quantification of stable isotope tracers relies on the separation of the
tracer using mass spectrometry (MS) which separates and measures compounds
according to their mass (Wolfe 1992). Tracer enrichment which is the amount of
tracer relative to the tracee is actually of the most interest (Patterson 1997). Measures
of enrichment are typically made as tracer-to-tracee ratio (TTR), which refers to the
ratio of the labelled and unlabelled molecules in the biological sample e.g., a TTR of
0.05 indicates that the amount of tracer is 5% of the amount of tracee, or mole
percent excess (MPE) or atom percent excess (APE), which refers to the molar ratio
of the labelled molecule/atom and the sum of the labelled and unlabelled
molecules/atoms in the biological sample e.g., a MPE or APE of 0.05 indicates that
the amount of tracer is 5% of the total amount of tracee plus tracer molecules/atoms.
The enrichment can also be assessed relative to a standard of known isotopic
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enrichment, in which case the enrichment of the biological sample is compared to the 
isotopic enrichment of a reference standard, and then the data can be expressed as 
delta i.e. the difference between the sample and the standard. Gas-chromatography 
(GC) MS in selected ion monitoring mode is usually used to determine the TTR, 
where the abundances of a particular fragment of the molecule containing the heavier 
isotope (tracer) or not (tracee) are compared. Isotope ratio (IR) MS can be used to 
analyze very low TTR values; now, GC combustion IRMS has become available, 
combining the resolution capabilities of GC with the accuracy and precision of IRMS 
(Patterson 1997). Tracers labeled with stable isotopes measure the TTR is able to 
readily determine the position of a label within a molecule with accuracy and 
precision (Coggan et al. 2005). Since stable isotope-labeled tracers are used to 
provide quantitative information about the metabolic fate of the tracee, it is important 
that tracers are given in accurate trace amounts in order to avoid disturbance to the 
system under study. Under steady state conditions (stable FFA concentrations and 
flux), the rate of FFA appearance (Ra) equals its rate of disappearance (Rd) (Basu 
and Jensen 2005). FFA flux is calculated using the isotope dilution technique which 
measures the dilution of the infused tracer with the endogenous FFA. The ratio of 
tracer infusion rate and the specific activity or enrichment of the tracer in plasma 
FFA provides a measure of FFA flux (Jensen et al. 1988).
The breakdown of TG is usually complete i. e. 1 mole of TG gives rise to 1 mole of
glycerol and 3 moles of FFAs. To measure the rate of adipose tissue lipolysis,
researchers normally measure the rate of appearance of glycerol or FFA in the
bloodstream by short-term constant infusions of glycerol and/or fatty acid tracers.
Both the studies of Coppack et al. (1999) and Wolfe and Peters (1987) showed that
quantitatively, whole-body lipolysis reflects adipose tissue lipolysis. On the other
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hand, Beylot et al. (1987) found that the release of FFA and glycerol in plasma does 
not always occur in the theoretical ratio of 3:1, because some FFAs are re-esterified 
to TG within adipocytes and do not enter the circulation. However, glycerol is 
completely released because adipose tissue contains little glycerol kinase activity 
(Reshef et al. 2003). Wolfe and Peters (1987) and Klein and Wolfe (1987) 
established that FFA Ra measurements provide a reasonable estimate of adipose 
tissue lipolytic activity under most circumstances. In the postprandial state, lipolysis 
of plasma TG provides some FFAs which may escape tissue uptake and enter the 
systemic circulation, however Miles et al. (2004) and Gormsen et al. (2006) found 
that this is not an important source of total plasma FFA flux during the 
postabsorptive or fasting state. Different types of FFAs are circulating in the plasma, 
which vary in structure and chain length. Palmitic acid (the single long chain fatty 
acid) appears to be suitable tracer for the entire FFA fraction in most instances 
(Hagenfeldt et al. 1972). Total plasma FFA flux can then be calculated by dividing 
the endogenous Ra of that fatty acid by its relative contribution to total plasma FFA 
concentration.
187
6.1.17 Objectives
To evaluate the effects of dietary extrinsic sugars on the rate of peripheral lipolysis 
using labelled palmitate (U-^^C palmitate). This will establish if dietary extrinsic 
sugars affect the availability of fatty acids from peripheral lipolysis for VLDL-TG 
synthesis.
To determine the effect of dietary sugars on the activity of endothelial lipases (LPL, 
HL) in post-heparin plasma. The measurement of lipase activities will provide some 
evidence for the effect of extrinsic sugars on the rate of clearance of TG-rich 
lipoproteins, in the fasting state.
6.1.18 Aim
The aim of this study was to examine the effects of two different test diets, high and 
low in dietary sugars (differing in the quality of carbohydrate but the same 
carbohydrate content in weight and total percentage energy) on peripheral lipolysis 
and endothelial lipases using a dietary exchange model (DEM), in two groups of 
male participants at risk of metabolic syndrome having different liver fat content, 
those with low liver fat content (<5%) or high liver fat content (8-35 %).
6.1.19 Hypothesis
With the diet high in extrinsic sugars compared with the diet low in extrinsic sugars 
there will be greater availability of fatty acids from peripheral lipolysis for the 
synthesis of TG in the liver. The extent of this effect will relate to the amount of liver 
fat.
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6.2 Methods
6.2.1 Clinical Protocol
This study was a randomised dietary intervention with a cross-over design. A dietary 
exchange model (DEM) was designed and formulated based on data from the 
National Diet and Nutrition Survey (NDNS) (Department of Health 2011). It 
received ethical approval from Surrey Research Ethics Committee (Ethics no. 
08/H1109/227) (Appendix 10). This study was part of a larger metabolic study 
funded by the Biotechnology and Biological Sciences Research Council (BBSRC) to 
address the impact of dietary sugars on plasma lipoprotein kinetics.
6.2.2 The Dietary Intervention
The DEM was designed according to the mean intakes of two groups of men, aged 
35-49 years and 50-64 years, as published by the NDNS (NDNS 2004). The two 
diets were (1) high non-milk extrinsic sugar and (2) low non-milk extrinsic sugar 
(Swan 2004). The total carbohydrate content of these two diets was set at 47% of 
total energy intake, which is the carbohydrate mean intake reported by the NDNS for 
men aged 35-49 years and 50-64 years . The target for the high and low intake of 
extrinsic sugars , 24% and 6% of total energy intake respectively, was based on the 
upper and lower limits of extrinsic intake of carbohydrate in 90% of the UK male 
population according to NDNS. Table 6.2 shows the target energy and macronutrient 
content in one portion of study food for the high and low sugar diet.
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Table 6.2: The target energy and macronutrient content in one
portion o f  study food for the high and low  sugar diet.
High sugar diet Low sugar diet
Total energy (MJ) 1.07 1.07
Protein (g) 9.84 9.84
Total CHO (g) 30.14 30.14
Sugar (g) 20.00 2.00
Starch (g) 10.10 28.10
Fat (g) 9.50 9.50
Saturated fat (g) 3.60 3.60
Dietary fiber (g) 1.77 1.77
The two diet interventions lasted for 12 weeks. All participants underwent a run-in 
diet for 4 weeks, and were then randomised to one of the intervention diets for 12 
weeks. First and second interventions were separated by a 4 week wash-out diet. 
Run-in and wash-out diets were based on the macronutrient intake of the average 
male in the UK, according to NDNS. During the high and low sugar phases, the 
sugar intake was 173 ± lO.Og and 56±4.0g respectively.
At the end of each intervention, metabolic studies were performed in order to 
measure fatty acid kinetics and lipoprotein lipase activity. Other metabolic 
measurements were also made which do not form part of this thesis.
6.2.3 Study Participants
6.2.3.1 Screening
The study aimed to recruit 30 men, 15 with high liver (>5%) at and 15 with low liver 
fat (<5%). The recruitment and screening for the study was performed by the
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recruitment and screening research team. Participants were recruited through an 
existing network of links with GP surgeries in the County of Surrey through primary 
care research network (PCRN) which provided pre-screening data on anthropometric 
measurements, plasma glucose and serum insulin concentrations and blood pressure 
allowing the selection of the suitable volunteers for the screening. Both the approved 
invitation letters and participant information sheets were sent to the selected 
participants by the GPs (Appendix 11). Other approaches included; direct contact 
with local authorities, companies and colleges via emails and letters, leaflets 
distributed to offices, shops and houses, posters displayed on local community notice 
boards. Initial telephone interviews and pre-screening questionnaires were 
performed before inviting the volunteers for the first screening appointment at 
CEDAR. In the first screening visit each participant completed a form for their 
personal details and basic health questionnaire and written consent was obtained. 
Anthropometry measurements such as height, weight, body composition using Bio­
impedance analysing method (Tanita Body Composition Analyser BC-418MA) and 
blood pressure (Dynoscope Fukuda Denshi DS-7100) were measured. A fasting 
blood sample was obtained and sent for analysis at the RSCH for the determination 
of basic biochemistry. Liver enzymes alanine amino transaminase (ALT), aspartate 
aminotransferase (AST), gamma glutamyl transferase (yGT), TAG, total LDL, HDL- 
Chol and ApoE phenotype were measured at the RSCH laboratory. Table 6.3 shows 
the inclusion and exclusion criteria.
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Table 6.3: The inclusion and exclusion criteria for CHOT study.
Inclusion criteria
Participants with the following criteria were included:
>Healthy Caucasian male aged 40-65 years 
>BMI 26-32
> Cardiometabolic score 4-10 
>ApoE3 homozygous
>Liver fat <5% or between 8-30%
Exclusion criteria
Participants with the following criteria were excluded:
> Alcohol consumption of more than 2 units/day
^Unstable body weight for past 3 months (max variance 2.5 kg)
>Any surgical procedure to lose weight 
>Liver fat >30%
>Diagnosis with/history of T2DM or other endocrine diseases 
>Diagnosis with/history of renal diseases 
>Diagnosis with/history of CHD, angina or stroke 
>Diagnosis with/history of liver diseases (except NAFLD)
>Diagnosis with/history of eating disorders
>0n lipid-lowering drugs or drugs that alter body weight and appetite 
(beta-blockers, statins, fibrates, metformin)
>Metal implants in the body
> Cancer
>Claustrophobia 
>Mental disorder
Selection and recruitment of the volunteers with cardiometabolic risks was based on 
the metabolic score adapted from the RISCK study (Jebb et al. 2010), Table 6.4 
shows the cardiometabolic scores criteria. Participants with score >4 were classified
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as being at increased risk of developing metabolic syndrome and suitable for the 
study and therefore were included. All participants were homozygous for the apo E3 
genotype, those who were carriers of apo E2 and apo E4 alleles were excluded from 
the study, since there is evidence that the presence of apo E2 is potentially cardio­
protective, whereas apo E4 predisposes to CHD.
Table 6.4: Criteria for cardiometabolic scores (Adapted from Jebb et al.
2007)
Parameter Score
Glucose >5.5 mmol/1 3
Insulin > 40 mmol/1 3
BM I25-30 kg/m^ 1
BMI > 30 kg/m^ 2
Waist circumference > 94 cm 1
Waist circumference >102 cm 2
TG >1.3 mmol/1 1
HDL <1.0 mmol/1 2
Blood pressure:
Systolic >140 mmHg 1
Dystolic > 90 mmHg 1
Total Score *
* If Total Score:
< 4 = Not at cardiometabolic risk —> Excluded
> 4 = At increased cardiometabolic risk Included
>10 = At high cardiometabolic risk “patient” —> Excluded
6.2.3.2 Liver Fat Determination
Magnetic resonance spectroscopy (MRS) was performed at the Robert Steiner Unit at 
the Hammersmith Hospital in London. Intra-hepatocellular lipid (IHCL) was
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determined by ^H-magnetic resonance spectroscopy and the spectra were acquired 
using a 1.5T multinuclear system (Philips Medical Systems, Netherland) from the 
right lobe of the liver, using the water signal as an internal reference. The fat content 
in the liver was expressed as a ratio to water content. Participants were included in 
the study and allocated into one of the two groups when they revealed low IHCL < 
5% or high IHCL between 8-35%. Those participants who did not fulfil these criteria 
were notified. For those participants who were recruited to the study their GP was 
informed. All eligible participants were contacted and booked for the initial visit at 
CEDAR.
6.2.4 The Study Protocol the i n  v iv o  Measurement of Fatty Acid 
Metabolism
6.2.4.1 Randomisation and First Pre-dietary Intervention Visit
Participants attended an initial visit at CEDAR after an overnight fast. Weight, body 
fat percentage and fat free mass were measured by bioimpedeance (Tanita), and 
fasting blood sample were taken. Participants were supplied with study food and 
given food portion sheets (to be completed on a daily basis for two weeks). During 
the interventions, participants were instructed to maintain their usual level of 
physical activity. The same procedure was followed at the start of the second 
intervention. Figure 6.7 shows the study design.
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6 .2  A . 2  End of Dietary Intervention
Liver fat was an end-point measure; therefore, participants were given the choice of 
optional second and third liver scans on a week before or after the kinetic study day 
to examine the effect of the dietary intervention on their liver fat. At the end of each 
dietary intervention participants underwent a clinical kinetic study under the 
supervision of the clinical research team at CEDAR. On the night before the study 
day, participants were provided with a standard evening meal to be consumed 
between 6 and 7 pm. They were asked to avoid vigorous exercise for two days and 
alcohol consumption for 24 hours before the study day.
On the day of study, after fasting for at least 12 hours two iv cannulas were inserted 
into each arm; one for the administration of the uniformly labelled U-^^Ci6 palmitate 
(98% enriched , sterilised and prepared for human use in the Pharmacy department, 
Guy’s and St Thomas’ Foundation Trust, London). The other cannula was for blood 
sampling throughout the day. Ten minutes before starting the iv infusion, i.e. at -10 
min and at 0 min blood samples were drawn for determination of the background 
enrichment of plasma palmitate and the plasma baseline NEFA, glucose and serum 
insulin. Immediately following blood sampling, a constant-rate continuous iv 
infusion (0.01 pmol.Kg'^min'^) of the uniformly labelled palmitate (U-^^Ci6 PA) 
bound to albumin (5%) was started using a calibrated IVAC pump (IVAC560 pump; 
IVAC, San Diego, USA) for 8 hours in order to determine the rate of appearance of 
palmitate (Ra palmitate) a measure of lipolysis. Blood samples were drawn at the 
following time points (0, 60, 90, 120, 150, 180, 240, 300, 360, 420 and 480 min) to 
determine the enrichment and the concentration of palmitate in plasma samples. At 
the end of the study an additional blood sample at (t = 480 min) was drawn as a
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sample of pre-heparin plasma, then an iv heparin injection (5U/Kg) was administered 
and a post-heparin plasma (PHP) sample was obtained at 10 min for the 
measurement of total and hepatic lipase activity determinations.
All blood samples were collected into suitable vacutainers containing the following 
coagulants; K2EDTA for the determination of NEFA; fluoride oxalate for plasma 
glucose and lithium heparin for plasma insulin. Then, all samples were mixed gently, 
kept on ice and centrifuged at 4°C (Sorvall Legend RT Centrifuge, Thermoelectron 
Corporation, Thermofisher Scientific, Hampshire, UK) at 2500 rpm (1439 xg) for 10 
min within 30 min of taking the samples. Aliquots of plasma (0.5 ml) were stored 
into labelled cryovials and stored at -80°C freezer until analysis by the researcher in 
the laboratories of the Diabetes and Metabolic Medicine department.
6.2.4.3 Measurements of Plasma Metabolites
The procedures followed to measure plasma NEFA, glucose and insulin were 
described previously in chapter 2.
6.2.4.4 Measurements of Palmitate Enrichment and Concentration
NEFAs were extracted from plasma, isolated and derivatized to their methyl esters. 
Isotopic enrichment of palmitate was determined by gas chromatography mass 
spectrometry (GC-MS). Palmitate concentration was also determined in the same 
sample using heptadecanoic acid as an internal standard.
6.2.4.5 Free Fatty Acid Extraction
Free fatty acid methyl esters (FAME) were prepared from NEFAs in plasma samples 
(Wolfe et al. 1980). Heptadecanoic acid (HA) (Sigma) prepared in heptane at 50
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pg/ml was used as internal standard. Plasma samples (all time points) were processed 
first in 3ml glass vials by adding 250pi of plasma to 250pl of HA and gently shaken 
on a horizontal platform vortexer (Shaker orbit 1000, Labnet international Inc., 
Woodbridge, DC) at 150 rpm speed for 3 min. To precipitate the proteins 3ml of ice 
cold acetone were added and vortexed vigorously on a multi-tube vortexer (VX- 
2500, Henry Troemrer LLC, USA) at speed 3 for 10 sec and incubated at -20°C for 
15 min. Then, the vials were centrifuged at 2500 rpm (xl400g) for 10 min, the 
supernatant was transferred to new 10 ml vials using Pasteur pipettes then 3ml of 
hexane and 3ml of water were added and vials were capped securely with Teflon- 
lined caps. The vials were gently shaken on the orbital shaker at 150 rpm speed for 
15 min then, centrifuged at 2500 rpm (x 1400g) for 10 min to separate the solvent 
and aqueous phase. The upper solvent phase was transferred carefully to a new 10ml 
vial using a Pasteur pipette, the solvent was evaporated by putting the vials under 
OFN. Over drying was avoided.
6.2.4.6 Derivatisation
In this step the FAME was prepared by adding to the vials 250pl of phosphate buffer 
(Appendix 12) and 250pl of freshly prepared iodomethane (1:10 vol/vol 
iodomethane in dichloromethane). The vials were vigorously mixed on the multi­
tube vortexer at speed 3 for an hour. The FAME was extracted by adding 3ml of 
hexane. The vials were vigorously mixed on the multi-tube vortexer for 30 min and 
centrifuged at 2500 rpm (x 1400g) for 10 min. The top solvent layer (~ 3ml) was 
removed with a Pasteur pipette and transferred to a new 10ml vial. The sample 
containing the FAME was concentrated carefully under OFN to 1.5 ml volume.
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6.2.4.7 Purification
An elution solution of 2% ethyl acetate (v/v) in hexane was prepared. A solid phase 
extraction (SPE) system was set by using SPE cartridges (LC-Si, 3ml size, Supelco, 
Bellefonte, USA) on a 12-port SPE vacuum manifold (Restek Corporation, 
California, USA) (Figure 6.8) and attached to a water vacuum tap. The SPE system 
was prepared first by washing the valves, outlets, and cartridges twice with 1.5ml 
hexane, all hexane eluate was collected in the waste tubes. After all solvent had run 
through the cartridges (without allowing them to dry) the 1.5ml samples were 
transferred on the top of the cartridges using glass Pasteur pipettes and ran through. 
The sample vials were rinsed with another 1.5ml and added to the top of the 
cartridges and this was also run through the columns, and all hexane eluates were 
collected in the waste tubes. When all hexane wash had run through the cartridge, the 
waste tubes were replaced with new 10ml collection tubes, FAME was eluted twice 
with 1.5ml ethyl acetate elution solution and the cartridges were let to run to dryness. 
The solvent was carefully evaporated under OFN flow. Samples were reconstituted 
with lOOpl hexane and transferred to GC-MS autosampler vials (0.3ml, Chromacol 
Ltd., Herts, UK).
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Figure 6.8: The 12-port solid phase extraction vacuum 
manifold (Restek Corporation, California, USA)
6.2.5 Gas Chromatography Mass Spectrometry (GC-MS)
6.2.5.1 GC-MS Instrumentation
The isotopic enrichment of plasma palmitate in the prepared FAME derivatives were
measured by electron impact (El) GC-MS. Samples were analysed with a GC-MS
system (5975 inert XL EEC! mass selective detector, Agilent Technologies,
Berkshire, UK), they were introduced to the column by 2 pi splitless injection using
an Agilent 7683 auto-sampler and the injector temperature was set at 250°C. The GC
was equipped with a HP IMS capillary column (100% dimethylpolysiloxane) (30
metre x 0.25 mm inner diameter (id), 0.25 pm film capillary column (J and W
Scientific, Inc. CA, USA) using helium as the carrier gas (1 ml/min). The GC oven
temperature was held at 100° C for 1 min and then increased at 25°C/min to a final
temperature of 300°C. The retention time for palmitate was about 14.5 mins and the
total GC run time was 20 mins. Ions were monitored in El mode and palmitate
enrichment and concentration were determined by selectively monitoring ions at
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286.3 m/z (ion fragment of U-^^Ci6 palmitate) representing the tracer and 270.3 m/z 
(ion fragment of un-labelled 6 palmitate) representing the tracee (Figure 6.9) and
284.3 m/z (ion fragment of the internal standard Cn heptadecanoic acid). The area 
under the peak was measured by auto-integration.
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Figure 6.9: Selective ion monitoring using El mode for ^^CiôFA at m/z 270.3 
and U- ^^CiôPA at m/z 286.3. Analysed with a GC-MS system (5975 inert XL 
EFCI mass selective detector, Agilent Technologies, Berkshire, UK),
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6.2.S.2 Standard Curves
Palmitate standards were made using a 30pg/ml stock solution of ^^Ci6Na-Palmitate
(Sigma, UK) and 2pg/ml stock solution of U-^^Cig uniformly labelled palmitate
(Cambridge isotopes, USA) as shown in Table 6.5.
Table 6.5: Preparation of standard curve of sodium palmitate (^^CiePA) and 
uniformly labelled palmitate (U-^^CiePA) for enrichment measurements
No.
Tracer
U-^^Ci6PA
w
Tracee
^ 'C i6?A
w
Theoretical
TTR
U -'^Ci6/''C i6
Measured
TTR
U -'^Ci6/''C i6
1 0 7.47 0 0
2 0.003 7.47 0.00053 0.00065
; 3 ■.. 0.007 7A7 0.00106 0.00119
4 0.015 7.47 0.00212 0.00221
: 5 ... 0T%3 7:47 0.00319 6:00335
6 0.031 7.47 0.00425 0.00437
; 7 . 0.039 7.47 0.00532 0.00539
8 0.047 7.47 0.00638 0.00649
9 0.063 7.47 (kÜ0851 0.00871
The standard curve was obtained by plotting the measured tracer/tracee ratio (TTR) 
of labelled to unlabelled palmitate against theoretical TTR. Figure 6.10 shows the 
linear relationship of the standard curve with a slope of 1.011 ±0.002 and R^=0.9997 
(n=5).
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Figure 6.10: The standard curve for GC-MS measurements of plasma 
palmitate enrichment. Results are presented as mean+SEM (n=5).
The QCs for this assay were prepared using the infusate (U-^^Ci6 palmitate, 1.5 
pmoEml 5% human albumins) mixed with human plasma, in order to explore the 
reliability of the drivatisation and GC-MS performance. The CV of the QC was 2.4% 
(n=10). In addition, to test GC-MS machine reliability and to check the background 
enrichment, RM6 a mixture of already derivatised fatty acid methyl esters (AOCS 
std#6, Thames Restek UK Ltd, Saunderton, Bucks, UK), with palmitate methyl ester 
(30 % by weight as one of the components) was included every time an assay was 
performed. The TTR achieved from this standard was expected to be close to zero. 
The intra-assay CV and the inter-assay CV was 5.4%, and was 8.9% respectively.
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For palmitate concentration determination, palmitate standards were prepared using a 
30pg/ml stock solution of CieNa-Palmitate (Sigma, UK) and 7.6pg/ml stock solution 
of the internal standard Cn heptadecanoic acid (Sigma) as shown in Table 6.6. The 
plotted standard curve produced a linear relationship with a slope of 0.912 ±0.02 and 
R^=0.995 (n=5) (Figure 6.11).
Table 6.6: Preparation of standard curve of sodium palmitate (Na-Palm) for 
concentration measurements using heptadecanoic acid (HA) as an internal 
standard. (n=5)
No. (PA) Ci6 
(Pg)
(HA) Ci7 
(Pg)
Theoretical 
ratio Ciô/Cn 
pg ratio
Measured
ratio
Ciô/Cn
Theoretical
ratio
Ciô/Cn
pmol ratio
1 0 7.6 0 0 0
2 2.988 7.6 0 J9 0.47 0TW3
3 5.976 7.6 (178 0.77 0.086
4 K964 7.6 1.17 1.05 0T29
5 11.952 7.6 1.57 1.44 0.172
6 14.94 7.6 1.96 1.85 0.215
7 29.88 7.6 3.92 3.64 0.430
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Figure 6.11: Standard curve for GC-MS measurements of plasma 
palmitate concentration using internal standard of heptadecanoic 
acid. Results are presented as meaniSEM (n=5).
6.2.5.3 Calculations of Palmitate Enrichment and Concentration
The isotopic enrichment of U- ^^ Ci6 palmitate in samples following the infusion was 
calculated at each time point. Ratios between peak areas of ions with m/z 286.3and 
m/z 270.3 were calculated at each time point as T,/Te (tracer to tracee) enrichment. 
TTR (tracer to tracee ratio) was calculated at each time point as T,./Te enrichment 
relative to baseline enrichment:
TTRt = (Tr/Te)t - (Tr/TJo  
Plasma palmitate concentration was measured by GC-MS using heptadecanoic acid 
as the internal standard. Peak area of the ion at m/z 270.3 (plasma palmitate-methyl 
ester) relative to peak area of the ion at m/z 284.3 (internal standard -heptadecanoic 
acid methyl ester) were used to calculate plasma palmitate concentration at steady 
state. Between 90-120 min of the ^^C-palmitate infusion, a physiological and isotopic
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steady state was assumed and therefore, to calculate the palmitate rate of appearance 
{Rd) or disappearance {Rd) Steele’s equation for steady state was used 
At steady state: Ra= Rd= F/TTR
Where F  is the infusion rate of palmitate in pmol/min, and TTR is the increase in the 
ratio of U^^C-to plasma palmitate during infusion, compared with background:
The total plasma FFA Ra (the measure of whole body lipolysis) was calculated by 
dividing palmitate Ra by the fractional contribution of palmitate to the total FFA 
concentration (which is usually about 25%).
6.2.6 Lipoprotein Lipase and Hepatic Lipase Activity
Determination in Pre- and Post-heparin Plasma
The total and hepatic lipase activity were measured using a continuous fluorometric 
lipase test (Conflulip lipase test. Progen, Biotechnik Gmbh, Heidleberg, Germany) 
by analysing triglyceride hydrolysis capacity in post-heparin plasma samples. The 
Progen kit contains a lipase substrate (l-trinitrophenyl-amino-dodecanoyl-2- 
pyrendecanoyl-3-O-hexadecyl-sn-glycerol), a triglyceride in which pyrene 
fluorescence is intra-molecularly quenched by the trinitrophenyl group. When the 
active lipase was added the quencher was hydrolysed and the pyrene fluorescence 
was detected. The fluorescence intensity increased in proportion to lipase activity by 
incubation at 37°C. The change in fluorescence intensities is proportional to the 
enzymatic activity in the sample. The two lipase kits use the same substrate for the 
enzyme, but they differ from each other in their assay buffer preparation. Total lipase 
(TL) assay kit (PR2003) measures lipase activity at pH 8.2 and at physiological salt
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concentration, whereas the HL assay kit (PR2004) measures HL activity at pH 8.8 
and at high salt concentration.
6.2.6.1 Preparation of Standards:
The standard provided with the kit was an un-quenched fluorescent derivative of the 
substrate, presenting endpoint fluorescence. The standard was required for both 
standard curve calibration and the pyrene group molar fluorescence calculation. Each 
kit contained a vial of a readymade standard which was freshly reconstituted on the 
day of the measurement in the assay buffer to obtain a final concentration of 
22.5pmol/ml. Standards were made using serial dilutions of the neat standard to 
obtain 5.625, 1.4 and 0.35 pmol/ml. In duplicates, 200 pi from each standard was 
transferred into a 96 well black plate (Micro plate, black, flat bottom, medium 
binding, Greiner Bio-one, Neuburg, Germany) and the fluorescence intensity was 
read in the fluorimeter (DTX880 multimode detector, Beckeman Coulter, Germany) 
at excitation wavelength 342 run and emission at 400 nm at 37°C. A standard curve 
was constructed using a unit of fluorescence intensity against concentration of the 
standards (pmol/ml), the response was linear for the assay range (Figure 6.12).
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Figure 6.12: Lipase activity measurement standard curve (Conflulip 
lipase test, Progen, Biotechnik Gmbh, Heidleberg, Germany). Results 
are mean ± SEM (n=5).
6.2.6.2 Preparation of QCs and Samples
The QCs used for this assay were donated by J.D Brunzel (University of
Washington, USA). The activities of the QCs for TL, HL and LPL were (754±0.034,
391.8±0.2, 362±0.09 nmol/ml/hr) respectively. The TL and HL activities of these
QCs had been determined using an established radioactive triolein assay. Specific
HL activity for this QC was determined in the same assay by inhibition of LPL in the
presence of specific antibody for LPL (Imamura et al. 2008). Samples and QCs were
thawed, centrifuged at 2500 rpm xlOOOg for 10 min and aliquoted. They were diluted
with assay buffer at 1:10 dilution for pre-heparin plasma and at 1:80 dilution for
post-heparin plasma. The lipase activity in the assay corresponded to the appearance
of the pyrene fluorescence of the unquenched product over time. Duplicates of 20pi
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of QCs and samples were placed sequentially in the plate. Then, 200pi of freshly 
reconstituted and warmed (37°C) substrate (provided with the kit) was added quickly 
with a multi-pipette into the wells and the kinetic measurement was started 
immediately for 10 min. The CV values of the QCs for TL and HL assays were 5.1% 
was 4.8% respectively. The slope of the line of fluorescence intensity collected from 
3-10 min was used in the calculation of the enzyme activity.
6.2.6.3 Calculation of Lipase Activity
The molar fluorescence of the pyrene group is required for the calculation of the 
concentration of the unquenched substrate which accumulates over time in the 
kinetic assay. The concentration of the unquenched product is the slope of the 
straight line obtained with the standards and their fluorescence. The molar 
fluorescence can be calculated from the standard curve using the difference of the 
fluorescence intensity (FI) (Y2-Y1) and the difference of the corresponding standard 
concentration (X2-X1) values as follows:
%  - 3 ^ )  __________F I  X p m o l  X m l
(W 2 - W , )
The unquenched pyrene fluorescence resulting from breakdown of the substrate by 
the lipase activity during the assay over time was represented by the slope of the 
straight line (x-axis: time versus y-axis: pyrene fluorescence). It was calculated from 
change in FU/change in time (min):
%  - 3^ )  _  F I  _  Z.T=  F I  X m in
— ^ 1 )  m i n
Lipase activity was then calculated as the ratio delta of the values obtained from 
fluorescence/time of the samples and the molar fluorescence from the standard curve
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a s .
FI X  m in  ^
FI X  pmol~^  X  m l
Lipase activity was expressed as pmol/ml/min. All calculations were corrected for 
the dilution factor and were normalised to the QCs from USA. This was achieved by 
multiplying the lipase activity of the unknown sample (pmol/ml^min) by the ratio of 
the assay result for the QC divided by its previously known determined value in 
nmol/ml/h. Figure 6.13 illustrates an example of LPL fluorescence activity plot.
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Figure 6.13: An example of lipase fluorescence activity of a post­
heparin plasma sample using Conflulip lipase test (Progen, Biotechnik 
Gmbh, Heidleberg, Germany).
6.2.7 Statistical Analysis
Analysis was conducted using the Statistical Package for the Social Sciences, version 
19 (IBM Corporation, New York, USA). All data were checked for normality of their 
distribution using Shapiro-Wilk analysis. Those values that were found to be skewed 
were normalized using an appropriate data transformation to achieve normality. 
Homogeneity of the variance was assessed by Levene’s statistic. All data were 
presented as means [±SEM] or otherwise indicated. A paired Student T-test or
2 1 0
Wilcoxon Signed Rank Test (for non-parametric) were used to analyse differences 
between (0 week) and after (12 wek) diets of all variables.
In order to explore the objectives, two way analysis of covariance (ANCOVA) was 
conducted. Separate two way ANCOVAs was done for each dependent variable. The 
main variables that were tested were liver fat (high versus low liver fat) and diet 
(high versus low sugar diet). The change in body weight between the start and end of 
the diet was used as the covariate. Statistical significance was determined if p  <0.05. 
Association between variables were determined using Pearson’s correlation (or 
Spearman’s Rho for non-parametric data).
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6.3 Results
Twenty five participants completed the study; 14 of the men had low liver fat (<5%). Forty 
four percent of those involved began with the low sugar diet, switching to the high sugar 
diet; the other 56% started off with the high sugar diet, switching to the low sugar diet. The 
entire group was subjected to both the low sugar and high sugar diet. However, 56% had a 
low liver fat percentage (<5%), while the other 44% had a higher liver fat percentage 
(>8%). Table 6.7 shows the participants’ physical and physiological features at screening.
Table 6.7: Characteristic of participants at screening visit, n=25
Characteristics Mean ± SEM
Age (Yr) 57.9 ± 1.4
Total body weight (Kg) 89.4 ± 1.7
BMI (Kg/m^) 28.6 ± 0.4
Body fat percentage (%) 25.5 ± 0.7
Fat mass (Kg) 23.1 ±1.2
Free fat mass (Kg) 66.6 ± 1.5
6.3.1 The Dietary Intake of Energy and Macronutrients
Table 6.8 shows the habitual and the actual intake of the two dietary regimens and the 
predicted target intake for total energy and energy fi*om each macronutrient. On average, 
the percentage of energy intake from sugar was 4% higher than the target for the high 
sugar diet, and 3% higher than the target for the low sugar diet. The total energy and 
protein intakes between the intervention diets were not different. However, there were
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significant differences in the intake of dietary CHO, sugars, fat, saturated fat and sodium
between the high and low sugar diets.
Table 6.8: Composition of the habitual, high and low sugar diet intakes. Data 
are mean ±SEM, n=25. (Ahmad 2013).
Nutrient Habitual
diet
High sugar diet Low sugar diet
Intake Target Intake Target
Energy (MJ/d) 9.8 ±0.5 10.6 ±0.5 - 9.9±0.4 -
CHO (g/day) 264±15.1 329±14.9 - 257±12.0 -
%Total energy 45±1.1 53±1.3"" 47 44±L3" 47
Sugar (g/day) 120±10.1 173±10.0 - 56±4.0 -
%Total energy 21±1.2 28±1.3^" 24 9±0.5b" 6
Protein (g/day) 90±5.3 92±4.5 - 97±4.8 -
%Total energy 16±0.7 15±0.5 15 16±0.5 15
Fat (g/day) 87±6.2 77±6.4 - 89±5.0 -
%Total energy 33±1.3 27±1.5"" 34 34±1.2" 34
Sat. fat (g/day) 33±2.8 30±3.0 - 35±2.8 -
%Total energy 13±0.7 10±0.8" 13 13±0.8 13
Fibre (g/day) 26±1.4 21±1.2a 16 24±1.5 16
Sodium (g/d) 3.0±0.2 2.9±0.2" - 3.7±0.2’’ -
Starch: Sugar 1:0.9 1:1.1 1:1.2 4:1 6:1
Habitual vs High sugar diet, ^<0.05 Habitual vs low sugar diet, ^<0.05 
High vs Low sugar diet.
6.3.2 Effect of the High and Low Sugar Diets on Physical Parameters
The difference in the weight of the participants between the start and end of the diets was
measured. Although it was intended to avoid body weight changes, both body weight and
BMI increased (0.7±0.4%, p<0.05) after the high sugar diet and decreased (2.6±0.6%,
/><0.001) after the low sugar diet (using Wilcoxon Signed rank test). In comparison to
baseline measurements, body fat percentage, fat mass and free fat mass all increased, after
the high sugar diet and decreased after the low sugar diet (Table 8.9) . There were
significant positive associations between changes in BMI and fat mass in the high sugar
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diet group and negative associations on the low sugar diet group both (p<0.05) 
(Spearman’s Rho).
Table 6.9: Changes in physical variables at baseline and after the 12 weeks 
dietary intervention, (n=25)
Variable High sugar diet Low sugar diet
Body weight (Kg) 0 Weeks 88.5 ± 1.7 89.3 ±1.8
12 Weeks 89.2 ±1.8 87.2 ± 1.9
Changes ±0.7 ± 0.4^ -2.1 ±0.5^
BMI (Kg/m^) 0 Weeks 28.3 ± 0.3 28.5 ± 0.4
12 Weeks 28.5 ±0.3 27.8 ± 0.4
Changes ±0.26 ± 0.6" -0.7 ± 0.2"^
Body fat (%) 0 Weeks 25.7 ±0.5 25.9 ± 0.7
12 Weeks 26.1 ±0.5 25.0 ±0.7
Changes ±0.4 ± 0.3 -1.0 ±0.2^
Fat mass (Kg) 0 Weeks 22.8 ± 0.7 23.3 ± 0.9
12 Weeks 23.3 ±0.7 21.9 ±0.9
Changes ±0.5 ± 0.3"" -1.4 ±0.3^"
Free fat mass (Kg) 0 Weeks 65.7 ±1.2 66.2 ± 1.3
12 Weeks 65.9 ±1.2 65.2 ± 1.3
Changes ±0.2 ± 0.2 -0.9 ± 0.3""
Values are mean ± SEM. Changes:= 12 weeks -  0 Weeks. Statistical
significant changes from baseline: ^<0.05, ^<0.01 using Wilcoxon Signed 
rank test; ^<0.05, ^<0.01 Correlation with change in BMI, ^<0.05 using 
Spearman’s Rho.
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6.3.3 Effect of the High and Low Sugar Diets on Liver Fat
At the screening visit, all participants had their first liver fat measurements; only 17 
participants had their liver fat measurements after the 12 week dietary intervention. Liver 
fat percentage has increased after the high sugar diet from 8.5±2.3% at baseline to 
12.13±3.7% (p<0.05) and significantly decreased after the low sugar diet from 8.5±2.3% at 
baseline to 6.6±2.2% (p<0.05). Liver fat percentage was significantly higher after the high 
sugar diet than the low sugar diet (p<0.05) (Wilcoxon Signed rank test) (Figure 6.14). 
There was a significant positive correlation between liver fat percentage and both fasting 
plasma glucose and serum insulin concentration (r=0.5 and r=0.4, j?<0.05) (Spearman’s 
Rho).
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Figure 6.14: Liver fat percentage changes after dietary intervention 
relative to baseline at screening, n=12. Results are median [25-75% 
IQR]. Differences between diets using Wilcoxon Signed rank test.
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6.3.4 Influence of Liver Lat on Physical Parameters in Response to the
High and Low Sugar Diet
Table 6.10 shows the characteristics of the participants when separated into two groups 
according to their liver fat percentage. The two groups were age and BMI matched. As 
expected, participants with raised liver fat had a significantly higher percentage of fat mass 
relative to the participants with lower liver fat.
Table 6.10: Baseline characteristics of participants in low (<5%) and high
(>5%) liver fat group at screening, n=25.
High liver fat 
n= ll
Low liver fat 
n=14
p  value
Age (Yrs) 59 ±1.7 54.7 ± 2.2 NS
Body weight (Kg) 90.7 ±2.3 89.5 ± 2.7 NS
BMI (Kg/m^) 28.7 ±0.5 28.5 ±0.6 NS
Liver fat (%) 15.4 ±2.1 2.8 ±0.4 p  <0.001
Body fat (%) 27.4 ± 0.5 24.1 ±0.7 NS
Fat mass (Kg) 24.6 ± 0.9 22.0 ±1.2 j9<0.01
Fat free mass (Kg) 65.2 ±1.9 67.6 ±1.5 NS
Data are mean±SEM, differences between 
unpaired t-test. NS: not significant
the two groups (p<0.05,
The high liver fat group showed a significant increase in body weight after the high sugar
diet (1.2±0.5, /><0.05, paired t-test). Body weight decreased significantly after the low
sugar diet by 2.1±0.6 and 2.2±0.9 in the low and high liver fat group, respectively (p<0.05
and /?<0.01, ANCOVA). Body fat percentage decreased significantly after the low sugar
diet by 0.8±0.4 and 1.1±0.3 in the low and high liver fat group, respectively (p<0.05,
ANCOVA); however there was no significant difference in body fat between the two
groups after adjustment for body weight change. Also, fat mass decreased after low sugar
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diet in both liver fat groups, but the percentage decrease was considerably higher in the 
high liver fat group, it was decreased by 6.9% (1.5±0.4,/>=0.004, paired t-test) and the low 
liver fat group decreased by 1.7% (1.2±0.4, /><0.01, paired t-test). The difference was 
significant even after adjustment for body weight change (Table 6.11). A significant 
relationship between change in weight and fat mass was found (p<0.05, Spearman’s rho). 
This suggests that, when statistically controlling for weight change, only liver fat 
influences fat mass after diet intervention; diet alone has no influence on fat mass.
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Table 6.11: Physical characteristics o f  participants in two liver fat groups before
0 weeks and after 12 weeks o f  high and low sugar diet.
Liver fat 
Diet
High liver fat 
n=l 1
0 weeks 12 weeks
Low liver fat 
n-14
0 weeks 12 weeks
Body weight 
(Kg)
High 
sugar 
Change 
Low sugar 
Change
88.0±2.2
+1.2±0.5
90±2.6
-2.2±0.7
89.8±2.5
/7=0.03
87.6±2.4
p=0.03
88.4±2.6
+0.5±0.4
88.8±2.6
-2.1±0.6
88.9±2.7
NS
86.7±2.9
/7=0.01
BMI (Kg/m^) High 28.5±0.4 28.8±0.8 28.1±0.4 28.2±0.5
sugar
Change
+0.4±0.2 /7=0.04 +0.1±0.1 NS
Low sugar 28.9±0.5 28.0±0.5 28.2±0.5 27.5±0.6
Change -0.7±0.3 /7=0.03 -0.7±0.2 /7=0.004
Body fat (%) High 26.6±0.8 27.1±0.7 25.0±0.7 24.8±0.7
sugar
Change
+0.8±0.5 NS -0.05± NS
Low sugar 27.6±0.8 26.4±0.9 24.6±0.9 23.8±0.8
Change -1.1±0.3 p<0.05 -0.8±0.4 /7<0.05
Fat mass(Kg) High 23.3±1.1 24.3±1.1 22.2±1.0 22.2±1.0
sugar
Change
+0.9±0.5 NS +0.1±0.2 NS
Low sugar 25.0±1.2 23.3±L2 22.1±1.3 20.6±1.2
Change -1.5±0.4 /7=0.004 -1.2±0.3 p=0.01
Fat free mass High 65.4±1.7 65.2±1.8 66.2±L8 66.7±1.8
(Kg) sugar
Change
-O.liO.4 NS +0.5±0.3 NS
Low sugar 65.3±2.0 64.6±1.8 67.0±1.7 65.9±1.9
Change -0.7±0.6 NS -l.liO .4 p=0.02
Data are mean±SEM, The change in body weight between the start (0 weeks) and 
end of the diet (12 weeks) (p<0.05 is significant, paired t-test), NS: not significant.
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6.3.5 Effect of the High and Low Sugar Diets on Glucose and Insulin
Measurements ( Insulin Sensitivity and Beta Cell Function)
Table 6.12 summarises the effect of high and low sugar diet after 12 weeks dietary
intervention on glucose and insulin measurements..
Table 6.12: Plasma glucose, serum insulin before (0 weeks) and after (12 weeks) the 
high and low sugar diets. (n=25)..
High sugar diet Low sugar diet
Plasma Glucose 0 weeks 4.98± 0.10 5.12 + 0.08
(mmol/1) 12 weeks 5.19 ±0.08 5.20 + 0.07
Changes +0.21 ± 0.09 /j=0.05 +0.08+0.10 NS
Serum insulin 0 weeks 126.9+ 6.2 113.35 +6.2
(pmol/1) 12 weeks 115.9 + 8.3 115.92+8.5
Changes -10.9 + 7.4 NS +2.57 + 8.1 NS
% Insulin sensitivity 0 weeks 39.84 + 2.15 44.3 + 2.25
(%S) 12 weeks 46.88 + 4.33 47.19+5.5 NS
Changes +7.04 ± 3.39 p=QM  +2.89 + 4.9
% Beta cell function 0 weeks 194.48 +10.7 167.04+6.3
(%B) 12 weeks 163.64 + 7.9 163.65+8.8
Changes -30.8+11.27 /7=0.01 -3.39+10.2 NS
Data are mean±SEM, The change 
end of the diet (12 weeks) (p<0.05
in body weight between the start (0 weeks) and 
is significant, paired t-test), NS: not significant.
Relative to 0 weeks, glucose concentration increased significantly after the high sugar diet 
by 5.3% (/7<0.05, paired t-test). After the high sugar diet, there was a significant increase in 
insulin sensitivity by 18.4±9.2% (p<0.05, paired t-test) while beta cell fiinction decreased 
significantly by 13±4.3% (p=0.01, paired t-test) (Figure 6.17). Serum insulin did not show 
any significant change after the high sugar diet. After the low sugar diet, there was no
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significant change in plasma glucose concentration, serum insulin concentration, insulin 
sensitivity and beta eell function. There was no significant difference between the values of 
above mentioned measurements at 0 week or after the 12 week of both diet interventions.
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Figure 6.15: Effect of high and low sugar diet on beta cell function 
between 0 week and after 12 weeks diet intervention in, n=25. 
Results are median (with interquartile ranges). Differences between 
diet group (p<0.05, paired t-test).
6.3.6 Influence of Liver Fat on Gucose, Insulin Measurements and Bta 
Cell Function in Response to the High and Low Sugar Diet
Table 6.13 summarises all the changes in glucose and insulin measurements in the two 
groups. The high liver fat group showed a significant 7.2±3.2% increase in the fasting 
plasma glucose concentration (p<0.05, paired t-test) along with a significant decrease in 
the percentage of beta cell function (15±6.6 % decrease, /?<0.05, paired t-test) following 
the high sugar diet. Insulin concentration decreased by 8±7.3% but did not reach 
significance. There was no significant change in insulin sensitivity following the high
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sugar diet. The low liver fat group did not show any significant difference in glucose 
concentration, nor did it show a significant difference in insulin concentration, insulin 
sensitivity and beta cell function measurements after both diets.
There was no significant difference between the two groups after the 12 week low sugar 
diet and high sugar diet in glucose concentration, serum insulin concentration, insulin 
sensitivity and beta cell function.
Results indicated that there was no significant relationship between the change in body 
weight and glucose concentration. Results also showed the presence of a significant effect 
caused by liver fat between the two groups (p<0.05, ANCOVA). Therefore, when 
statistically controlling for body weight change as the covariate, using diet type and liver 
fat as factors and using plasma glucose concentration, serum insulin concentration, insulin 
sensitivity and beta cell function as the dependent variables, only liver fat influenced 
glucose concentration; diet alone was not influential. There was a significant positive 
correlation between fat mass and fasting plasma glucose concentration (r=0.4, /><0.05, 
Pearson’s correlation) and a negative correlation between fat mass and insulin sensitivity 
(r=-0.3,j9<0.05, Pearson’s correlation).
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Table 6.13: Glucose and insulin measurements o f  participants in two liver fat
groups before 0 weeks and after 12 weeks o f  high and low  sugar diet.
Liver fat High liver fat Low liver fat
Diet 0 week 12 week 0 week 12 week
Glucose High sugar 4.76±0.13 5.06m. 1 5.25±0.09 5.35±0.09
(mmol/1) Change 0 .3m  14 /7<0.04 o .im .i NS
Low sugar 4 .99m  11 5.11±0.08 5.28m. 12 5.29±0.15
Change 0 .1 2 m . 1 1 NS 0.0 im .l9 NS
Insulin High sugar 119.3±8.2 107.2±8.3 136.6±9.12 127.04±15.4
(pmoEl) Change -12±9 NS -9.5±12.5 NS
Low sugar 106.11±8.I 106.18±14 127±8.8 132.5±4.9
Change -.06±13.28 NS 2.57±8.1 NS
Beta cell High sugar 205.4±18 165.2±11.5 180.6±7.2 161.6±11.1
function Change -40.0±18.6 p<0.05 -19±9.8 NS
(%) Low sugar 167.6±8.2 I56.2±12.6 171.26±9.9 177.96±11.8
Change -11.4±14.7 NS -11.4±14.7
Insulin High sugar 42.8±3.2 49.3±6.0 36.0±2.5 43.8±6.4
sensitivity Change 6.5±4.2 NS 7.8±5.8 NS
(%) Low sugar 47.5±3.06 55.04±9.3 38.4±2.7 35.8±1.3
Change 7.6±8.5 NS -2.58±2.5 NS
Data are mean±SEM, Separate two way ANCOVAs have been done for each 
dependent variable (meausrement). The main two variables are liver fat content 
and type of diet. The change in body weight between the start (0 weeks) and end of 
the diet (12 weeks) has been used as the eovariate. NS: not significant.___________
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6.3.7 Effect of the High and Low Sugar Diets on Plasma NEFA and TG
Concentration
All participants showed a significant increase in plasma NEFA concentration after both 
diets relative to baseline, after high sugar diet plasma NEFA increased by 0.21 ± 0.04 
mmol/ld by 0.13±0.06 mmol/1 ,(p<0.0001, paired t-test) and increase after the low sugar 
diet. The change in NEFA was not significantly different between the two dietary 
interventions (Figure 6.18). The plasma TG increased significantly after the high sugar diet 
0.25 ± 0.04 mmoEl, (p<0.01, pared t-test) and decreased after the low sugar diet - 
0.35±0.16 mmol/1, (p<0.05, paired t-test).There was a significant difference in plasma TG 
following the 12 week diet interventions. After adjusting for the interaction between diet 
and body weight change, the difference between plasma TG remained significant after both 
diets (Two way ANCOVA) (Table 6.14) and (Figure 6.16).
Correlation analysis revealed association between concentration at 0 week and after 12 
week diet intervention for both plasma TG and NEFA measurements, suggesting an order- 
effect on plasma TG and NEFA (r=0.8 and r=0.7 respectively, all /><0.001) Pearson’s 
correlation).
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Table 6.14: Plasma NEFA and TG before (0 weeks) and after (12 weeks) the high
and low sugar diets
High sugar diet Low sugar diet
Plasma NEFA 
(mmol/1)
0 week 
12 week 
Changes
0.37 ±0.06 
0.57 ±0.05 
±0.21± 0.04 /?<0.0001
0.34±0.050
0.50±0.05
±0.13±0.06 p<0.001
Plasma TG 
(mmol/1)
0 week 
12 week 
Changes
1.49 ±0.14 
1.74 ±0.15 
±0.25 ± 0.04 p<0.01
1.83 ±0.25 
L48± 0.13* 
-0.35±0.16 j9<0.05
n=25, data are mean±SEM, paired t-test. 12 week Low sugar vs High sugar 
*/?<0.05, paired t-test.
<  0 . 0  0  1
Figure 6.16: Effect of high and low sugar diet on NEFA concentration 
relative to baseline and after 12 weeks intervention, n=25. Results are median 
(with interquartile ranges).
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6.3.8 Influence of Liver Fat on Plasma NEFA and TG Concentration in 
Response to the High and Low Sugar Diet
As illustrated in Figure 6.17, participants with low liver fat had a significantly lower 
plasma NEFA concentration (0.44±0.03 mmol/1) after the high sugar diet than participants 
with high liver fat (0.66±0.04 mmol/1). Participants with low liver fat showed lower NEFA 
values (0.53±0.03 mmoEl) after the low sugar diets compared to participants with high 
liver fat (0.55±0.04 mmol/1), though it was not significant (Table 6.15).
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Figure 6.17: Effect liver fat on NEFA concentration, at 0 week and after 12 
weeks of high and low sugar diet. Data are mean±SEM, n=25.
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Table 6.15: NEFA and TG concentration of participants in two liver fat groups 
before 0 weeks and after 12 weeks of high and low sugar diet. Data are 
meaniSEM, NS: not significant.
Liver fat High liver fat Low liver fat
Diet 0 week 12 week 0 week 12 week
NEFA High sugar 0.4U0.1 0.66±0.1 0.29±0.09 0.44±0.09
(mmol/1) Change 0.3±0.14 /7<0.0001 O.liO.l p<0.0001
Low sugar 0.42±0.11 0.55±0.08 0.32±0.12 0.53±0.15
Change 0.55±0.11 /7<0.05 0.01±0.19 /7<0.0001
TG High sugar 1.8±0.2 2.16±0.2 1.24±0.1 1.41±0.2"
(mmol/1) Change 0.36±0.1 p<0.05 0.16±0.1 /?<0.05
Low sugar 2.47±0.4 1.89±0.2 1.33±0.23 1.16±0.23
Change 0.58±0.11 /7<0.05 0.17±0.19 NS
Results indicated that there was no significant relationship between the change in body 
weight and fasting plasma NEFA concentration. Results also showed the presence of a 
significant effect caused by liver fat between the two groups (p<0.05, ANCOVA). 
Therefore, when statistically controlling body weight change as the covariate, using diet 
type and liver fat as factors and using NEFA concentration as a dependent variable, liver 
fat had a significant effect on the NEFA concentration, but so too did the interaction of diet 
and liver fat (p<0.05, ANCOVA); diet alone did not affect NEFA concentration. This 
suggests that participants with higher liver fat will have higher NEFA concentrations 
regardless of the diet they are exposed to.
6.3.9 Effect of the High and Low Sugar Diets on the in  v iv o  Lipolysis
Fatty acid (palmitate) rate of appearance during the stable isotopes study was used as an 
index to measure in vivo lipolysis.
226
6.3.9.1 Fatty Acid (Palmitate) Rate of Appearance
Twenty five participants attended two study days for fatty acid kinetic measurements after 
12 weeks of each dietary intervention. Palmitate rate of appearance (PARa) was measured 
and used as a measurement of whole body lipolysis. PARa was normalized for fat mass 
and was used to provide an index of fatty acids released into plasma with respect to 
endogenous adipose tissue TG stores. Palmitate and NEFA concentration during the stable 
isotope infusion were measured and the contribution of palmitate concentration to the total 
body NEFA concentration was calculated.
There was no significant change in PARa between the low and high sugar diet
interventions and palmitate concentration (Table 6.16).
Table 6.16:The stable isotope tracer study: palmitate rate of appearance and 
concentration after (12 weeks) of the high and low sugar diets.
High sugar diet Low sugar diet
(PARa) per whole body weight 
(pmol/min/Kg)
1.88 ±0.1
NS
1.83 ±0.13
(PARa) per fat mass 
(pmol/min/Kg fat mass)
7.40 ± 0.5
NS
7.52 ± 0.6
PA concentration (pmol/1) 197 ±11.7
NS
215 ±14.09
NEFA concentration (pmol/1) 
during the infusion (at 300 min)
643 ± 26.6
NS
645 ±25.6
% ofPA  in NEFA 31.03 ± 1.5
NS
33.72 ± 1.9
n=24, data are mean±SEM, differences between diets a paired t-test was used, 
j9<0.05 was considered statistically significant. NS: not significant
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6.3.10 Influence of Liver Fat on Fatty Acid (Palmitate) Rate of 
Appearance in Response to the High and Low Sugar Diet
Results indicated that there was no significant relationship between the change in body 
weight and palmitate rate of appearance or palmitate concentration. The low liver fat group 
did not show any significant difference in palmitate measurements between the high and 
low sugar intervention (Table 6.17). The palmitate concentration decreased significantly 
after the high sugar diet compared with low sugar diet (p<0.001, paired t-test) in the high 
liver fat group. In this group, the percentage of palmitate to total NEFA in the circulation 
(PAiNEFA) decreased significantly after the high sugar diet, this value was significantly 
lower than the value after the high sugar diet in the low liver fat group (27.5± 1.35 and 
33.8± 2.48% respectively, ^<0.05, ANCOVA). However, the palmitate rate of appearance 
increased after the high sugar diet in the high liver fat group, but did not reach significance
(p=0.06).
Table 6.17 The stable isotope tracer study: palmitate rate of appearance and 
concentration after (12 weeks) of the high and low sugar diets in high and low liver 
fat groups.
High liver fat 
n= ll
High sugar Low sugar 
diet diet
Low liver fat 
n=14
High sugar Low sugar 
diet diet
PARa (pmol/min/Kg 1.87±0.10 1.67±0.12 1.89±0.17 1.96±0.20
body weight) /?=0.06 NS
PARa (pmol/min/Kg 6.88±0.35 6.41±0.53 7.81±0.81 8.39±0.95
fat mass) NS NS
PA concentration 186±10.8 220.3±11.9 206.2±21.19 210.3±28.8
(pmol/1) /7<0.001 NS
NEFA concentration 0.68± 0.03 0.63±0.03 0.61±0.05 0.64±0.05
(mmol/1) NS NS
%ofPA in NEFA 27.5± 1.35 35±2.99 33.8± 2.48 32.7± 2.99
/7<0.05 NS
n=24, data are mean±SEM, differences between diets in two liver fat groups 
(p<0.05, un-paired t-test). NS: not significant
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6.3.11 Effect of the High and Low Sugar Diets on Endothelial Lipolysis
After the 12 week diet intervention, blood samples from 24 participants were tested for 
post-heparin lipolysis. It was not possible to take a blood sample fi*om one participant due 
to an incident of participant’s dizziness. The activity of the three lipolytic enzymes, total, 
hepatic and lipoprotein lipase was measured. Table 6.18 shows the effect of high and low 
sugar diet on the enzymes’ activity after the 12 week diet intervention.
Table 6.18: The post heparin endothelial lipase activity in plasma samples after (12 
weeks) of the high and low sugar diets.
High sugar 
diet
Low sugar 
diet
p  value
Total lipase activity (TL) 2.65 ± 0.22 2.55 ± 0.27 NS
(pmol/ml/min)
Hepatic lipase activity (HE) 1.38 ±0.21 1.11±0.18 <0.05
(pmol/mEmin)
Lipoprotein lipase activity (LPL) 1.35 ±0.17 1.69 ±0.21 NS
(pmol/ml/min)
n=24, data are mean±SEM, differences between diet a paired t-test was used, 
p<0.05 was considered statistically significant. NS: not significant
In the whole study group, hepatic lipase activity was significantly higher after the high 
sugar diet than after the low sugar diet (p<0.05, paired t-test). This study did not find any 
significant effect of 12 weeks dietary intervention on TL and LPL activity.
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6.3.12 Influence of Liver Fat on Endothelial Lipolysis 
in Response to the High and Low Sugar Diet
Table 6.19 shows the effect of liver fat on the three enzymes’ activity after the two
different diet interventions.
Table 6.19: The post heparin endothelial lipase activity after (12 weeks) of the high 
and low sugar diets in high and low liver fat groups.
High liver fat 
n=10
High sugar Low sugar 
diet diet
Low liver fat 
n=14
High sugar Low sugar 
diet diet
TL (pmol/mEmin) 3.05±0.39 2.3±G.31 2.37±G.24 2.73±G.4
j9<G.G5 NS
HE (pmol/mEmin) 2.13±G.48 1.43±G.38 1.G1±G.17 G.9G±G.18
p<0.05 NS
LPL (pmol/ml/min) 1.33±G.31 1.3G±G.21 1.36±G.19 1.97±G.32
p=0.06 NS
n=24, data are mean±SEM, differences between diets, (p<0.05, two way 
ANCOVA), NS: not significant
In order to see if endothelial lipases’ activity is affected by different sugar diets, the results 
were analysed with two way ANCOVA using diet type and liver fat as factors, lipase 
activity as the dependent variable and change in weight as the covariate.
TL results indicated that there was a statistically significant effect for diet and liver fat on 
TL activity. There was a significant relationship between change in body weight and TL 
(p<0.05, Pearson’s correlation). The two way ANCOVA suggests that when statistically 
controlling for weight change, liver fat and diet have influence on TL; and weight loss is 
significantly related to TL.
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Figure 6.18: Effect of liver fat on total lipase activity after 12 weeks of high 
and low sugar diet, n=25. Data are mean ± SEM,/?<0.05, two way ANCOVA.
Results indicated that there was no significant main effect for liver fat on LPL and no 
significant relationship between change in body weight and LPL, and no interaction effect 
for diet and liver fat. There was a trend of an increased LPL activity with high sugar diet 
but it did not reach significance (p=0.06, paired Student T-test).
There was no statistically significant main effect of the diets on HL. There was no 
significant relationship between change in weight and HL. However, there was a 
significant effect of liver fat on HL activity (p<0.05, two way ANCOVA), where 
participants with high liver fat had increased HL activity after the high sugar diet compared 
with participants with low liver fat on the same diet (p<0.05, two way ANCOVA) (Figure 
6.19). A positive relationship was found between body fat mass and HL activity (r=0.5, 
^<0.05, Pearson’s correlation).
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Figure 6.19: Effect of liver fat on HL activity after 12 weeks of high and low 
sugar diet, n=25. Data are mean±SEM, two way ANCOVA.
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6.4 Discussion
Effect of High Sugar Diet on Liver Fat
Results from this study showed significant increase in liver fat content after the high sugar 
diet Mittendorfer and Sidossis (2001) and Roberts et al. (2008) suggested that the 
metabolic compensation to the high sugar diet, causes reduction of fat oxidation in the 
liver, which promotes the accumulation of fat in it. In rodents, a high-sucrose diet rapidly, 
within one week, increased intrahepatie fat deposition (Pagliassotti et al. 1996). Ectopic 
lipid deposition in the liver and muscle is linked to tissue-specific insulin resistance (Unger 
2003).
Lê et al. (2009) found that administration of twice as much fructose participants (healthy 
offspring of type 2 diabetes) over only 7 days induced a significant increase in hepatic and 
intramyocellular fat content compared to control group. The increase in intrahepatie fat 
positively correlated with the increase in fasting VLDL-TG, suggesting that these two 
factors may be driven by a shared mechanism, apparently a stimulation of hepatic de novo 
lipogenesis. Their findings agree with findings from the current study, that increased 
plasma VLDL-TG and intrahepatie fat content was enhanced in participants with lower 
insulin sensitivity (high liver fat group). This may indicate that the dyslipidaemic effects of 
fimctose are enhanced by the presence of insulin resistance.
A relationship between disturbed lipid mtabolism and insulin resistance has been 
demonstrated. While it was initially thought that increased NEFA concentration was the 
major players in lipid-induced insulin resistance, it is now known that both high NEFA and 
high plasma TG concentrations are related to insulin resistance (Shulman 2000). It has 
been suggested that liver fat is positively associated with insulin insensitivity and 
abdominal obesity (Marchesini et al. 2001, Adiels et al. 2008, Kotronen et al. 2007).
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A high sugar diet has a potentially adverse effect mediated through increased plasma TG 
and NEFA, this can be reversed by lowering dietary sugars and therefore lowering CVD 
risk by lowering both plasma TG and NEFA. Therefore, lowering dietary sugar (9%E 
from sugar) decreased the production of TG and glucose in the liver via increased inulin 
sensitivity, together with a limitation of the availability of NEFA from the periphery for 
TG production (Parks et al. 1999, Schwarz et al. 2003, Frayn 2010b). Fructose produces a 
slight impairment of hepatic insulin's actions, but does not reduce whole body insulin 
sensitivity (Tappy and Lê 2010). In the current study the diet intervention did not alter 
insulin sensitivity in either groups. However, beta cell function was significantly reduced 
after the high sugar diet in the high liver fat participants. Insulin resistance has been 
correlated with intracellular TG stores, which are involved in lipotoxicity and beta cell 
failure leading to diabetes. (McClain n.d.)(McClain n.d.)(McClain n.d.)(McClain 
n.d.)(McClain n.d.)
Changes in plasma TG after the high sugar diet were associated with the degree of obesity, 
Grundy (1999) and Adiels et al. (2008) showed that obese participants had a significant 
increase in plasma TG and NEFA compared to overweight participants in response to a 
high sugar diet. This can be due to increased insulin resistance especially in the liver in 
obese participants, which could lead to a higher lipid accumulation in this organ. Teff et al. 
(2009) found that the effect of fimctose was significantly increased in obese 
hyperinsulinaemic participants compared with normal-weight participants, suggesting that 
fimetose may produce more severe alterations of lipid homeostasis in insulin-resistant 
individuals.
It is has been shown that an increased level of insulin in people with type 2 diabetes is 
associated with increased HL activity (Syvanne et al. 1995). Participants in the current
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study with high liver fat showed signifieant increase in postheparin HL and TL activity 
after the 12 week high sugar diet.
In this study, the high sugar diet in high liver fat participants caused a higher NEFA 
concentration possibly produced by increased peripheral and endothelial lipolysis. Delarue 
and Magnan (2007) suggested that the increase in FF A flux resulting from increased 
lipolysis secondary to adipose-tissue insulin resistance induces or aggravates insulin 
resistance in liver through direct or indirect secretion of metabolites, altering the insulin 
signalling pathway.
6.5 Conclusion
The present study revealed that the dietary exchange model used in this study was effective 
and produced modest effects on plasma TG and NEFA. The high sugar diet resulted in 
adverse effects on BMI, percentage of liver fat, plasma TG, NEFA and fasting glucose, 
which are increased CVD risk factors. Participants with high liver fat showed increased 
sensitivity to both high and low sugar diets. The metabolic isotope tracer study and post 
heparin lipase activity revealed that increased peripheral lipolysis and endothelial lipolysis 
may contribute to the increased NEFA delivery to the sites of insulin resistance (liver and 
adipose tissue) causing less insulin sensitivity. In conclusion, reducing sugar intake may be 
advantageous in managing cardiometabolic risk, especially in people with high liver fat, 
who stand to gain greater benefits fi*om this dietary model.
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CHAPTER SEVEN: GENERAL DISCUSSION
Obesity, metabolic syndrome and T2DM increase the risk of CVD. Research on AT 
mtabolism is needed to investigate the causes and effects of any metabolic abnormalities in 
this tissue and possible adverse effects of these abnormalities on whole body mtabolism 
and CVD. This thesis has focused attention on white AT mtabolism in both healthy 
participants and participants with type 2 diabetes, by looking at the effect of different types 
of treatments for diabetes (oral hypoglycaemic agents and insulin). It also focused on the 
relationship between dietary sugars and AT mtabolism in overweight men. At risk of 
metabolic syndrome with nioderately high and low liver fat.
7.1 AT Regional Differences
A number of studies have investigated the regional differences in AT mtabolism and the 
effect of obesity, age, gender and body fat distribution in both the healthy and diabetic 
population. The results of these studies are equivocal. Many investigators, however, 
(Hoffstedt et al. 1997, Van Harmelen et al. 1997, Hellmer et al. 1992, Marin et al. 1992, 
Busetto et al. 1993) accept the concept that OMAT has a greater association with risk of 
CVD than SCAT. In-vitro studies suggest that OMAT has higher lipolytic activity than 
SCAT both basally and after adrenergic stimulation. NEFAs from OMAT are directly 
released into the portal circulation, it may be hypothesised that omental adiposity exposes 
hepatocytes to high concentrations of NEFA. This may decrease hepatic insulin sensitivity 
(Bugianesi et al. 2005) and increase hepatic glucose output (Abate et al. 1995). In addition, 
NEFA are also known to reduce hepatic insulin clearance (Larsson et al. 1984).
In the current study, in the healthy group, OMAT had higher basal lipolysis, higher
isoproterenol stimulated lipolysis and a higher response to insulin antilipolytic activity than
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SCAT. Also, healthy participants showed a higher response to insulin antilipolytic activity 
in SCAT compared with OMAT. This data (stimulated lipolysis OM>SC) suggests that 
NEFA are more readily mobilized from OMAT than from SCAT and this supports the 
finding of many previous studies. Based on previous studies this would be expected to be 
exaggerated in T2D. Contrary to that expectation in patients with T2D (treated with 
metformin) compared to healthy participants in this study there was a lower responsiveness 
to isoproterenol stimulation in OMAT and a greater effect of insulin to inhibit 
lipolysis.This may be a consequence of metformin treatment. Although the exact 
mechanisms by which metformin acts at the molecular level remains unknown, it has been 
shown that the drug inhibits a step in the mitochondrial respiratory-ehain (Viollet et al. 
2012). Zhang et al. (2009) looked at the effect of metformin on lipolysis in primary rat 
adipocytes. They examined metformin at 250-500 pM and found that it attenuated NEFA 
and glycerol release from adipocytes stimulated with IpM isoproterenol.ie metformin 
suppresses the lipolytic response to catecholamines. They elucidated that during 
isoproterenol stimulated lipolysis, metformin decreased cellular cAMP production, reduced 
activity of protein kinase A (PKA) and mitogen-activated kinase (MAPK 1/3), and 
attenuated the phosphorylation of perilipin. This antilipolytic effect could be a cellular 
basis for metformin decreasing plasma NEFA levels and improving insulin sensitivity.
Tchemof et al. (2006) investigated the regional differences in AT mtabolism and the effect
of obesity and body fat distribution in healthy women. The study showed that SCAT had
higher LPL activity than OMAT. In the current study LPL activity was higher in OMAT
than SCAT in both healthy subjects and subjects with T20H. The subjects in the current
study were older and had a higher BMI and may consequently have been more insulin
resistant than the women in the Tchemof study. This suggests that insulin resistance is
predominantly affecting SCAT. LPL activity in SCAT was higher in the patients with
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T20H. This may also be due to the effects of metformin. Ohira et al. (2007) found that 
after three months treatment with metformin in patients with type 2 diabetes, their pre­
heparin plasma LPL mass was increased significantly. They suggested that metformin may 
diminish insulin resistance and increased LPL production. LPL is insulin dependent and all 
participants were on metformin for more than six months which might have increased their 
insulin sensitivity and therefore increased their LPL activity.
Implications and Future Work
To test the hypothesis that metformin has a beneficial effect on AT lipolysis in T2D SCAT 
and OMAT lipolysis would need to be measured in newly diagnosed T2D and then the 
measurement could be repeated after several months of treatment. If metformin can 
improve AT lipolysis it would also be interesting to investigate the effect of metformin on 
SCAT and OMAT lipolysis in people with metabolic syndrome.
7.2 Insulin Detemir
It has been established that the weight sparing effect of insulin detemir compared to NPH
insulin is not explained by the reduction in hypoglycaemia episodes (Davies et al. 2008). In
the current study, weight increased significantly over the treatment period with NPH but
did not change after insulin detemir confirming the effect of weight sparing. There was no
difference in HbAlc, energy intake, total, visceral or subcutaneous adipose tissue. Fasting
NEFA decreased significantly with detemir compared to NPH. In line with this basal
lipolysis in the fat biopsies showed a significant reduction with detemir treatment with no
significant change following NPH treatment. LPL mass and activity increased significantly
after 16 weeks treatment with detemir compared to NPH. This data suggests that chronic
treatment with insulin detemir (16 weeks) may improve the insulin sensitivity of lipolysis.
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Over-insulinisation of the periphery has been shown to cause insulin resistance which 
would lead to an increase in lipolysis. It has been proposed the insulin detemir has a 
greater effect on the liver than peripheral tissue thus a reduction in peripheral insulin would 
be expected. This study suggests that detemir has the potential to restore the physiological 
insulin gradient, which may have therapeutic advantages such as a less weight gain over 
the conventional NPH.
Implications
Although the exact mechanisms of insulin detemir’s weight-sparing effect remain to be 
confirmed, it is possible that its unique structure partly explains this effect. These findings 
suggest that insulin detemir might be a particularly useful basal insulin with a role in the 
management of insulin-associated weight gain, which is of concern to patients and health 
care professionals. Insulin detemir may provide a clinical advantage in terms of reduced 
weight gain in the treatment of overweight patients with T2D. This study is expected to 
contribute to the growing body of evidence on the efficacy and safety of insulin detemir in 
T2D.
Future Work
The main limitation of this study was the small number of subjects who had an AT biopsy. 
The large variability in lipolysis between subjects also suggests a parallel group study was 
not the optimal study design. Further studies are needed in a larger number of subjects with 
T2D in a cross-over study design to confirm the findings in this study. This could be 
combined with the measurement of lipolysis measured in vivo with a stable isotope of 
glycerol and/or palmitate.
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7.3 The Dietary Intervention
This study was part of a much larger BBSRC funded trial to investigate the effects of 
dietary sugars on lipoprotein kinetics. This research thesis has focused attention on the 
evidence for a relationship between dietary sugar and lipid mtabolism. It also addressed the 
impact of liver fat on the response to diets, high and low in dietary sugars.
The 12 weeks of the two dietary interventions, high and low in sugars, resulted in a 
signifieant increase and decrease in plasma TG, respectively. The high sugar diet was 
associated with changes in other components of a cardio-metabolie risk profile, including 
increased BMI, plasma glucose, plasma NEFA and percentage of liver fat. Conversely, the 
low sugar diet was associated with favourable effects on components of CVD risk, 
including reduced BMI, plasma TG and percentage of liver fat. The high liver fat group 
expressed more pronounced changes to both high and low sugar diets, relative to the low 
liver fat group.
The metabolic stable isotopes tracer study revealed an increased peripheral lipolysis after 
the high sugar diet in participants with high liver fat but not in those with a low liver fat. 
Also, the post-heparin lipase activity measurements revealed increased endothelial 
lipolysis in the high liver fat group compared to the low liver fat group, which may 
contribute to the increased NEFA delivery to the liver and adipose tissue causing less 
insulin sensitivity/more insulin resistance. These findings suggest that individuals with 
raised liver fat may gain greater benefit from reducing the sugar content of their diets, 
which may be advantageous in managing cardio-metabolie risk.
Unforeseen, body weight was not maintained throughout the dietary intervention. Although
strict instructions were given to the participants not to change their normal physical
activity throughout the study, complete compliance was not possible. This was observed by
the other researcher who was responsible of recruitment and follow up through personal
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communication. As a result, there was variation in body weight during the interventions, 
most notably weight loss after the low sugar diet. However, the weight changes were 
relatively small and not associated with changes in other variables. Appropriate statistical 
adjustment was undertaken to correct for changes in body weight, and for baseline values, 
especially at the beginning of the second dietary intervention, after 4 weeks of washout 
period.
This study provided clear evidence of the adverse effect of dietary sugars, especially on 
plasma lipids, and thus reinforces the need of dietary guidelines to recommend a limit on 
the intake of sugar to reduce dyslipidaemia and its associated cardio-metabolie risk. The 
current study was conducted in middle-aged men, but the outcomes are applicable to 
women, and especially postmenopausal women expressing increased cardio-metabolie risk. 
This study was unique in comparing the lipid response to high and low sugar diets in 
groups with low and high liver fat. As a result, it provides evidence-based, dietary 
information for the management of cardiovascular health in patients with fatty liver 
disease, and more specifically, the potential for increased sensitivity of these patients to 
diets containing in excess of 27% of total energy as sugar. These findings support the 
current recommendations from the American Heart Association (Johnson et al. 2009), for 
women and men, which is to limit their added intake of sugar to less than 6 and 9 
teaspoons per day ( equivalent to 100 and 150 kcal/day), respectively, to promote a healthy 
and balanced diet. The current dietary recommendation for the management of patients 
with fatty liver disease is to reduce fat in the diet. However, the outcome from the current 
study highlights the need for a moderate intake of CHO (45-50%E) and to restrict sugar, as 
NMES to less than 10% of food energy, to reduce the risk arising fi*om dyslipidaemia and 
hepatic steatosis. Also, whenever possible dietary recommendations should give
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consideration to an individual’s predisposition to cardio-metabolie risk arising from 
increased liver fat and insulin resistance.
Implications and Future work
This research project has identified a number of limitations and practical constraints, the 
correction of which would improve future studies.
1. Physical activity should also be measured to determine how this impacts the 
variation in body weight, fat distribution and plasma lipids.
2. Extending the wash-out period i.e. > 4 weeks or similar length as the intervention 
would help to minimise any order or carry-over effects between dietary 
interventions.
3. Outcomes from this study, especially from the analysis of smaller groups, would 
also be more reliable with a larger sample size.
4. This dietary model could be applied to other (at risk) populations, such as 
postmenopausal women, off spring of patients with T2D, or other ethnic groups at 
high risk of T2D such as Afidcan Caribbeans and Asians).
5. It would also be interesting to conduct this model in a study in metabolic ward 
settings.
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Appendix 1; University Ethics Committee approval letter for AT
metabolism study
^  UNIVERSITY OF
Mrs Najlaa Alsini SURREY
Dept of Diabetes and Endocrinology
Postgraduate Medical School Ethics Committee
FHMS
19.02.18 
Dear Najlaa
Development and validation of methodology to be used to investigate adipose 
tissue Metab
EC/2008/09/FHMS - Fast-Track
On behalf of the Ethics Committee, I am pleased to confirm a favourable ethical opinion 
for the above research on the basis described in the submitted protocol and supporting 
documentation.
Date of confirmation of ethical opinion: 19 February 2008
The list of documents reviewed and approved by the Committee under its Fast Track 
procedure is as follows:-
Document Date
Summary of the Project 19 Feb 08
Detailed Protocol 19 Feb 08
Information Sheet 19 Feb 08
Consent form 19 Feb 08
Standard Letter 19 Feb 08
Risk Assessment 19 Feb 08
Protocol Submission Proforma: Insurance 19 Feb 08
NHS Surrey Research Ethics Committee 19 Feb 08
This opinion is given on the understanding that you will comply with the University's 
Ethical Guidelines for Teaching and Research.
The Committee should be notified of any amendments to the protocol, any adverse 
reactions suffered by research participants, and if the study is terminated earlier than 
expected with reasons.
You are asked to note that a further submission to the Ethics Committee will be required 
in the event that the study is not completed within five years of the above date.
Please inform me when the research has been completed.
Yours sincerely 
Aimee Cox (Miss)
Secretary, University Ethics Committee 
Registry
cc: Professor T Desombre, Chairman, Ethics Committee
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National Research Ethics Service
Surrey Research Ethics Committee
Educafion Centre 
Royal Surrey County Hospital 
■ EgertonRoad 
GUILDFORD 
Surrey 
GU2 7XX
Tel: 01483 406898 
Fax:
22 Septem ber 2009 
Mrs Najlaa Alsini
Wclfson Unit for Translational Research 
Diabetes & Endocrinology 
PGMS, University of Surrey 
Daphne Jackson Road 
Manor PaM(
GU2 7WG
Dear M
Study title;
REC reference: 
Amendment number; 
Amendment date:
Development and validation of methodology to be used 
to investigate adipose tissue metabolism.
07/H1109/182 
3.1
18 September 2009
The above amendm ent was reviewed at the meeting of the Sub-Committee held on 21 
Septem ber 2009.
Ethical opinion
The m em bers of the Committee taking part in the review gave a favourable ethical opinion 
of the amendm ent on the basis described in the notice of amendment form and supporting 
documentation.
Approved documents
The documents reviewed and approved a t the meeting were:
Dafe.,:;. i  1
Summary/Synopsis Undated
Participant Information Sheet 5 ■ 01 September 2009
Protocol 3 01 September 2009
Notice of Substantial Amendment {non-CTlMPs) 3.1 18 September 2009
Annual Progress Report 4.0 18 September 2009
Membership of the Committee .
The m em bers of the Committee who took part in the review are  listed on the attached 
sheet.
This Research Ethics Com mittee is an advisory com m ittee  to  South East Coast Strategic Health Authority  
TheJ^athnal Research EMcs Service (NRES) represents the NR£S Directorate within 
thé National Retient Safety Agency and Research Ethics Committees In England
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4^  UNIVERSITY O F
t i i  SURREY
Faculty of Health and Medical Science 
P o s t g r a d u a t e  M e d i c a l  S c h o o l  
Wolfson Unit for Translational Research 
Diabetes and Endocrinology Department 
Daphne Jackson Road, Manor Park 
Guildford, Surrey GU2 7XH UK 
www.surrev.ac.uk/Dams________
Centre Number: Study Number:
Patient Identification Number for this trial:
CONSENT FORM
Title of Project:
Development and validation of m ethodology to  be used  to Investigate ad ipose  tissu e
Metab
Name of R esearcher: NAJLAA ALSINI
Please Initial
1. I confirm that I have read and understand the information sheet dated 
September 2009 (Version 5) for the above study and have had the 
opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected.
3. I understand that sections of any of my medical notes may be looked at by 
the medical doctors involved in the study. I give permission for these 
individuals to have access to my records.
4. I agree to take part in the above study.
 /  / .............
Name of Patient
N a m e o f  R e s e a r c h e r
 /  /.
S ig n a tu r e
Date Signature
D a te
1 for patient: 1 for researcher; 1 to be kept with hospital notes VERSION 5 SEPTEMBER 2009
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4 ^  U N IV E R S IT Y  O F
#  SURREY
Faculty of Health and Medical Science 
P o s t g r a d u a t e  M e d i c a l  S c h o o l  
Wolfson Unit for Translational Research 
Diabetes and Endoerinology Department 
Daphne Jackson Road, Manor Park 
Guildford, Surrey GU2 7XH UK 
www.surrev.ac.uk/pams
Study title
Development and validation of methodology to be used to investigate 
adipose tissue Metab.
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part.
Thank you for reading this.
What Is the purpose of the  study?
Fat cells are metabolically as active as other tissues in human body. They respond to the 
actions of hormones. Fat cells store fat from digested food and release the stored fat when 
energy is required e.g. during fasting and exercise. With the increase in obesity and lack of 
effective treatment, there is a growing need to understand more about fat tissue Metab and how 
it is controlled so effective treatment can be developed. This study will investigate different 
aspects of fat cell Metab in two distinct fat depots: subcutaneous and visceral.
If we are to understand more about human fat cell Metab and how it may change in diabetes we
need cells from human fat tissue obtained from people without (control) or with diabetes. Fat cells
are very fragile and easily destroyed if handled without care. We require freshly acquired fat
tissue to isolate the fat cells from intra-abdominal and subcutaneous fat tissues which are easily
accessible under abdominal surgery. In addition we will need 5 ml of blood sample just prior to
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the anaesthesia process. This will allow us to study fat cell Metab in the laboratory in response to 
various hormones.
Why have I been chosen?
You have been chosen for the study because you are undergoing abdominal surgery.
Do I have to  take part?
It is up to you to decide whether or not to take part. I f  you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. I f  you decide to take part you are still free to 
withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard o f  care you receive.
W hat will happen to me if I take part?
If you agree to take part the surgeon will take some fat tissue from the incision site which has 
already been made to your skin as part of your surgical procedure. The amount of fat from each 
depot will be as large as a thumb. You will be asked to give 5 ml of blood just prior to surgery and 
before infusing anaesthesia. This will not involve any extra pain or time above the usual surgical 
procedure.
This is a part of Mrs. Najlaa Alsini’s PhD research in the department of Diabetes and 
Endocrinology in the Postgraduate Medical School in University of Surrey. A senior scientist from 
the postgraduate medical school, Dr. Fariba Shojaee Moradie will be one of her supervisors. Dr. 
John Wright is a consultant endocrinologist and Dr. Ben Sheldon is a Clinresearch fellow in the 
department of Diabetes and Endocrinology and internal medicine at the Royal Surrey County 
Hospital. Both have honorary contracts with the University. They will ask your surgeon’s 
permission to approach you about the study.
What do I have to  do?
There will be no intervention to your diet or life style.
What is the  procedure that is being tes ted ?
The tissue samples are going to be utilised to prepare and set up methods and validate 
techniques that require fresh fat cell preparations in test tubes in the laboratory to measure 
lipolytic and lipogenic activities of each fat depots. The cell sizes will also be assessed. The 
tissues will be transferred to Post graduate Medical School’s labs. Once in the lab a small portion 
of each tissue, about the size of a small pea, will be dissected from each fat depot and frozen
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immediately. The frozen tissue will be stored in the laboratory at -80°C for later analysis for 
enzyme activity. On the day of procedure at the end of the experiment the cells will be disposed 
of in a manner according to Health and Safety Guidelines.
W hat are the  side effects of any treatm ent received when taking part?
There are no side effects.
W hat are the  possib le d isadvan tages and risks of taking part?
Taking 5 grams of fat tissue in the way proposed is very unlikely to cause any harm.
W hat are the possib le benefits of taking part?
You will not directly benefit from taking part in this study. The information we get from this study 
may help us to understand the fat cell Metab and therefore the changes that may happen in terms 
of obesity or interventions to life style for example exercise and diet.
W hat happens when the research study  s to p s?
Your care will continue as per normal practice.
W hat if som ething goes w rong?
I understand that in the event of my suffering a significant and enduring injury (including illness or 
disease) as a direct result of my participation in the study, compensation will be paid to me by the 
University, subject to certain provisos and limitations. The amount of compensation will be 
appropriate to the nature, severity and persistence of the injury and will, in general terms, be 
consistent with the amount of damages commonly awarded for similar injury by an English court 
in cases where the liability has been admitted.
Will my taking part In th is study  be kept confidential?
Regardless of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this surgery, the normal National 
Health Service complaints mechanisms should be available to you. There will be no information 
related to your personal detail and hospital number stored in any computers outside NHS 
computers. The scientists will not have access to your details. Tissue samples will be assigned a 
number. Your name will not be linked to the number.
What will happen to the results of the research  study?
The results of research will be published in peer reviewed journals. You will not be able to be 
identified in any report or publication.
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Who is organising and funding the research?
The research is being organised at the University of Surrey. The research is funded by the 
University.
Your doctor conducting the research is not being paid for including you in the study.
Who has reviewed the study?
The study design has been reviewed by the Surrey Research Ethics Committee.
Thank you for taking part in the study.
Contact for Further Information 
Dr John Wright
Dept of Diabetes and Endocrinology, CEDAR Centre, the Royal Surrey County Hospital.
Tel No: 01483 571122 ext 4844 
i.wriaht@surrev.ac.uk 
Dr Ben Sheldon
Dept of Diabetes and Endocrinology, CEDAR Centre, the Royal Surrey County Hospital.
Tel No: 01483 571122 ext 4844 
bensheldon71 @hotmail.com 
Dr Fariba Shojaee-Moradie
Dept of Diabetes and Endocrinology, Post Graduate Medical School, University of Surrey.
Tel No: 01483 688644 
f.shoiaee-moradie@surrev.ac.uk 
Mrs Najlaa Alsini
Dept of Diabetes and Endocrinology, Post Graduate Medical School, University of Surrey.
Tel No: 01483 688642 
nailaa.alsini@surrev.ac.uk
You will be given a copy o f  the information sheet and a signed consent form to keep.
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Appendix 5: Preparation of KRB solution
Preparation of Stock Salt for KRB solution:
Made the solution to 500 ml with distilled water and store at 4°C Fridge.
1. Weigh the following amounts of salts
MWt Weight Final Conc.
Sodium Chloride NaCI 58.44 7.00 g 0.24 M
Potassium Chloride KG! 74.55 0.359 g 0.01 M
Potassium Hydrogen Phosphate KH2 PO4 136.085 0.164 g
Magnesium Sulphate MgS0 4 .7 H2 0 138.38 0.610 g
Sodium Bicarbonate NaHCOs 84.0066 2.176 g
Hepes 238.3
2. Measure out 450 ml distilled water. While gentle stirring the water, add the powders. Stir
until dissolved. DO NOT HEAT
3. Rinse the plastic weighing boats with the 50 ml of water to remove all traces of powder
into the solution. (Total water volume is 500 ml).
4.Y0U CAN KEEP THIS SALT SOLUTION IN THE 4°C FRIDGE.
Preparation of Krebs Ringer Buffer (KRB) Solution
Take 125 ml stock salt solution; add 100 ml distilled water (in a conical flask).
Add 0.0473 gm of CaCI2.2H20 and 0.025 gm D- Glucose them to the conical flask while gently 
stirring. Rinse the plastic weighing boats with 25 ml of water to remove all traces of powder 
into the solution.(Total watervolume is 125 ml)
While stirring, adjust pH of the medium to 7.4 using 1M NaOH and 1M HCI. n o t  Gone, hoi
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BSA Buffer: KRB + Bovine Serum Albumin
First thing, make up KRB solution.
(If salt solution in the fridge bring it out to be at room temp)
Preparation of Krebs Ringer Buffer (KRB) Solution
1. Take 125 ml stock salt solution; add 100 ml distilled water (in a conical flask).
2. Weigh 0.0473 g of CaCI2.2H20 and 0.025 g of D- Glucose (from desiccator); add them 
to the conical flask while gently stirring. Rinse the plastic weighing boats with 25 ml of water to 
remove all traces of powder into the solution.(Total WATER volume is 125 ml)
3. While stirring, adjust pH of the medium to 7.4
4. warm up Bovine serum Albumin BSA (from fridge) to avoid any humidity absorbance
5. Add 2.5 g BSA to the conical flask, and leave to dissolve and stand for 10-15 min and 
cover with parafilm. This gave a 1% BSA buffer.
To prepare 2% BSA add 5g BSA to the 250 ml solution.
6. Stir by placing a magnetic fleece in the flask together on an auto-vortex (near the pH 
meter).
7. While stirring, adjust to pH 7.4 by pH meter after adding BSA.
★(With 1M HCI and 1M NaOH... NOT Conc. HCI)
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Appendix 6: Lipolysis with Isoproterenol
Table 2: Lipolysis in isolated human adipocytes with Isoproterenol 
(Sigma) +/- Insulin in the presence of Adenosine deaminase (Sigma)
Tubes #
Cell
suspension H2O
S u l 
Isoproterenol 
conc. (10* mol/1).
S u l
ADA
S u l  
Insulin 
conc......
I 2 100 ul 15 ul - - -
3 4 100 ul 10 ul - 5ul -
5 6 100 ul 5ul -9 5ul -
7 8 100 ul 5ul -8 5ul -
9 10 100 ul 5ul -7 5ul -
11 12 100 ul 5ul -6 5ul -
13 14 100 ul 5ul -5 5ul -
15 16 100 ul 5ul - 5ul 5ul
17 18 100 ul - -9 5ul 5ul
19 20 100 ul - -8 5ul 5ul
21 22 100 ul - -7 5ul 5ul
23 24 100 ul - -6 5ul 5u l
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Appendix 7: Lipolysis with Adrenaline
Table 3: Lipolysis in adipocytes with Adrenaline +/- Insulin in the presence of 
Adenosine deaminase.
Tubes #
Cell
suspension H 2O
Adrenaline conc. 
(10* mol/1). 
5 u l ADA
Insulin  
conc......
1 2 100 ul 15 ul - - -
3 4 100 ul 10 ul - 5u l -
5 6 100 ul 5ul -9 5u l -
7 8 100 ul 5ul -8 5ul -
9 10 100 ul 5ul -7 5ul -
11 12 100 ul 5ul -6 5ul -
13 14 100 ul 5ul -5 5ul -
15 16 100 ul 5ul - 5ul 5ul
17 18 100 ul - -9 5u l 5ul
19 20 100 ul - -8 5ul 5ul
21 22 100 ul - -7 5ul 5ul
23 24 100 ul - -6 5ul 5ul
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Appendix 8 :  PIS for Extrinsic sugar study u n i v e r s i t y  OF
SURREY
Participant Information Sheet
study Title: "TAie Effect o f D ietary Carbohydrate on Lipids.”
You are being invited to take part in a study investigating how dietary carbohydrate 
affects fat Metab. Before you decide if you wish to participate, it is important for you 
to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with your friends, 
relatives and anyone involved with your care. Please ask us if there is anything that 
is not clear or if you would like more information.
Why have I been chosen?
In this study we are looking for men, aged between 40-65, who are overweight but 
do not have diabetes. We want participants to be weight stable and not taking any 
other medication that may affect Metab.
Do I have to take part?
It  is up to you to decide whether to take part or not. I f  you decide to take part you 
will be given this information sheet to keep and asked to sign a consent form. If  you 
decide to take part you are still free to withdraw at any time and without giving a 
reason.
What would happen to me if I take part?
I f  you are interested in taking part in this study, you wouid come to the Cedar Centre 
at the Royal Surrey County Hospital in the morning, without having had breakfast, 
for an initial chat about the project, when we would measure your height, weight, 
take your blood pressure and take a small blood sample to measure your glucose, 
insulin, blood chemistry and fat levels. After this you will be provided with a snack 
and drink. This is a screening visit (VISIT 1) to make sure you do not have diabetes 
or any other disorder that may affect you taking part in the study. We also ask you 
to fill in two short questionnaires about your general health and diet. We would 
normally inform you of your results within 2 weeks of this visit.
I f  following this screening visit, you are found to fuifil the recruitment criteria and 
you are still happy to take part we will ask you to visit the Hammersmith Hospital in 
London for a second screening visit (VISIT 2) to measure the amount of fat in your 
liver. We are recruiting subjects with very low or moderate levels of liver fat. I f  you 
fulfil these criteria we will ask you to undertake a dietary intervention for a period of
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32 weeks. This will comprise a 4 week diet based on the average UK diet followed by 
a 12 week diet with
either high or low sugar foods, followed by a 4 week diet based on the average UK 
diet and finally a 12 week diet with either high or low sugar foods (depending on 
which diet you followed for the first 12 weeks). Half the men in the study will have 
the high sugar foods first and the low sugar diet second and the other half will have 
the low sugar diet first and the high sugar diet second. The nutritionist will give you 
guidance and advice on how to follow this diet at the Cedar Centre before you start, 
and on how to complete a 3-day diet diary (VISIT 3). Diet diaries will be completed 
at the end of the run-in diet, and at 6 and 12 weeks during each 12 week dietary 
period. We will ask you to meet the nutritionist every 2 weeks, who will also contact 
you by telephone during the weeks you do not meet.
At the end of the first 4 week diet we will ask you to visit the Cedar Centre at the 
Royal Surrey County Hospital for a blood test to measure your blood fat levels (VISIT 
4). You will then be allocated to one of the two diets. At week 11 of the diet you will 
be asked to visit Hammersmith Hospital for another MRI scan (VISIT 5). This visit is 
identical to visit 2. At the end of the first 12 week diet we will ask you to visit the 
Cedar Centre on 2 successive days for a series of tests (VISITS 6 and 7). At the end 
of the second 4 week wash-out we will ask you to visit the Cedar Centre for a blood 
test to measure fat levels (VISIT 8) to start the next diet. At the end of the second 
12 week diet at week 11 you will be asked to visit Hammersmith Hospital for another 
MRI scan (VISIT 9). This visit is identical to visit 2 we will ask you to visit the Cedar 
Centre on 2 successive days for a series of tests (VISITS 10 and 11). These tests 
will be identical to the tests done at visits 6 and 7.
VISITS 2, 5 and 9
You will be asked to go to the Hammersmith Hospital, London after a 10 hour fast to 
have an MRI (magnetic resonance imaging) scan. MRI is a body scanning 
technique, which is used in hospitals worldwide to create images of the inside of the 
body. MRI has been used safely for several decades and has no known side-effects. 
Each scan is directed to the specific requirements of the research study in which you 
are taking part. The MRI scan is purely for the detection of liver fat and is not 
for the purposes of a health check.
You will be given an appointment for magnetic resonance scans at the Robert Steiner 
MRI unit and asked to come fasted (nothing to eat or drink for 10 hours before your 
scan) however you may drink some water and take any medication you would 
normally do.
As the MRI scanner uses high magnetic field we have to make sure you do not have
any metallic object in or on your body to ensure your safety. Before starting the
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scanning we will ask you to complete a short checklist. This will ensure that you do 
not have any magnetic implant (such as a cardiac pacemaker) which will stop us 
performing the scan. These scans are safe and do not involve any radioactivity or X 
rays.
You wiil be in the MR scanner for up to 1 hour. None of the magnetic resonance 
imaging techniques uses ionising radiation or intravenous contrast agents and may 
be performed during a single imaging session. You lie flat in the scanner and are 
automatically moved through the scanner. Whole body anatomical MR scanning wiil 
be performed to determine total and regional fat volumes, and magnetic resonance 
spectroscopy (MRS) performed to measure lipid content in internal organs, such as 
liver (IHCL) and muscles (IMCL), such as soleus and tibialis.
You may hear a knocking noise during part of the procedure, and you wiil experience 
no discomfort. We will give you an alarm bell to sound at any time if you are upset or 
worried during the examination and if the procedure does not suit you for any reason 
it can be stopped at any time.
ANTHROPOMETRY
Baseline anthropometric measurements including height, weight, waist and hip 
circumference, skinfold thickness, blood pressure, body-volume, and bioelectrical 
impedance analysis of percentage body fat. The bioelectrical impedance is a painless, 
safe procedure which involves either lying on a couch with sticky pads placed on a 
hand and foot, or standing on a metal platform for 1 minute so that the body's 
electrical resistance can be measured.
What i f  anything abnormal is discovered?
MRI is a powerful, diagnostic body scanning technique used in hospitals worldwide to 
create images of the inside of the body. MRI has been used safely for several 
decades and has no known side-effects. These scans cannot be viewed as a health 
screening procedure. However, very rarely, unexpected information can be detected 
which may warrant further investigation. In this event, a report will be sent to your 
GP, who will arrange further tests and coordinate your further care. The doctor 
involved in the research study will also be informed.
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VISIT 3
This will involve a brief consultation with the nutritionist at the Cedar Centre who will 
give you dietary advice for the run-in diet and guidance on how to complete a diet 
diary.
VISIT 4
You will be asked to come to the Royal Surrey County Hospital in the morning having 
fasted since 10 pm the previous day. At this visit we will take a blood sample to 
measure fat levels. After the sample is taken you will be provided with a snack and 
drink. You will then meet with the nutritionist who will explain about the 12 week diet 
we would like you to be on. She will supply you with the food you will need for this 
period. I f  you do not attend by car, we can arrange for the food to be delivered to your 
home. This visit will take about 30-45 minutes.
VISIT 5
Hammersmith Hospital MRI scan. This visit is identical to visit 2.
VISIT 6
This visit will take place at the end of the 12 week diet with high or low sugar 
content. We ask you to attend the Cedar Centre at the Royal Surrey County Hospital. 
A blood sample will be taken and you will be given 2 smali bottles of water 
containing labelled water and one large bottle of water containing labelled water. You 
will be asked to drink one small bottle of the labelled water at 7pm after your 
evening meal and the other small bottle at 10pm the same night. After 7pm, if you 
need to drink we will ask you to drink only the water in the large bottle without any 
other food. This visit will take about 20 minutes. We will provide you with a standard 
ready-meal for your evening meal (of your choice) to take home.
VISIT 7
The next day you will be asked to come to the Cedar Centre at the Royal Surrey 
County Hospital at 7.30am having fasted since 8pm the previous day. We wiil 
provide you with a standard ready-meal for your evening meal to eat at home the 
day before the study. We ask you not to undertake any vigorous activity for 2 days 
before this visit and not to drink alcohol the day before.
We will put 3 fine plastic tubes into your veins. Two will be placed in a vein in each 
elbow and one in a wrist vein. The tubes are made of a flexible plastic and so once 
placed should not cause any discomfort and will not impede your arm movements. 
After taking a baseline blood sample, we will inject a labelled molecule of glycerol 
(which is a non-harmful fat that our body normally produces) to measure how much
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fat your liver is making. We will also start pumping (infusing) 2 solutions at a slow
rate into one of the tubes in your eibow for 10 hours. This contains a labelled
molecule of palmitic acid (another non-harmful fat that our body normally produces) 
bound to a blood protein aibumin which can be used to measure how much fat your 
body is burning. This solution also contains a labelled amino acid which measures the 
number of particles of fat that your liver makes. At frequent time intervals during the
10 hour study blood samples will be taken from the vein in your elbow and the vein in 
your wrist. While we are taking blood from your wrist we will ask you to place your 
hand inside a "hot-box" for 20 minutes before we take a blood sample. This box is 
made of Perspex and heats the blood in your wrist making the blood similar to blood 
found in arteries. I t  will make your hand hot but this is not uncomfortable. You will 
not feel the blood samples being taken. At the end of the study we wiil measure the 
activity of 2 enzymes which break down fat in your blood. A small amount of a 
substance called heparin will be injected which releases the enzymes then a blood 
sample will be taken 15 minutes later. The total amount of blood we will take in this 
test is 11 tablespoons of blood (220mls).
During the study you will be free to write/read or watch DVDs within the unit. 
Drinking water will be made available throughout the study although food will only 
be provided at the end of the study. Although you will be connected to an infusion 
pump, that pump can be moved so there will be no lim it to going to the toilet etc. At 
the end of the study day you will be provided with a meal of your choice with tea or 
coffee. The whole procedure (from arrival to going home) would take approximately
11 hours.
VISIT 8
This is before you start your second diet and identical to visit 4.
VISIT 9
Hammersmith Hospital MRI scan. This visit is identical to visit 2.
VISITS 10 and 11
These are at the end of your second diet and identical to visits 6 and 7.
Expenses
All travelling expenses wiil be reimbursed and there will be an inconvenience 
allowance of £200 payable upon completion of the study.
What do I have to do?
You will need to have fasted overnight (for 12 hours) for some of the visits. This 
means having no food or drink, other than water, after your evening meal the day 
before your visit. In addition, we will ask you to eat a standard ready-meal, which we 
wili provide for you to eat at home, for your evening meal the night before visit 6
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and visit 9. We also ask you to refrain from vigorous exercise for 2 days before these 
visits and to avoid alcohol.
What are the possible disadvantages and risks of taking part?
The risks of having a cannula in a vein are those associated with any blood sample. 
These are slight pain, possible bruising and, in principle, a local infection. We will try 
and avoid these problems.
In visit 5 and 8 one of the labelled molecules is bound to albumin. As this is a blood 
protein there is a small risk of allergic reaction. Albumin is a blood protein and is 
purified from human blood. As such there is a very small risk of transmission of 
infectious diseases. To minimise this, the albumin is purified from blood donors who 
have been screened for pathogenic viruses and the albumin is heat treated to 
inactivate viruses.
In visit 5 and 8 we will administer a small amount of heparin which thins the blood. 
You will be advised to avoid caffeine for 4 hours after this. You may have excessive 
bruising if you hit yourself hard within 4 hours of the procedure.
What are the possible benefits of taking part?
You will be helping medical science to understand how different types of 
carbohydrate affect fat Metab. This will help formulate appropriate dietary advice for 
men at risk of metabolic syndrome.
What if something goes wrong?
I f  you are harmed by taking part in this research project then you may have grounds 
for legal action. Regardless of this, if you wish to complain about any aspect of the 
way you have been approached or treated during the course of this study, the 
normal University complaints mechanisms are available to you.
Complaints
Any complaint or concerns about any aspects of the way you have been dealt with 
during the course of the study wili be addressed. Please contact Prof. Bruce Griffin, 
Principal Investigator on 01483 689724.
Would my taking part in this study be kept confidential?
All information which is collected about you during the course of this research would 
be kept strictly confidential. Any information about you which leaves the hospital or 
University would have your name and address removed so that you cannot be 
recognised from it. With your permission, your GP will be notified of your 
participation in this study.
What would happen to the results of the research study?
The results of this study will be published in the scientific press and you wiil not be 
identifiable in any way. It is our usuai practice to send copies of any resultant 
publications to research participants.
2 8 0
Who is organising the funding and research?
This research is being funded by the Biotechnology and Biological Sciences 
Research Council, a government funded research body.
Who reviewed this study?
The study was reviewed by the Surrey Research Ethics Committee.
Contact for further information?
Cheryl Isherwood (01483 688642) c.isherwood@surrey.ac.uk
Prof Bruce Griffin (01483 689724) b.griffin@surrey.ac.uk
Dr John Wright (01483 571122 ext 4844) john.wright@surrey.ac.uk
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Appendix 9: Consent form for extrinsic sugar study
U NIVERSITY O F
S U R R E Y
Volunteer Consent Form
I ftg undersgnsd v’okintarlly to take part irt iha study 'Row doos dfotaTy
catbùkydiate tnlluehc  ^me fofmslîo» of am alberogenrc fipopfotein phenotype?"
*  I tiave read ann understood Hie Entormalism Sheet provided. I have been given a  lull 
exgiBPaüoh by the ir^'esligators oS thg nature, purpose, tocation and IW y d ic tio n  of the 
aludy, aad of \%tiai I v%ill be expecled to do. I lave been advised about any diseoniloct 
and posslbfe lll-elfecte on my hoailh and %%11-belng wNch may result. I have been given 
the opgortimiiy usk qucçhor^ on àJI of ^ho study and htïi'e undorslo^d the 
advice arid inlormatbn gfi'sn as a resul.
» I agree to compV wilh any instruction pven lo me dwing the study ard  to co-operata tutv
wi|h fliG kivOOlTgntO:?. Î intpcm Ihten irïirapââlçlj' if I siiflpr any dMeriOfairon Of an>' 
kind In my hea%h cf %ell-belng, or experience any unexpected or urusual symptoms,
* I agree to She investigators contacting my general practitioner about my participation in the 
study, and I authorise my GP to cDsctose details of my rele^'ant medical or drug history, in 
confidence,
* I consent to my personal data, a s  outlined m the accompanying informagon shod, b r^ g  
used iof the researcti pjoject detaîed In the intormatcn sheet, and agree that data 
cotected mai' be shared with other eesearchers or interested parties. I imdarstand that all 
personal data relating to voljnteers ia fiekf and processed ëi the strictest oontidenoa, and 
In accordance with me Data Protection Act (igGBj.
* I imdcr#and that I am free to with^aw from the study at any time wlhoyt needing to 
juslity my decision and Ailhout prejudice.
* I acknowledge that In conslderatlcn to? completing itie study t shElI receive the sum of 
C205- I roct^nisp ttmt I ho sum ^vpyld bo loss, and at th*o discrotbn o1 Ihp Princpgl 
Investigator, a I wilhdraw iKfore completicn of the s tu %
'  I urderstEhd that In the event of my suffering a  s'gn^ioant and ensfuring in|uf>' (indudng 
i&ioss Of (3soOso) OS a arfecl r<:Sajll pl pr-otE'pfiiiipn in the study, oompçfisaliç:! wit] be 
paid to me by lt% Unlversty, subject to certati provisos and limitations. The amount d  
oompoi^atkm will fco appmpr^alo to tho naturo, so^fority and pcrsistcnoo of the ir(urs' and 
win, in general terms, be consistent with the amount of damages commonly awarded tor 
similar injury by an English court m cases where thie liability has been admitted
* I confirm that I hm'O road end undmstosd tho nbcft'o and freely consent to podisipatin^p in 
this study. I have been given adequate time to consider my paiUdpatlcn and agree to 
comply'A^h tho anstructjors and rostrictions of tfic study.
Name of volunteer (BLOCK CAPfTAiSj
Signed
Date
Name ot reseEmheii'persai taWng -consent 
I9L0CK CAPITALS)
Signed
Date
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Appendix 10: Ethical approval for the extrinsic sugar study
Surrey Research Ethics Committee
Education Centro 
Royal Surrey County Hospital 
Egerlon Road 
GUILDFORD 
Surrey 
GU27XX
Telephone; 01483 406898 
Facsimile:
11 March 2009
Dr Bruce Griffin 
Reader
Faculty of Health & Medical Science 
University of Surrey 
Guildford 
GÜ2 7XH
Dear Dr Griffin 
Full title of study:
REG reference number:
How does dietary carbohydrate influence the formation 
of an atherogenic lipoprotein phenotype 
08/H1109/227
Thank you for your letter of 23 February 2009, responding to the Committee's request for 
further information on the above research.
The further information has been considered on behalf of the Committee by the Chairman. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
revised documents, subject to the conditions specified below.
Ethical review of research sites
The Committee has designated this study as exempt from site-specific assessment (SSA). 
The favourable opinion for the study applies to all sites involved in the research. There is no 
requirement for other Local Research Ethics Committees to be informed or SSA to be 
carried out at each site.
Conditions of the favourable opinion
The favourable opinion is subject to the following conditions being met prior to the start of 
the study.
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned.
Management permission at NHS sites (“R&D approval’) should be obtained from the Royal 
Surrey County Hospital in accordance with NHS research governance arrangements.
An advisory com m ittee  to  South East Coast S tra teg ic  H ealth  A uthority
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Appendix 11: Ethical approval for the extrinsic sugar study
Guidance on applying for NHS permission is available in the Integrated Research 
Application System or at http://vvww.rdforum.nhs.uk.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document . • /  , Version Dale
Referee Reports
Letter from Funder 29 October 2008
Advertisement (University Staff only)
GP Letter (Advising Participation) 1 22 August 2005
Recruitment Letter-University CRC 1 06 January 2009
Participant Consent Form 1 01 January 2009
Participant information Sheet 1 05 January 2009
GP/Consultant Information Sheets 1 06 January 2009
Letter of Invitation to participant GP/V1 06 January 2009
Advertisement
Questionnaire: Non-validated
Compensation Arrangements 21 July 2008
Summary/Synopsis
Protocol 1 05 January 2009
Investigator CV
Application 2.0 08 January 2009
Prof J Bell
Prof G Frost
Dr M Slolinski
CV-Dr J Wright
Response to Request for Further Information 23 February 2009
Participant Information Sheet 2 23 February 2009
Advertisement 23 February 2009
Application 2.0 23 February 2009
Statem ent of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National Research 
Ethics Website > After Review
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website.
The attached document "After ethical review-guidance for researchers" gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:
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Appendix 12: Ethical approval for the extrinsic sugar study
• Notifying substantial amendments
• Progress and safety reports, 
o Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencearoup@nres.npsa.nhs.uk.
108/H1109/227 P lease quote th is num ber on all correspondence ~
With the Committee’s best wishes for the success of this project 
Yours sincerely
Prof David R ussell-Jones 
Chair
Email; ethics.committee@royalsurrey.nhs.uk
Enclosures: “After ethical review -  guidance for researchers”
Copy to: Professor Terry Desombre
Chair of University REG 
University of Surrey 
6*^  Floor, Senate House 
Guildford 
GU2 7XH
Mr Imran Malik 
R&D Manager
Royal Surrey County Hospital
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Appendix 13: Letter from GP for approved participants
Letterhead
<date>
<title><initial><Surname>
<address>
<address>
<town>
<county>
Dear <Name>
Re: Recruitm ent for a research  study  entitled ‘'How does dietary carbohydrate influence 
the formation of an atherogenic lipoprotein phenotype”
Researchers in the Department of Diabetes and Endocrinology at The Postgraduate Medical 
School and the Division of Nutrition at the University of Surrey are carrying out a study 
investigating how diets high and low in sugar influence the development of atherosclerosis (a 
condition in which fatty material collects along the walls of arteries).
This research is supported by one of the UK research councils which is funded from the 
Government's Department for Innovation, Universities and Skills.
The study is suitable for men aged between 45-65 years who are overweight but not diabetic. 
Please find enclosed a Patient Information Sheet which will give you more details about the 
study. Please check the section, “Why have I been chosen” which will give you an indication of 
your eligibility.
You will be compensated for your time on the study and travel expenses will be paid for. Please 
also be aware that this is a clinical study and if you are enrolled you will not be able to sign up for 
any other study during this time.
I would like to assure you that your patient confidentiality has in no way been compromised and 
at no time have any researchers had access to your personal Information. If you are interested in 
finding out more about the above study, please contact Cheryl Isherwood on 01483 688642 or 
email c.isherwood@surrev.ac.uk.
Yours sincerely.
D r .....................
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Appendix 14; Phosphate buffer preparation
Phosphate Buffer Solution (PBS) 
Store @ 4°C Fridge for 2 weeks
Mwt of K2HPO4 = 174.176 g/mol 
Mwt of KH2PO4 = 136.0857 g/mol
To prepare 0.1 M Potassium Phosphate buffer pH 7.0 (in 1 Litre)
1. Weigh 17.4 g of K2 HPO4 , and 13.6 g of KH2 PO4
2. Dissolve in 800 ml of distilled water, mix well until completely dissolve.
3. Adjust to pH 7.0 (with 1M HCI and 1M NaOH)
4. Fill with distilled water to 1 Litre
To reduce the amount of solution (Do not need this much)
To prepare 0.1 M Potassium Phosphate buffer pH 7.0 (in 100 ml)
5. Weigh 1.74 gm of K2HPO4, and 1.36 gm of KH2PO4
6. Dissolve in 80 ml of distilled water, mix well until completely dissolve.
7. Adjust to pH 7.0 (with 1M HCI and 1M NaOH)
8. Fill with distilled water to 100 ml.
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